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Summary 
The renin angiotensin system (RAS) is an important regulator of blood pressure, 
volume and electrolytes. Angiotensin II (AngII) is the main modulator of RAS 
effects, in tissues such as heart, blood vessels, brain, kidney, adrenal cortex and 
adipose tissue, via the angiotensin type 1 receptor (AT1R) or the angiotensin type 2 
receptor (AT2R). The characteristic actions of AngII are mediated by the AT1R and 
over-activity of AngII and the AT1R play a fundamental role in the pathophysiology 
of hypertension and heart failure. The AT2R is expressed in embryonic tissue and in 
disease states and may antagonize AT1R-mediated pathophysiological signalling, 
however this is still controversial. The recent discovery of a novel RAS enzyme 
angiotensin converting enzyme 2 (ACE 2) expressed in brain, testis, kidney and 
cardiomyocytes, changed the classical view of the RAS. ACE 2 cleaves AngI and 
AngII to form the novel peptides Ang1-9 and Ang1-7, respectively. It has been 
demonstrated that by activating the Mas receptor, Ang1-7 antagonizes many of the 
pathophysiological actions of AngII. Ang1-9 has been described as an inhibitor of 
ACE, and as a substrate to form Ang1-7. The work in this thesis assessed the effects 
of the novel RAS peptides Ang1-7 and Ang1-9 in cardiac hypertrophy in vitro and in 
vivo in the stroke prone spontaneously hypertensive rat (SHRSP), an experimental 
model of hypertension. Further work generated gene transfer vectors for over-
expression of Ang1-7 and Ang1-9 to facilitate delivery of these peptides to specific 
cell types. 
First, rat H9c2 cardiomyocytes were stimulated with AngII and cardiomyocyte 
hypertrophy was confirmed by increased cell size, elevated gene expression of the 
hypertrophy marker brain natriuretic peptide (BNP) and reorganization of α-actin 
filaments following exposure to AngII.  Addition of Ang1-7 or Ang1-9 to AngII-
stimulated H9c2 cardiomyocytes blocked the increase in cell size and in BNP gene 
expression as well as α-actin filament reorganization. Similar effects were observed 
in adult rabbit primary left ventricle cardiomyocytes, where AngII induced a 
significant increase in cell width which led to increased cell volume, an effect 
blocked by both Ang1-7 and Ang1-9. Inhibition of ACE with captopril did not affect 
the antihypertrophic effect of Ang1-9, supporting the hypothesis that conversion to 
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Ang1-7 was not necessary for the antihypertrophic effects of Ang1-9. Next, the 
receptor signalling mechanisms for Ang1-7 and Ang1-9 were studied by focusing on 
Mas, the AT1R and the AT2R. Addition of the Mas antagonist A779 to H9c2 and 
rabbit primary cardiomyocytes blocked the antihypertrophic effect of Ang1-7 
without affecting Ang1-9, demonstrating an independent role for Ang1-9. To 
investigate the role of the AT1R we used arg-vasopressin to induce hypertrophy and 
blocked the AT1R with losartan. Addition of losartan had no effect on the 
antihypertrophic effect of Ang1-7 or Ang1-9, indicating that neither of these 
peptides signalled through the AT1R and that both peptides were able to block 
hypertrophy induced by different stimuli. However, addition of PD123,319, an 
AT2R antagonist, blocked the antihypertrophic effect of Ang1-9, while Ang1-7 was 
unaffected, indicating that Ang1-9 may signal through the AT2R.  
In vivo delivery of Ang1-9 to the SHRSP was achieved by the use of osmotic 
minipumps. Blood pressure was monitored via radiotelemetry from 11 weeks of age 
until the end of the experiment. During the study three echocardiograms were 
performed (at 11 weeks, 15 weeks and 17 weeks of age). After sacrifice of the rats, 
aorta and heart were collected for further study. After 4 weeks of Ang1-9 delivery in 
SHRSP no significant difference in blood pressure was observed between groups. 
Echocardiography showed no difference in cardiac hypertrophy between control and 
Ang1-9 infused groups. However, co-infusion of Ang1-9 with PD123,319 produced 
a significant increase in left ventricular mass index. There was a significant increase 
in cardiac output in SHRSP infused with Ang1-9 compared to control, an effect that 
was abolished by co-infusion with the AT2R antagonist. Furthermore, histological 
assessment of the heart showed reduced perivascular fibrosis in Ang1-9-infused rats 
when compared to controls. Interestingly, co-infusion of PD123,319 increased 
interstitial fibrosis, suggesting that the AT2R might have an intrinsic basal effect in 
the SHRSP. In addition, pressure myography showed a significant increase in basal 
nitric oxide bioavailability in the aorta of Ang1-9-infused rats when compared with 
controls, an effect that was abolished by the co-infusion of PD123,319, suggesting 
Ang1-9 effects were mediated by the AT2R. 
The development of gene transfer approaches has facilitated research in 
cardiovascular disease. Thus, in order to develop tools to study the effects of Ang1-7 
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and Ang1-9 in specific cells, adenovirus vectors were generated which utilized a 
fusion protein expression cassette. Expression of the fusion protein was confirmed 
by western immunoblotting. Over-expression of Ang1-7 or Ang1-9 via the 
recombinant adenovirus was able to block AngII-induced hypertrophy. To confirm 
this effect was a result of peptide secretion from transduced cells a conditioned 
media assay was performed in which HeLa cells were transduced with RAdAng1-7 
or RAdAng1-9 and 48 hours later conditioned media was transferred to AngII-
stimulated H9c2 cells. Conditioned media from RAdAng1-7 or RAdAng1-9 
transduced HeLa cells inhibited AngII-induced hypertrophy.  
In summary, Ang1-9 and Ang1-7 inhibit cardiomyocyte hypertrophy in vitro induced 
by AngII or arg-vasopressin. Importantly we ascribe a direct biological role for 
Ang1-9 as a RAS hormone, signalling via the AT2R in vitro and in vivo. 
Furthermore, Ang1-9 increased cardiac output, improved endothelial function and 
reduced cardiac fibrosis in an experimental model of hypertension supporting direct 
biological effects of Ang1-9. These results have implications for our understanding 
of RAS function and identification of new therapeutic targets in cardiovascular 
disease. 
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1.1 The renin-angiotensin system 
The renin-angiotensin system (RAS) is one of the most important processes by 
which the body regulates blood pressure, volume and electrolytes (Keidar et al., 
2007). The relationship between hypertension and renal disease has long been 
known and in 1898 Tigerstedt and Bergman discovered renin and described it as a 
pressor compound (Tigerstedt, 1898). Many efforts were made to establish the 
pathway between the kidney and the development of hypertension, mainly through 
attempting to identify direct effects on arterial pressure through kidney function. By 
the end of the 1930’s the presence of a pressor agent in the venous blood of the 
ischemic kidney was described (Fasciolo et al., 1938). Two studies confirmed these 
findings (Goldblatt, 1937, Harrison, 1937), and a pressor protein (originally called 
hypertensin) was then isolated from the blood (Braun-Menéndez, 1939) and 
described as a potent short duration pressor protein, completely different from renin. 
To further investigate the relationship between renin and this newly discovered 
hypertension protein, semi-purified kidney extract was incubated with plasma and a 
similar compound to hypertensin was generated and isolated (Braun-Menéndez, 
1939). The description of renin as a protease led to the search for its substrate which 
was found to be formed in the liver and was subsequently named angiotensinogen 
(Leloir, 1942). Finally, the octapeptide pressor protein angiotensin II (AngII) was 
described for the first time (Bumpus et al., 1957) and this led to major studies which 
have contributed to our in depth knowledge of the RAS. 
1.2 The classical RAS 
The renin-angiotensin cascade system initiates via the release of renin from the 
juxtaglomerular complex in the kidney (Figure 1-1), a segment of the distal tubule 
that passes through the angle between the afferent and efferent arteriole. The 
epithelial cells of the distal tubule proximal to arterioles termed the macula densa 
detect changes in sodium chloride and promote the release of renin from the granular 
cells. Alternatively, renin is also released when hypoxia or a decrease in arterial 
blood pressure is sensed or by the action of the sympathetic
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nervous system (β1 adrenergic receptor stimulation) (Guyton, 2007, Rhoedes and 
Tanner, 1997). Once secreted, renin cleaves the 12 amino acid peptide 
angiotensinogen. Angiotensinogen is a glycoprotein constitutively produced mainly 
in the liver and cannot be stored (Deschepper, 1994). The cleavage of 
angiotensinogen between the leucine and valine amino acids (11
th
 and 12
th
 amino 
acids) forms the decapeptide angiotensin I (AngI). AngI is then converted into AngII 
through the cleavage of the N-terminal amino acids via angiotensin converting 
enzyme (ACE), first discovered in the 1950’s (Skeggs et al., 1956). ACE is an ecto-
peptidase attached to the luminal side of the endothelial membrane which as well as 
forming AngII also inactivates bradykinin (Erdos et al., 1999, Yang et al., 1970) The 
ACE gene is located on chromosome 17 and encodes for two different isoforms, the 
somatic and the germinal form (Soubrier et al., 1988, Rigat et al., 1992). The 
somatic form is expressed in endothelium, mainly in the lung but also in kidney, 
intestine, placenta and choroid plexus; while the germinal form is expressed mainly 
in testes. Both ACE isoforms are bound to the membrane and hydrolyze circulating 
peptides, such as AngI (Turner and Hooper, 2002, Guyton, 2007, (Erdos and 
Skidgel, 1987) (Figure 1-2).  
1.2.1 Angiotensin II 
AngII is the main active peptide of the RAS with a half life of 30 seconds in 
circulation and 15 to 30 minutes in tissue. Normal concentration in arterial blood of 
AngII has been described as 4.7 ± 1.2 pg/mL (Vilas-Boas et al., 2009). Once formed 
AngII acts in heart, blood vessels, brain, kidney, adrenal cortex and adipose tissue. 
There are two receptors known to mediate most of the effects of AngII. The 
angiotensin type 1 receptor (AT1R) and angiotensin type 2 receptor (AT2R) are 
seven transmembrane G-protein coupled receptors (GPCR) which interact with 
several G-proteins to activate cell signalling pathways causing vasoconstriction, 
central nervous system stimulation, cell proliferation, hypertrophy, inflammation, 
extracellular matrix remodelling and aldosterone release (Mehta and Griendling, 
2007).  
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Figure 1-1.  The juxtaglomerular complex of the kidney. 
The juxtaglomerular complex is situated outside the nephron’s glomerulus. It is composed of a group 
of specialized cells. The macula densa, which is a specialized epithelium sited in major density in the 
distal tubule of the nephron, is in close contact with the granular cells or juxtaglomerular cells 
(smooth muscle cells from the afferent and efferent arterioles before entering Bowman’s capsule) 
(Diagram taken from (Lopez-Franco, 2004)). 
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Figure 1-2.  The classical renin-angiotensin system. 
(A) Angiotensinogen (a 12 amino acid peptide) is released from the liver and cleaved by renin 
(released from the glanular cells of the juxtaglomerular complex) forming AngI. AngI is cleaved by 
ACE expressed on endothelial cells in the lung and is transformed into AngII. AngII is the main 
active peptide of the RAS and acts through binding to the AT1R or the AT2R. The AT1R is 
responsible for the vasoconstriction, pro-proliferation, pro-inflammation and extracellular matrix 
remodelling actions of AngII, while AT2R seems to mediate opposite actions to the AT1R. (B) 
Schematic of amino acids sequence of AngI and AngII. ACE cleaves the last two amino acids of AngI 
to transform it to AngII. 
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1.2.1.1  The angiotensin type 1 receptor 
The AT1R is a 40 kDa receptor that is distributed in most organs. It regulates the 
physiological and pathological actions of AngII and is responsible for the 
characteristic actions of AngII. Once AngII bind to the transmembrane domain of the 
AT1R, the receptor undergoes rapid desensitization and endocytosis (Griendling et 
al., 1987). Desensitization of the AT1R involves phosphorylation of the receptor by 
G-protein receptor kinases (Mehta and Griendling, 2007). Once desensitized, 
internalization of the AT1R occurs via clathrin-coated vesicles mediated by β-
arrestin (Gaborik et al., 2001). β-arrestins promotes activation of mitogen-activated 
protein kinases (MEK) and c-Jun terminal kinases (Kim et al., 1997). 
There is also evidence that the AT1R is internalized by caveolae (non-clathrin coated 
vesicles) (Ishizaka et al., 1998). These vesicles are associated with caveolin and are 
colocalized with signalling molecules such as Src (Rothberg et al., 1992). Caveolae 
are abundant in smooth muscle cells, fibroblasts and endothelial cells (Rothberg et 
al., 1992, Zuo et al., 2005, Peters et al., 1985). In smooth muscle cells caveolin-1 
seems to be important for the activation of Ras-related C3 botulinum toxin substrate 
1 (Rac-1) (Zuo et al., 2005).  Approximately 25% of these internalized receptors are 
recycled to the cell membrane for reactivation via agonist binding (Griendling et al., 
1987). To regulate AT1R internalization studies have described the presence of 
novel accessory proteins that bind to GPCR. Tsurumi et al. (2006) demonstrated that 
overexpression of the AT1R-associated protein (ATRAP) reduced expression of the 
AT1R in mouse cardiomyocytes by inhibiting cell surface expression (Tsurumi et 
al., 2006) while Guo et al. (2001) showed that ARAP1 (AT1R-associated protein 1) 
promoted recycling of the AT1R to the cell membrane following internalization 
(Guo et al., 2001).  
In recent years cell signalling through dimerization between membrane receptors has 
been identified (Lyngso et al., 2009). Homodimers of AT1R linked by the 
intracellular factor XIIIA transglutaminase have been reported (AbdAlla et al., 
2004). Homodimerization of the AT1R with the B2 bradykinin receptor and the 
AT2R and Mas receptor have also been shown to influence receptor activation 
(Canals et al., 2006, Castro et al., 2006, AbdAlla et al., 2005, AbdAlla et al., 2000, 
Chapter 1  
7 
Kostenis et al., 2005) and signalling responses. These influences depend upon each 
individual receptor subunit, e.g. AT1R heterodimerization with the B2 bradykinin 
receptor enhances AngII signalling in rat renal mesangial cells, while AT1R and Mas 
or AT2R homodimerization decreases AngII signalling (AbdAlla et al., 2005, Castro 
et al., 2005). Furthermore, AngII also acts by transactivating other receptors such as 
the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor 
(PDGFR) or insulin-like growth factor receptor (IGF-IR) (Saito and Berk, 2001). 
Transactivation of the EGFR by AngII leads to activation of the Ras-extracellular 
signal-regulated kinase (ERK) pathway (Yang et al., 2005, Ohtsu et al., 2008, 
Lautrette et al., 2005), stimulates Akt and p38 and results in an increase in c-fos 
expression (Suzuki et al., 2005) contributing to cell growth. PDGFR transactivation 
by AngII induces activation of phospholipase C (PLC), protein kinase C (PKC) and 
ERK in cardiomyocytes and smooth muscle cells (Kuma et al., 2007, Wang et al., 
2008). IGF-IR transactivation by AT1R activates Src and inositol triphosphate (IP3) 
kinases (Zahradka et al., 2004). In vivo experiments, however, show less clear 
effects of AngII transactivation of the IGF-IR as opposite effects of IGF-IR 
transactivation on vascular tone have been observed (Nguyen and White, 2005, Cao 
et al., 2006). 
1.2.1.2  The angiotensin type 2 receptor 
The AT2R is a 41 kDa 7 transmembrane receptor consisting of 363 amino acids 
(Mukoyama et al., 1993) and is located on the X chromosome (Mukoyama et al., 
1993)(Koike et al., 1995). Although AngII binds with a similar affinity to both the 
AT1R and the AT2R, nucleotide homology between them is only approximately 
32% (Mukoyama et al., 1993). Both receptors are ubiquitously abundant but 
distributed differently. The AT2R is more highly expressed in foetal tissues than the 
AT1R (Shanmugam et al., 1996)(Grady et al., 1991). Furthermore, expression of the 
AT2R decreases rapidly after birth, resulting in the AT1R having a higher density in 
tissues in adults (Shanmugam et al., 1996). Furthermore, the AT2R is induced in 
pathological conditions (Akishita, 1997, Nio et al., 1995), for example in humans it 
has been shown that AT2R is 3.5-fold upregulated in dilated cardiac myocytes in 
cardiomyopathy (Porrello et al., 2009b, Kim and Iwao, 2000, Mehta and Griendling, 
2007).  
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The AT2R is a 7 transmembrane GPCR, but unlike the AT1R, the AT2R has some 
unusual characteristics. For example, it is not internalized once bound to its ligand 
and it can demonstrate constitutive activation, as well as ligand-independent 
activation (Schluter and Wenzel, 2008, Funke-Kaiser et al., 2009) (Miura and 
Karnik, 2000). These non-classical characteristics support the concept that the AT2R 
can also act as a non-GPCR and has meant that the cellular pathways activated by 
the AT2R have been difficult to elucidate.  
There is evidence that the AT2R couples to differential signalling networks. For 
example, the AT2R couples to the Gαs-subunit in COS-7 cells (Feng et al., 2002), 
which reinforces the concept of AT2R being a non-classical GPCR through not 
coupling to the classical Gαq-subunits. A second interaction described is with the Src 
homology 2 domain containing phosphatase 1 (SHP-1). SHP-1 is a tyrosine 
phosphatase described to have a protective role in endothelial oxidative stress by 
inhibiting nicotinamide adenine dinucleotide phosphate (NAD(P)H) through 
blocking the regulatory subunit p38 of phosphoinositide 3 kinase (PI3K) and 
Rac1(Krotz et al., 2005). More recently some studies have shown an anti-apoptotic 
effect mediated by SHP-1 in vascular, mast and PC12W cells (Geraldes et al., 2009, 
Inoue et al., 2009, Cui et al., 2002). In accordance with this, antagonism of SHP-1 
with small interfering RNA targeting SHP-1, in an acute myocardial ischemia model 
in mice reduced infarct size and promoted angiogenesis (Sugano et al., 2005). AT2R 
interaction with SHP-1 occurs via activation of the Gαs-subunit (Cui et al., 2001, 
Zhang et al., 2008). Through AT2R stimulation, SHP-1 inhibits mitogen-activated 
protein (MAP) kinase activity in smooth muscle cells increasing apoptosis and 
proliferation. The AT2R has also been described to interact with the ubiquitin-
conjugating enzyme like protein MMS2 in neuronal cells (Mogi et al., 2007), a 
protein involved in the deoxyribonucleic acid (DNA) repair system (Broomfield et 
al., 1998). AT2R association with MMS2 has been demonstrated in neurones, where 
activation of the AT2R upregulates MMS2 expression leading to neuronal 
differentiation (Li et al., 2007).  
One class of proteins described to directly interact with the AT2R are the accessory 
proteins which bind to the carboxyl terminus of the AT2R and modulate receptor 
trafficking and signalling (Bockaert et al., 2004). The interaction of the AT2R with 
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these accessory proteins could explain the differential functions of the receptor. The 
AT2R interacting or binding protein (ATIP1) (Nouet et al., 2004), also called AT2R 
binding protein (ATBP50) (Wruck et al., 2005) or mitochondrial tumour suppressor 
gene (MTSG) (Seibold et al., 2003) has been shown to mediate trans-inactivation of 
tyrosine kinases when associated with the AT2R (Mogi et al., 2007). Overexpression 
of the AT2R has also been shown to inhibit ERK2 through interaction with the 
ATIP1 in CHO-AT2R transfected cells (Nouet et al., 2004). Also, AT2R stimulation 
translocates ATIP1 protein to the nucleus promoting neuronal differentiation (Funke-
Kaiser et al., 2009, Mogi et al., 2007). In two studies stimulation of the AT2R 
promotes the association and nuclear translocation of ATIP with SHP-1, leading to 
neuronal differentiation (Mogi et al., 2007). Promyelocytic zinc finger protein 
(PLZF) is a transcription factor expressed robustly in the heart and it has been shown 
that stimulating the AT2R with AngII promotes PLZF interaction with the AT2R in 
eukaryotic transfected cells (Senbonmatsu et al., 2003). Once bound, the 
AT2R/PLZF complex was internalized and translocated to the nucleus where PLZF 
crossed the nuclear membrane and increased the expression of the p85α-PI3K gene. 
Furthermore, upregulation of the p70(S6) kinase, whose role is important in protein 
synthesis, was also observed (Senbonmatsu et al., 2003).  
Like the AT1R, AT2R homodimers have also been reported (Miura et al., 2005, 
AbdAlla et al., 2001). Promotion of apoptosis in murine fibroblasts in the absence of 
AngII stimulation has been reported following homodimerization of the AT2R 
(Miura et al., 2005) while heterodimerization of the AT2R and the AT1R leads to 
inhibition of AT1R activation (AbdAlla et al., 2001). The bradykinin B2 receptor has 
been also reported to associate with the AT2R, leading to inhibition of fibrosis and 
promotion of vasodilatation through B2 receptor-mediated activation of endothelial 
nitric oxide synthase (eNOS) (Kurisu et al., 2003, Yayama and Okamoto, 2008, 
Munk et al., 2007, Abadir et al., 2006). A recently observed characteristic of the 
AT2R is that, unlike the AT1R, activation can be ligand-independent (Miura et al., 
2005). Several studies have shown that overexpression of AT2R in different cell 
types (e.g. neonatal cardiomyocytes, endothelial cells, and COS-1 cells) can induce 
apoptosis, growth and regulation of gene expression in the absence of ligand-
mediated activation (Porrello et al., 2009b, Mogi et al., 2007).  
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1.2.2  The cellular actions of AngII 
Most of AngII’s cellular responses are mediated by the AT1R, due predominantly to 
activation of the Gαq/11 protein subunit (de Gasparo et al., 1995, Wang et al., 1995). 
AngII, through Gαq/11, activates PLC which in turn forms IP3 and diacylglycerol 
(DAG) (Bai et al., 2004). These second messengers have direct effects on Ca
2+
  
handling in many cell types (Heineke and Molkentin, 2006, Liu et al., 2008). AngII-
mediated induction of IP3 and DAG has also been shown to activate PKC 
(Chintalgattu and Katwa, 2009, Qin et al., 2001, Liao et al., 1997). The effects of 
AngII on Ca
2+
 handling and PKC-δ activation have been reported to result in 
contraction in vascular smooth muscle cells or hypertrophy in cardiac myocytes 
(Liao et al., 1997, Liu et al., 2008). AngII also activates the Ras/Raf/MEK/ERK 
pathway in cardiac myocytes, vascular smooth muscle cells and fibroblasts via the 
AT1R, promoting hypertrophy, proliferation, cell migration and fibrosis (Aplin et al., 
2007, Liao et al., 1997, Min et al., 2005, Olson et al., 2008).  
Beside the ERK pathway, AngII also promotes the phosphorylation of stress-kinases 
like c-Jun kinases (JNK) and p38 in monocytes, macrophages and smooth muscle 
cells (Kim and Iwao, 2000), promoting expression of atrial natriuretic peptide, 
skeletal α-actin and transforming growth factor beta 1 (TGF-β1) and triggering 
inflammatory responses (Force et al., 1996). AT1R activation also leads to 
stimulation of cytosolic phospholipase A2 (cPLA2) and formation of arachidonic acid 
resulting in oxidation of NAD(P)H and vasoconstriction in vascular smooth muscle 
cells (Rao et al., 1994). Phospholipase D is also activated by AngII in vascular 
smooth muscle cells, generating choline and phosphatidylic acid. Phosphatidylic acid 
transforms into DAG which activates PKC which in turn phosphorylates several 
proteins associated with growth and contraction (Kim and Iwao, 2000)(Touyz and 
Schiffrin, 2000).  
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) 
pathway play important roles in the signalling of several cellular functions, for 
example, inhibiting proliferation, growth, haematopoiesis, and immune response 
(Berk and Corson, 1997, Hefti et al., 1997). Once JAK is activated, it induces 
dimerization of STAT proteins, and STAT then translocate to the nucleus to mediate 
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transcription of the early growth response genes (c-fos and c-myc) (Aaronson and 
Horvath, 2002). AngII induces activation of JAK through the AT1R in astrocytes 
supporting the concept that AngII mediates cell growth, migration and remodelling 
(Kandalam and Clark, 2009, Mehta and Griendling, 2007).  
AngII can lead to phosphorylation of several intracellular proteins by activating the 
c-Src tyrosine kinase in smooth muscle cells (Taniyama et al., 2003). This activation 
can also be mediated by the AT1R when coupled to the β G-protein subunit, 
resulting in activation of several pathways such as Ras, JAK/STAT, focal adhesion 
kinases (FAK) and PLC (Mehta and Griendling, 2007, Kodama et al., 1998). By 
regulating FAK activation AngII promotes cell adhesion to extracellular matrix and 
activation of cytoskeletal proteins to allow remodelling of cell shape and movement 
in cardiomyocytes (Mehta and Griendling, 2007, Kodama et al., 1998). 
Reactive oxygen species (ROS) are molecules produced as intermediates in the 
process of oxygen transformation to water (Harman, 1956). Physiologically these 
molecules act as important second messengers in cell signalling as they diffuse 
between membranes and act on downstream molecules to produce transient effects 
(Cakir and Ballinger, 2005, Sedeek et al., 2009). AngII stimulates ROS production 
by activating NAD(P)H oxidase, an enzyme involved in the production of ROS in 
many cell types, including vascular smooth muscle cells, endothelial cells and 
fibroblasts (Griendling et al., 1994, Pagano et al., 1998, Rajagopalan et al., 1996). 
The major targets of ROS are ion channels, matrix metalloproteinases, MAP kinases, 
tyrosine kinases and transcription factors such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), activator protein 1 (AP-1) and nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) leading to inflammatory, anti-oxidant and growth 
responses (Mehta and Griendling, 2007, Choudhary et al., 2008, Touyz, 2004).  
AngII can also regulates extracellular matrix remodelling by increasing synthesis of 
collagen and fibronectin, promoting the accumulation of proteoglycans and 
increasing expression of TGF-β via the AT1R in cardiac fibroblast (Ju and Dixon, 
1996, Huang et al., 2008, Tiede et al., 2003, Brilla et al., 1993, Schroder et al., 
2006). 
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1.3 The counter-regulatory RAS 
The counter-regulatory RAS has been identified through the concept of a local RAS 
which was based on two fundamental discoveries, first expression of all components 
of the RAS in specific tissues. For example in the heart renin and angiotensinogen 
have been shown to be expressed, although the levels are very low (Paul et al., 
1993). ACE has also been detected in the heart of rats and humans (Hirsch et al., 
1991)(Paul et al., 1993, Burrell et al., 2005). The presence of AngI and AngII in 
cardiomyocytes was demonstrated by van Kats et al. (1998), who by measuring 
plasma and tissue levels of infused radiolabeled angiotensin peptides they were able 
to show cardiac synthesis of both peptides (van Kats et al., 1998). Both the AT1R 
and the AT2R have also been shown to be expressed in cardiac cells (Booz and 
Baker, 1996). All these findings suggested that generation and consequently AngII-
mediated signalling could be initiated directly in individual tissues without the 
requirement for systemic, circulating RAS components. The second discovery was 
the identification of new components of the RAS expressed in specific tissues, 
predominantly the enzyme Angiotensin converting enzyme 2 (ACE 2). These 
findings resulted in the theory of a “local and tissue-specific” RAS. Since the 
recognition of this local tissue-specific RAS many studies have been described in 
order to elucidate the actions and mechanisms of their components and to attempt to 
segregate these actions from those mediated by circulating AngII produced via the 
classical pathway. This has led to the characterization of the physiological and 
pathophysiological action of the RAS in different organs. Local tissue-specific RAS 
has been described in the heart, blood vessels, kidney, adrenal gland, nervous 
system, reproductive system, skin, digestive system, lymphatic and adipose tissue 
and in foetal development. (Figure 1-3). 
1.3.1 Angiotensin Converting Enzyme 2 
ACE 2 is a zinc metalloproteinase that acts as a carboxypeptidase (Warner et al., 
2004). The gene maps to the X chromosome and has 42% homology with ACE in 
the catalytic site. ACE 2 is a membrane-bound enzyme expressed mainly in cardiac 
blood vessels and tubular epithelia of the kidney and testis (Tipnis et al., 2000). 
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The main action of ACE 2 is the cleavage of the COO-H terminal amino acid from 
AngI and AngII generating the new peptides angiotensin 1-9 (Ang1-9) (from AngI) 
and angiotensin 1-7 (Ang1-7) (from AngII) (Figure 1-3) (Chappel and Ferrario, 
2006, Donoghue et al., 2000, Trask et al., 2007, Vickers et al., 2002). ACE 2 also 
cleaves des-Arg(9)-bradykinin but not bradykinin and is not affected by ACE 
inhibitors (Donoghue et al., 2000). 
1.3.2 Angiotensin peptide metabolites 
1.3.2.1 Angiotensin III (2-8) 
Angiotensin III (AngIII) peptide is generated from the cleavage of the AngII N-
terminal amino acid by aminopeptidase A (Zini et al., 1996) (Figure 1-3). This 
peptide has been shown to signal through the AT1R, however, its affinity for the 
AT1R is 10 times lower than AngII (Pendleton et al., 1989). AngIII has been shown 
to have similar actions to AngII in the brain. Furthermore AngIII actions in the brain 
are similar to AngII actions, for example infusion of AngIII to rat’s brains stimulated 
release of vasopressin (Yamaguchi et al., 1979, Reaux et al., 2001, Hohle et al., 
1995), suggesting that AngIII is an active metabolite of the RAS in the brain. 
1.3.2.2 Angiotensin IV (3-8) 
Angiotensin IV (AngIV) is formed from the cleavage of AngIII at the N-terminus 
amino acid by aminopeptidase N and was considered originally an inactive peptide. 
However, it has been shown that this peptide binds with high affinity to the insulin-
regulated aminopeptidase (IRAP) (Swanson et al., 1992, Albiston et al., 2001) 
(Figure 1-3). The distribution of the IRAP receptor is tissue specific being mainly 
expressed in different areas of the brain (Chai et al., 2000), in the heart, adrenal 
cortex, kidney and vascular smooth muscle cells (de Gasparo et al., 2000). AngIV 
has been shown to have a role in the cognitive and sensory functions of the brain 
such as memory and locomotor behaviour (Wright et al., 1993, Braszko et al., 1988).  
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Figure 1-3 The tissue-specific renin-angiotensin system. 
(A) AngI and AngII are cleaved by ACE 2 to form Ang1-9 and Ang1-7, respectively. Ang1-9 is 
further cleaved by ACE to form Ang1-7. AngI can also be cleaved by cathepsin A (CpA) and 
carboxypeptidase A (Cx A) to form Ang1-9; or by prolyl endopeptidase (POP), neutral endopeptidase 
(NEP) and thimet oligopeptidase (TOP) to form Ang1-7. Ang1-7 is an active peptide that can 
antagonise AngII signalling whose effects are mediated by the Mas receptor. Ang1-7 is further 
cleaved by ACE to form the inactive peptide metabolite Ang1-5. AngII is also converted to AngIII 
through the cleavage of the N-terminus amino acid by Aminopeptidase A (Amp A). AngIII mediates 
actions through the AT1R. AngIII is further cleaved by Aminopeptidase N and transformed into 
AngIV. AngIV binds to the insulin-regulated aminopeptidase (IRAP). (B) Schematic of angiotensin 
peptides and cleavage sites. 
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1.3.2.3 Angiotensin 1-7 
Ang1-7 is one of the novel peptides of the local tissue-specific RAS and is the result 
of several pathways. Ang1-7 is a seven amino acid peptide first described to be 
generated in the endothelium (Santos et al., 1992). Ang1-7 is mainly formed by the 
cleavage of the terminal amino acid of AngII (phenylalanine) by ACE 2 (Garabelli et 
al., 2008). Alternatively AngI can be converted into Ang1-7, via either cleavage by 
ACE 2, to form Ang1-9 which is then hydrolyzed by ACE transforming it into 
Ang1-7, or by a direct conversion by the action of prolyl endopeptidase, neutral 
endopeptidase or thimet oligopeptidase (Welches et al., 1993, Keidar et al., 2007, 
Trask et al., 2007) (Figure 1-3). The half life of Ang1-7 in the circulation is 
approximately 10 seconds before it is cleaved by ACE to form the inactive 
metabolite Ang1-5 (Yamada et al., 1998, Chappell et al., 1998). In normal conditions 
the circulating levels of Ang1-7 are much lower than AngII (20.1 pg/mL and 47 
pg/mL, respectively) (Yamada et al., 1998, Vilas-Boas et al., 2009). Ang1-7 acts 
through engaging the orphan Mas proto-oncogene (Santos et al., 2003). The interest 
in Ang1-7 comes from the fact that it is able to antagonize many of the effects of 
AngII. Roks et al. demonstrated for the first time that in human blood vessels Ang1-
7 inhibited AngII-induced vasoconstriction (Roks et al., 1999). Ang1-7 has also been 
shown to mediate vasodilatation, antiproliferative, anti-inflammatory and 
cardioprotective effects.  
Ang1-7 was originally proposed to mediate its effects via the classical AngII 
receptors in peripheral arterioles (Kono et al., 1986). However, Santos et al. 
generated Mas-knockout mice and showed through a radioligand binding assay in rat 
kidneys a lack of Ang1-7 binding (Santos et al., 2003). In addition chinese hamster 
ovary (CHO) cells were transfected with Mas cDNA and fluorescent labelled Ang1-
7 was shown to bind to the receptor, confirming that Ang1-7 bound to this orphan G-
protein coupled receptor Mas (Santos et al., 2003). The gene encoding the Mas 
receptor has been mapped to the distal half of chromosome 6q and encodes for a 325 
amino acid protein (Alenina et al., 2008).  Its distribution is tissue-specific and it is 
expressed largely in the brain, but is also found in the testis, heart and kidney 
(Metzger et al., 1995). Several studies have been carried out to demonstrate that the 
effects of Ang1-7 are mediated via Mas (see later).  
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As described for the AT1R and the AT2R, the existence of crosstalk between Mas 
and other receptors has been shown (Castro et al., 2005, Kostenis et al., 2005, Soares 
de Moura et al., 2004). Castro et al. showed differences in perfusion pressure when 
stimulating Mas with Ang1-7 in the presence or absence of AT1R and AT2R 
antagonists, suggesting crosstalk between the three receptors (Castro et al., 2005). In 
Mas
-/- 
mice the changes in perfusion pressure were not seen. In CHO-K1 cells 
overexpression of Mas and AT1R demonstrated an interaction between the two 
receptors (Kostenis et al., 2005). In the presence of both receptors the initial AngII-
induced production of inositol phosphate and intracellular Ca
2+
 mobilization 
decreased approximately 50%, suggesting that Mas acted as an antagonist of the 
AT1R. However, it has also been suggested that Mas expression upregulates AT1R 
expression and activates PKC (Canals et al., 2006). Furthermore, an interaction 
between Mas and the bradykinin B2 receptor has also been shown as relaxation of 
mesenteric arteries in Mas
-/- 
mice is abolished both basally and when stimulated with 
bradykinin (Peiro et al., 2007). Soares de Moura et al. demonstrated that both Mas 
and the AT2R enhanced the vasodilator effect of the bradykinin B2 receptor (Soares 
de Moura et al., 2004). 
1.3.2.4 Angiotensin 1-9 
Ang1-9 is a 9 amino acid peptide that results from the metabolism of AngI by ACE 2 
as ACE 2 cleaves the terminal amino acid leucine of AngI and transforms it into 
Ang1-9 (Donoghue et al., 2000, Li et al., 2005c). Although ACE 2 is the main 
enzyme to form Ang1-9, it has also been reported that following incubation of AngI 
with human heart homogenates Ang1-9 was also formed through the enzymatic 
activity of carboxypeptidase A (Kokkonen et al., 1997). This was also confirmed in 
ACE
-/-
 and ACE 2
-/-
 null mice where Ang1-9 was the main product of AngI 
following its cleavage by carboxypeptidase A (Garabelli et al., 2008). These reports 
also show that formation of Ang1-9 from AngI is the main pathway in 
cardiomyocytes (Kokkonen et al., 1997, Garabelli et al., 2008). Furthermore 
Jackman et al. showed that the conversion of AngI to Ang1-9 can also occur through 
the action of cathepsin A in human heart extracts (Jackman et al., 2002). Once 
Ang1-9 is formed ACE cleaves the 2 last amino acids (phenylalanine and histidine) 
generating the active peptide Ang1-7 (Figure 1-3). Very little is known about Ang1-
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9. Ang1-9 has been described to be a competitive inhibitor of ACE because it is an 
ACE substrate (Snyder and Wintroub, 1986). Ang1-9 has also been shown to 
potentiate bradykinin B2 receptor activity, by enhancing the release of arachidonic 
acid in human atria and ventricles induced by a B2 agonist 3-fold (Erdos et al., 
2002). It also enhances intracellular Ca
2+
 concentration and nitric oxide (NO) 
synthesis triggered by exposure of endothelial cells to bradykinin by 5-fold (Erdos et 
al., 2002). Importantly, it was also shown that Ang1-9 was an active peptide and that 
it was a more potent in potentiating the effects of bradykinin than Ang1-7 (Erdos et 
al., 2002, Jackman et al., 2002). However, a direct receptor-mediated role for Ang1-
9 is unclear and the importance of Ang1-9 not well understood, notwithstanding the 
fact that it is an indirect pathway by which angiotensin I is transformed into Ang1-7.  
1.4 The role of AngII and the RAS in cardiovascular 
disease 
Cardiovascular diseases (CVD) are the number one cause of death in the world, with 
an estimated 17.5 million people dying of CVD in 2006 (30% of all deaths) (World-
Health-Organization, 2009). Coronary heart disease and stroke cause the highest 
mortality, accounting for the deaths of 7.6 million people and 5.7 million people 
worldwide, respectively. 
Through the years the RAS has been the main target for treatment of CVDs. Clinical 
trials blocking the RAS have shown reduction in target organ damage in the heart, 
blood vessels and kidney (Dahlof et al., 2002, Mancini et al., 1996, Jandeleit-Dahm 
et al., 2005). Drugs to block the RAS are classified into three basic groups. The first 
group is the β-blockers which inhibit renin release from the kidney and therefore 
AngII production. The second group is the ACE inhibitors. These drugs also block 
AngII generation via ACE cleavage; however, it is important to mention that these 
drugs do not block AngII formation. The third group is the angiotensin receptor 
blockers which block AngII engagement to the AT1R by binding to this receptor. 
AngII mediates effects on almost all cardiovascular cells, including cardiomyocytes, 
fibroblasts, smooth muscle cells, endothelial cells and macrophages often inducing 
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identical signalling pathways, but producing differential phenotypes depending on 
the cell type stimulated (Mehta and Griendling, 2007). For example, by inducing 
activation of the MEK pathway, AngII promotes hypertrophy in cardiomyocytes, 
proliferation and cell migration in smooth muscle cells and remodelling in 
fibroblasts (Mehta and Griendling, 2007). These differential actions are a major 
contributor to the development of many CVDs.  
1.4.1 Atherosclerosis 
Atherosclerosis is the most common underlying cause for many CVD, including 
coronary heart disease (CHD), stroke and thrombosis. The risk factors associated 
with atherosclerosis (hyperlipidemia, hypertension, obesity, smoking and high levels 
of cholesterol) are common in the populations of developed countries; in fact 
statistics show that 17 out of every 1000 people have atherosclerosis (Fauci, 2008, 
Tedgui and Mallat, 2006). 
The theory of atheroma plaque formation was proposed by Russell Ross in the 
1970´s (Ross and Glomset, 1976a, Ross and Glomset, 1976b), who described an 
initial endothelial lesion and as a consequence the adherence of platelets. This theory 
was further modified in 1993 when inflammatory factors in the plaque were 
discovered (Tedgui and Mallat, 2006). As a definition atherosclerosis is the 
inflammatory thickening of the artery, leading to diminished lumen size of the 
vessel. This thickening occurs due to a lesion in the wall of the arteries usually 
initially due to endothelial damage. The process of plaque development is then 
influenced by inflammatory factors such as cytokines produced by macrophages and 
leukocytes, smooth muscle cells, matrix, and lipids (cholesterol). These lesions 
initiate as fatty streaks and develop into larger lesions that eventually can lead to 
total occlusion of the vessel, blocking the blood supply, potentially triggering a 
myocardial infarction if the blockage is in a coronary artery or a stroke if in a 
cerebral vessel (Tedgui and Mallat, 2006, Robbins, 1998, Fauci, 2008). 
The later modified theory of atherosclerosis proposed it as a chronic inflammatory 
disease, whereby an initial injury to the endothelium, caused by several factors 
including hypertension, hyperglycaemia, toxins from smoking, infection, oxidative 
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(ox) low density lipoprotein (LDL) and infection (Robbins, 1998). This lesion causes 
dysfunction of the endothelium, characterized by higher permeability and cell 
division, and a higher adhesion of monocytes due to the expression of adhesion 
molecules such as intracellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1) (Libby, 1995). The lesion in the endothelium also 
triggers the accumulation of lipids to the subintimal layer forming a fatty streak 
(Robbins, 1998). Monocytes migrate to the intima and transform into macrophages 
where they ingest LDL and convert into foam cells (Ghosh et al., 2009). 
Concurrently, macrophages and T lymphocytes release inflammatory mediators such 
as interleukin-1-β (IL-1-β) and tumour necrosis factor alpha (TNF-α). These two 
proinflammatory factors promote the proliferation and migration of smooth muscle 
cells and also contribute to changes in the endothelium overlying the plaque 
(Bevilacqua et al., 1984). The changes mediated by IL-1-β and TNF-α also 
transform the anticoagulant surface of the endothelium to a prothrombotic state by 
reducing the production of tissue plasminogen activator and protein-S, and 
stimulating higher production of matrix metalloproteinases, endothelin-1, platelet 
activating factor, ICAM-1 and VCAM-1 (Isoda and Ohsuzu, 2006, Robbins, 1998, 
DeGraba, 2004, Ohsuzu, 2004, Tedgui and Mallat, 2006). The natural development 
of the plaque leads to erosion and rupture which triggers thrombosis and acute 
blockage. AngII induces increased production of ROS in the endothelium of the 
atheromatous wall leading to activation of apoptosis pathways and promotion of 
thrombosis (Dimmeler et al., 1997). In vascular smooth muscle cells, AngII induces 
expression of plasminogen-activator inhibitor type 1, inhibiting fribrinolysis and 
promoting thrombosis (Feener et al., 1995). 
The involvement of AngII in the pathogenesis of atherosclerosis is clear. AngII has 
been shown to be localized in the atheroma plaque (Schieffer et al., 2000) and AngII 
has also been shown to induce endothelial dysfunction, smooth muscle cell 
proliferation and migration, and activation of pro-inflammatory pathways (Mehta 
and Griendling, 2007). In endothelial cells the main action of AngII is related to the 
stimulation of oxidative stress (Watanabe et al., 2005). NO bioavailability is 
significantly impaired by the action of AngII (Imanishi et al., 2006) as it has been 
shown that AngII promotes the production of ROS by either increasing NAD(P)H 
oxidase activity or by uncoupling eNOS (Dimmeler et al., 1997)(Yan et al., 2003a, 
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Doughan et al., 2008). AngII also, promotes the uptake of oxLDL by the 
endothelium which leads to decreased production of NO (Li et al., 1999).  
In vascular smooth muscle cells AngII promotes migration and proliferation through 
the activation of the Akt and ERK1/2 pathway (Ohtsu et al., 2008, Bunkenburg et al., 
1992, Kyaw et al., 2004, Min et al., 2005, Yang et al., 2005). In similarity to 
endothelial cells, AngII induces ROS generation via activation of NAD(P)H oxidase 
but it has been suggested that ROS production from endothelial cells may act as 
second messengers to promote vascular smooth muscle cell hypertrophy or 
hyperplasia (Griendling et al., 1994).  
AngII also directly promotes inflammation during atheroma plaque formation 
(Ferrario and Strawn, 2006). Through the AT1R, AngII activates NF-κB (Ruiz-
Ortega et al., 2000b) the key pro-inflammatory transcription factor, leading to 
increased expression of E-selectin, monocyte chemoattractant protein (MCP-1), 
VCAM-1 and ICAM-1 in endothelial and smooth muscle cells, increasing leukocyte 
adhesion to the site of rupture in the atheromatous plaque (Moreno et al., 2009, Ruiz-
Ortega et al., 2000b). It has also been demonstrated that AngII mediates direct 
effects on the atherosclerotic plaque by increasing production of IL-6 (Kandalam and 
Clark, 2009)(Schuett et al., 2009, Rojas et al., 2009), IL-8 (Souza et al., 2009, 
Moreno et al., 2009) and IL-18 (Naka et al., 2008, Sahar et al., 2005, Doi et al., 
2008). IL-6 increases leukocyte adhesion to the vessel wall and promotes the release 
of pro-inflammatory cytokines as well as activating matrix metalloproteinanses. By 
increasing production of IL-8 and IL-18 in vascular smooth muscle cells, AngII 
induced chemotaxis of neutrophils and activation of PKC, and transcription factors 
NF-kB and AP-1 (Sahar et al., 2005, Moreno et al., 2009). 
Conversely, Kaschina et al. showed that stimulation of AT2R with the oral agonist 
compound 21 in post-myocardial infarction rats diminished the expression of the 
inflammatory factors monocyte chemoattractant protein-1, myeloperoxidase, and the 
inflammatory cytokines IL-6, IL-1β and IL-2 (Kaschina et al., 2008). Furthermore, 
reductions in scar size and improvement in systolic and diastolic function were also 
demonstrated. This evidence suggests that AngII, via activating the AT2R, also has 
anti-inflammatory actions. The AT2R has also been implicated as a positive 
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regulator of atherosclerotic lesion formation in apolipoprotein E knockout (ApoE
-/-
) 
mouse, where loss of the AT2R gene augmented atherosclerotic lesion development 
(Sales et al., 2005). Also, the AT2R has been reported to have a positive action in 
the adipose tissue of the atherosclerotic plaque, improving adipocyte function and 
differentiation (Iwai et al., 2009). Furthermore, the AT2R has also been shown to be 
expressed in human atherosclerotic plaques (Johansson et al., 2008). The role of 
ACE 2 in atherosclerosis has also been studied. In a rabbit atherosclerosis model, 
adenovirus-mediated overexpression of ACE 2 resulted in reduction of macrophage 
numbers, lipid deposits and collagen which led to higher plaque stability (Dong et 
al., 2008). Conversely, to date there have been no study on the role of Ang1-7 in 
atherosclerosis published. 
1.4.2 Stroke 
Stroke is the interruption of blood flow to the brain due to rupture of a blood vessel 
(hemorrhagic stroke) or vessel occlusion by a clot (ischaemic stoke), and can cause 
brain tissue damage and death. Ischemic stroke is the major cause of stroke and the 
primary risk factors are hypertension and hyperlipidemia. Symptoms of stroke 
depend on the area affected, usually with an acute presentation. The most common 
symptoms of a stroke are sudden weakness or numbness of the face, arm or leg, most 
often on one side of the body, difficulty to walk, loss of balance or coordination, 
dizziness, vomiting, difficulty to speak or understand speech, to see with one or both 
eyes, severe headache, confusion, fainting and unconsciousness  (Andreoli, 2001, 
Fauci, 2008). 
AngII has been shown to promote the pathogenesis of intracerebral haemorrhage via 
increasing levels of oxidative stress and matrix metalloproteinase 9 via the AT1R 
(Wakisaka et al., 2009). However, neuroprotection in stroke has also been reported 
as an action of the AT2R. The AT2R is upregulated in the peri-infarcted zone 2 days 
after an ischemic event (Li et al., 2005b). This expression seems to be distributed 
through the brain but limited at the cellular level to neurons in mouse models of 
ischemia, caused by cerebral artery occlusion (Li et al., 2005b). Deletion of the 
AT2R in murine models of stroke has been shown to increase the area of ischemia 
and decrease neuronal survival and neurite growth (Iwai et al., 2004, Li et al., 
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2005a)(McCarthy et al., 2009).  Furthermore, in AT2R knockout mice there is 
increased activity of NAD(P)H oxidase and increased superoxide production 
suggesting suppression of oxidative stress is an AT2R pathway in ischaemia 
protection (Iwai et al., 2004). In AT2R knockout mice cognitive function due to 
ischaemia is also impaired (Iwai et al., 2004, Mogi et al., 2007, McCarthy et al., 
2009). All these studies indicate a beneficial action of AT2R in protection of 
neuronal tissue in stroke and it may therefore be an important therapeutic target. 
1.4.3 Hypertension 
Hypertension has been identified as one of the most important risk factors for CVD 
(Robbins, 1998, Raizada and Der Sarkissian, 2006). The British Heart Foundation, in 
accordance with the European Hypertension Society and the World Health 
Organization-International Society of Hypertension, established the definition of 
hypertension in 2004: systolic blood pressure of 140 mmHg or higher; or diastolic 
blood pressure of 90 mmHg or higher. However, diagnosis of hypertension is 
complicated and several grades of high blood pressure have been defined to help 
guide intervention. Grade 1 or mild hypertension is defined as systolic blood 
pressure from 140 to 159 mmHg and diastolic blood pressure from 90 to 99 mmHg. 
Grade 2 or  moderate hypertension is defined as systolic blood pressure from 160 to 
179 mmHg and diastolic blood pressure from 100 to 109 mmHg, and grade 3 is 
severe systolic blood pressure above 180 mmHg and diastolic blood pressure above 
110 mmHg (Table 1) (Williams et al., 2004)(Mancia et al., 2007, World-Health-
Organization, 1999). According to the World Health Organization around 11% of all 
disease in developed countries is triggered by initial development of hypertension, 
including 50% of all CHD and 75% of all stroke events. Furthermore the 
INTERHEART study showed that around 22-25% of myocardial infarctions in 
Europe were due to hypertension and that history of hypertension doubled the risk of 
developing a myocardial infarction (World-Health-Organization, 2009, Yusuf et al., 
2004). British surveys of 2006 showed that around 30% of women and men over 16 
years of age had hypertension (Allender, 2008), while the American Heart 
Association statistics of 2006 showed that 30% of the adult population had high 
blood pressure (Lloyd-Jones et al., 2009). 
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In a very simplistic way the cause of hypertension can be divided into an increase in 
blood volume or an increase in peripheral resistance. In every contraction cycle the 
heart pumps 70 mLs of blood into the arterial system. This perfusion puts pressure 
on the arterial wall, so blood pressure is the result of the cardiac output multiplied by 
the peripheral resistance. Peripheral resistance is defined by the vessel’s radius, 
length and wall smoothness. The ejection of blood from the heart is periodic, 
meaning that the pressure in arteries is pulsatil; the highest pressure is detected when 
a bolus of blood is going through the artery and the lowest after it has passed. These 
different pressures are known as systolic (highest) and diastolic (lowest) blood 
pressure (Guyton, 2007). Blood pressure is controlled by several systems which are 
interconnected and grouped into two basic responses, 1) acute control of blood 
pressure or baroreceptor reflex and 2) long term control of blood pressure. 
Baroreceptors, chemoreceptors, ischaemia of the central nervous system and the 
release of hormones are the first response when blood pressure drops. These four 
mechanisms activate within seconds and remain activated, resulting in adaptation to 
the new blood pressure. Over time this results in a permanent resetting of sensitivity, 
leading to basal blood pressure elevation (Guyton, 2007, Rhoedes, 1997, Lifton et 
al., 2001). The arterial baroreceptor reflex arc consists of terminal axons of afferent 
fibers that are in the adventitia of the aortic arch, carotid sinuses which are part of 
the internal carotid arteries. 
Depolarization of such sensors happens when the wall vessel is stretched. Signals 
travel through the glosso-pharyngeal and vagus cranial nerves from carotid sinus and 
aortic arch baroreceptors respectively to the nucleus tractus solitarii (NTS), caudal 
ventrolateral medulla and rotral ventrolateral medulla. From this central nucleus 
efferent fibers are projected to the intermediolateral cell column where sympathetic 
preganglionic neurons project to organs such as heart and blood vessels. 
Baroreceptor stimulation results in vasodilatation of peripheral vessels and a 
decrease in heart rate and cardiac output. If the blood pressure drops, the firing rate 
of baroreceptors also drops causing vasoconstriction (Guyton, 2007). The adaptation 
of this reflex to new levels of blood pressure results in transient loss of sensitivity to 
the response. However if this reset is chronic (48 hours after high blood pressure) the 
baroreceptor reflex sensitivity is impaired (Moreira et al., 1992).  
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Category Systolic Blood Pressure 
(mmHg) 
Diastolic Blood Pressure 
(mmHg) 
Blood Pressure   
Optimal < 120 < 80 
Normal < 130 < 85 
High Normal 130 - 139 85 - 89 
Hypertension   
Grade 1 (mild) 140 – 159 90 – 99 
Grade 2 
(moderate) 
160 – 179 100 – 109 
Grade 3 (severe) ≥ 180 ≥ 110 
Isolated Systolic 
Hypertension 
  
Grade 1 140 - 159 < 90 
Grade 2 ≥ 160 < 90 
 
Table 1. Blood pressure classification. 
The classification of blood pressure according to systolic and diastolic blood pressure measurements. 
Measurements should be taken on three different occasions. Blood pressure is considered normal 
when blood pressure is between 120/80 and 139/89 mmHg. Blood pressure above 140/90 mmHg is 
considered hypertension, which depending on the systolic and diastolic blood pressure measurements 
can be divided into mild, moderate and severe. Table was been reproduced from Williams et al. 
(Williams et al., 2004). 
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Chemoreceptors in the wall of the aorta and carotid arteries sense the drop in levels 
of oxygen or augmentation in carbon dioxide levels and fire triggering sympathetic 
drive to motoneurons which constricts the vessel. A similar reaction is triggered 
when chemoreceptors in the medulla oblongata sense augmentation in carbon 
dioxide. In addition, when ischaemia is sensed in the brain stem, specifically in the 
NTS, by inadequate perfusion an intense activation of the sympathetic neurones 
takes place. This ischemic response leads to increased blood pressure to supra-
physiological levels to the extent of totally occluding peripheral vessels. This 
sympathetic nerve activity has been thought to mediate the development of essential 
hypertension (Grassi, 2004).  
The hormonal mechanisms controlling blood pressure include noradrenaline-
adrenaline, vasopressin, the RAS and natriuretic peptides. Noradrenaline-adrenaline 
is liberated by autonomic nervous system stimulation of the adrenal medulla, and 
enters the blood stream and causes peripheral vasoconstriction for around three 
minutes before being metabolized. By the same action of the sympathetic nervous 
system vasopressin is liberated from the posterior pituitary gland. Besides the 
antidiuretic and antinatriuretic effect, vasopressin also has a direct vasoconstrictor 
effect on arterial walls causing intense vasoconstriction. AngII has 6 basic functions: 
1) it triggers the release of aldosterone from the suprarenal cortex; 2) it increases the 
kidney’s reabsorption of sodium; 3) it mediates vasoconstriction; 4) induces an 
increase in water ingestion; 5) it increases activation of the sympathetic nervous 
system and; 6) it promotes vasopressin release. Over-activity of the RAS has been 
described as one of the most frequent cause of hypertension. Natriuretic peptides are 
hormones produced in the heart and secreted by myocytes in response to high 
cardiac filling pressures. There are three types: atrial natriuretic peptide (ANP) 
produced mainly in myocytes of the atria, brain natriuretic peptide (BNP) produced 
mainly in ventricular myocytes and C-type natriuretic peptide (CNP) produced in the 
brain. Once in the blood stream ANP and BNP cause natriuresis, diuresis and 
vasodilatation while inhibiting aldosterone synthesis and renin secretion. In the last 
decade it has been shown that ANP and BNP also have direct effects on 
cardiomyocyte growth (discussed later) (Rhoedes, 1997, Guyton, 2007)(Pocock, 
2004, Nishikimi et al., 2006).  
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The main action of AngII is in maintaining blood pressure by promoting 
vasoconstriction and releasing aldosterone, which leads to retention of sodium and 
water to maintain the blood volume (Wolf et al., 1999). Based on this, by definition 
AngII is a pro-hypertensive peptide and this pro-hypertensive action is mediated by 
the AT1R (Wolf et al., 2003). The literature that supports AngII as hypertensive 
peptide is vast. As examples, AngII has been shown to induce vasoconstrictive 
signalling via the AT1R by increasing formation of arachidonic acid and formation 
of the nitrite tyrosine residues forming 3-nitrotyrosine (3NT) (Wattanapitayakul et 
al., 2000). In hypertensive rat aortas, treatment with losartan (an AT1R blocker) 
abolished the AngII-induced vasoconstriction (Cosentino et al., 2005). By inducing 
the release of aldosterone from the adrenal glands, AngII increases the retention of 
sodium and excretion of potassium which leads to increases in blood volume 
(Guyton, 2007). Furthermore, in vascular smooth muscle cells it has been described 
that aldosterone promotes the formation of ROS and potentiates AngII-induced MAP 
kinase activation (Mazak et al., 2004). Also, the reduced blood pressure in AT1R 
knockout mice has been shown to be a direct effect of AngII signalling through the 
AT1R (Audoly et al., 2000). 
AngII has also been described to have a role in central nervous system blood 
pressure control. A decreased baroreceptor reflex sensitivity was shown when AngII 
is intravenously infused in rabbits (Guo and Abboud, 1984). Interestingly, AngII is 
unlikely to cross the blood barrier, which suggested production of AngII in the brain. 
Several studies have described the presence of high density AngII-containing 
neurones which express the AT1R in the NTS (Healy et al., 1989, Gutkind et al., 
1988, Paton and Kasparov, 1999). In addition to this and supporting the theory of 
local brain production of AngII, in the spontaneously hypertensive rat levels of 
AngII were described to be elevated only in the brain (Ferguson and Washburn, 
1998, Campbell et al., 1995, Morishita et al., 1995). Furthermore, Paton et al. 
showed an increase in NO levels in the NTS when locally infusing AngII, which was 
mediated through the AT1R, (Paton et al., 2001a). AngII-induced release of NO 
promoted gamma-aminobutyric acid (GABA) release from the NTS which led to 
depression of the baroreceptor reflex (Wang et al., 2006b). Moreover, blockade of 
eNOS in the NTS with an adenovirus expressing a dominant negative mutant form of 
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eNOS, abolished the AngII-induced baroreceptor reflex inhibition (Paton et al., 
2001b), showing a clear role of AngII in the neurogenic control of blood pressure.  
Recently it has been shown that an inflammatory process in the brainstem may 
participate in the development of essential hypertension (Waki et al., 2009, Waki et 
al., 2007). Inflammatory processes can obstruct blood flow resulting in localized 
hypoxia leading to activation of the central nervous system ischemic reflex. 
Consistent with this, Waki et al. demonstrated an up-regulation in junctional 
adhesion molecule-1 (JAM-1), glycoprotein-39 precursor (gp39), ICAM-1, VCAM-
1 and MCP-1 expression in NTS of spontaneously hypertensive rat (SHR) compared 
to Wistar Kioto (WKY) rats (Waki et al., 2007, Waki et al., 2008). AngII is a high 
pro-inflammatory molecule and it has been shown that blockade of AT1R in SHR 
reduces macrophage infiltration and ICAM-1 expression in the microvasculature of 
SHR brains when compared to control rats (Ando et al., 2004). Similar to what has 
been observed with AngII, infusion of AngIII into the supraoptic and the 
paraventricular nucleus stimulated release of vasopressin (Yamaguchi et al., 1979, 
Reaux et al., 2001, Hohle et al., 1995). In addition, inhibition of aminopeptidase A in 
mice brains blocked the AngII-induced vasopressin release (Reaux et al., 2000, Zini 
et al., 1996). Furthermore, in hypertensive animal models, AngIII has shown to 
induce a similar increase in blood pressure to AngII by increasing sympathetic nerve 
activity and inhibiting the baroreceptor reflex at the NTS level (Wright et al., 1989, 
Abhold et al., 1987). All these results suggest AngIII as a regulator of central blood 
pressure. 
One of the first recognized actions of AT2R stimulation was the regulation of 
vascular tone. Strong evidence in vivo has shown that AT2R heterodimerization with 
the B2 bradykinin receptor induce vasodilatation in hypertensive rodent models 
through the production of eNOS (Yayama and Okamoto, 2008). Similarly, this 
heterodimer has been shown to promote the formation of NO and cyclic guanosine 
monophosphate (cGMP) (Abadir et al., 2006). However, there is also evidence for 
AT2R activation directly triggering vasodilatation (Lemarie and Schiffrin, 2009). 
Ritter et al. showed increased production of eNOS in cardiomyocytes and aortic 
endothelial cells due to stimulation of AT2R with AngII (Ritter et al., 2003). ENOS 
activation was mediated by the calcineurin/nuclear factor of activated T-cells 
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(NFAT) pathway. Furthermore, stimulation of the AT2R in denuded rat aorta 
stimulated inducible nitric oxide synthase (iNOS) mediated vasodilatation (Lee et 
al., 2008). AT2R activation has also been shown to inhibit AT1R-induced membrane 
translocation of Ras homolog gene A (RhoA) and myosin light chain 
phosphorylation in smooth muscle cells, leading to vasodilatation in the stroke prone 
spontaneously hypertensive rat (Guilluy et al., 2008). Furthermore, it has been 
shown that inhibition of RhoA was due to AT2R-dependent activation of the SHP-1 
pathway and the serine/threonine kinase Ste20-related kinase (SLK) (Guilluy et al., 
2008). 
In the kidney AT2R activation also regulates pressor responses leading to induction 
of vasodilatation (Siragy, 2009). Studies with AT2R knockout mice have shown an 
increase in blood pressure as well as a decrease in NO, cGMP and bradykinin 
production. Overexpression of the AT2R in mice increased vasodilatation (Ichiki et 
al., 1995, Tsutsumi et al., 1999). A phenomenon that appeared to be related to 
blocking nitric oxide formation or B2 receptor activation (Siragy et al., 1999). Pro-
inflammatory effects in the kidney have also been allocated to AngIII. An increase in 
TGF-β and MCP-1 expression and fibronectin production was observed when 
mesangial cells were incubated with AngIII (Ruiz-Ortega et al., 1998). Furthermore, 
AngIII was also able to increase activation of NF-κB in mesangial cells (Ruiz-Ortega 
et al., 2000a).  
Due to the cleavage of AngII and the consequent generation of Ang1-7, ACE 2 was 
thought to participate in the regulation of blood pressure, but its actual role is 
controversial. In transgenic SHRSP overexpression of ACE 2 in vascular smooth 
muscle cells led to increased levels of Ang1-7 and a reduction in blood pressure, as 
well as attenuated AngII-mediated vasoconstriction (Rentzsch et al., 2008). It has 
also been reported that lentivirus-mediated overexpression of ACE 2 in the heart 
diminished blood pressure, cardiac hypertrophy (evaluated by body:heart weight and 
left ventricular wall thickness) and perivascular and interstitial fibrosis (Huentelman 
et al., 2005, Diez-Freire et al., 2006). 
Ang1-7 triggers vasodilatation by activating several pathways, the most studied is 
the NO production pathway. Benter et al. showed that co-treatment of SHR with N-
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(G)-nitro-L-arginine methyl ester (L-NAME) (a NO synthesis inhibitor) and Ang1-7 
prevented the development of severe hypertension and heart damage (Benter et al., 
2006). In addition, Zhi et al. compared the effect of Ang1-7 in different blood 
vessels and showed that Ang1-7 induced endothelium-dependent vasorelaxation 
mediated by the NO pathway (Zhi et al., 2004). Independently, Sampaio et al. 
demonstrated the role of Ang1-7 in regulating the phosphorylation of eNOS through 
increasing eNOS activation in human aortic endothelial cells when stimulated with 
Ang1-7 (Sampaio et al., 2007b). Furthermore, Heitsch et al. measured NO in Ang1-
7-stimulated bovine aortic endothelial cells and showed an increase in its release 
(Heitsch et al., 2001). These studies showed a direct effect of Ang1-7 over NO 
production. Other pathways that have been considered for Ang1-7-mediated 
vasodilatation are: the release of prostaglandins; an antagonistic role blocking the 
actions of AngII by acting as a competitor at the AT1R; or affecting bradykinin 
(Abbas et al., 1997, Keidar et al., 2007, Paula et al., 1999, Benter et al., 1995). Zhu 
et al.  showed that administration of Ang1-7 to rats significantly reduced baseline 
levels of PKC and ERK1/2 and the levels triggered by AngII stimulation (Zhu et al., 
2002). In aortic injury models, Tallant et al. demonstrated that Ang1-7 inhibited 
vascular smooth muscle cell growth by promoting the release of prostacyclin (PGI2) 
to augment cyclic adenosine monophosphate (cAMP) and activate protein kinases 
(Tallant and Clark, 2003). This reduction of activation was notable when the MEK 
were stimulated with AngII. In this same context Gallagher et al. showed the effects 
of Ang1-7 in lung cancer cells, proving it diminished growth and reduced activation 
of ERK1/2 in this cell line (Gallagher and Tallant, 2004). This has also been 
observed in rat kidney cells where Ang1-7 inhibits AngII-mediated activation of 
MEK (Su et al., 2006). 
The role of Mas signalling in the development on oxidative stress has also been 
confirmed by the use of knockout mice (Ferrario et al., 1998). These mice have 
impaired endothelial function and diminished production of NO due to decreased 
eNOS expression, leading to impaired vessel relaxation and increased blood pressure 
following Ang1-7 infusion (Dias-Peixoto et al., 2008, Peiro et al., 2007, Xu et al., 
2008). AngIV has also been shown to have an effect in blood vessels. In vascular 
endothelium AngIV induced NO production by increasing eNOS activity leading to 
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vessel dilatation; however AngIV signalling through the IRAP was not tested (Cheng 
et al., 1994, Li et al., 1997, Kramar et al., 1998). 
1.4.4 Cardiac dysfunction and heart failure 
Heart failure (HF) is defined as the inability of the heart to pump adequate amounts 
of blood to meet the requirements for tissue metabolism due to an abnormality in 
cardiac function. Many disorders result in HF, hypertension being one of the most 
common. There are several forms of HF for example, it can be systolic or diastolic, 
of high output or low output, left or right sided and finally chronic or acute. When 
HF is systolic the heart does not contract strongly enough which diminishes the 
ejection fraction due to an inadequate ventricular emptying leading to cardiac 
dilatation and high ventricular diastolic pressure. In diastolic HF there is an 
abnormal relaxation of the myocardium; this can be due to transitory ischaemia or 
thickening of the myocardial wall. Even though hypertrophic cardiomyopathy results 
in diastolic HF, it can also be present in the systolic form. HF is classified as high 
output when there are elevated metabolic demands and the heart is unable to achieve 
them; while a low output heart failure the heart is unable to meet metabolic demand 
at rest or at times of high metabolic demand. Left or right HF depends on whether 
the right or the left side of the heart is affected (Andreoli, 2001, Fauci, 2008).  
Signs and symptoms that accompany HF are dyspnoea which is worsened in a 
recumbent position and after several hours of sleep (paroxysmal nocturnal 
dyspnoea), fatigue due to diminished blood flow to muscles, peripheral oedema 
which worsens during the day, distended neck veins and congested liver. At 
auscultation increased heart rate can be detected, crackles in the lung field can be 
heard; also a third heart sound or gallop can be detected. Electrocardiograms show 
no specific signs and a chest radiograph usually shows enlargement of the heart and 
signs of pulmonary oedema (Fauci, 2008, Andreoli, 2001). 
HF is also characterized intracellularly by re-expression of foetal gene program, 
cardiomyocyte hypertrophy and fibrosis, and activation of apoptotic pathways (Lips 
et al., 2003). Deleterious effects in cardiomyocytes and fibroblasts mediated by 
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AngII in HF are similar to those described during the development of cardiac 
hypertrophy (see later).  
There are very few studies investigating the effects if the AT2R during HF, although 
AT2R stimulation has been shown to inhibit inotropy (Masaki et al., 1998, Castro-
Chaves et al., 2008, Nakayama et al., 2005). These results may suggest that AT2R 
has a protective role in HF, although as yet there is no direct evidence. 
Ang1-7 is produced in the heart via either AngI or from AngII (Zisman et al., 2003, 
Wei et al., 2002). Several authors have described Ang1-7 as a regulator of the 
cardiac conduction system (Ferreira et al., 2001, De Mello et al., 2007, Castro-
Chaves et al., 2009, Stewart et al., 2009). It has been described that in induced 
ischaemia in rat hearts Ang1-7 reduces the incidence of arrhythmias after reperfusion 
compared to AngII perfused hearts (Ferreira et al., 2001), as well as inducing 
vasodilatation in postural tachycardia syndrome (Stewart et al., 2009). De Mello et 
al. showed that in cardiomyocytes exposed to Ang1-7 the cardiac action potential 
was reduced and there was an increase in conduction velocity due to the activation of 
the sodium pump, assigning Ang1-7 antiarrhythmic properties (De Mello et al., 
2007). Interestingly, when cardiomyocytes were treated with higher doses of Ang1-7 
the action potential was not only not decreased, but augmented as well as the early-
after depolarisations leading to promotion of arrhythmias. In rabbit papillary muscle 
Ang1-7 has been shown to reduce muscle contraction (Castro-Chaves et al., 2009). 
Relaxation was related to the integrity of endocardial endothelium, suggesting that 
Ang1-7 has negative inotropic effects mediated through endothelium. However, the 
effects of Ang1-7 were completely abolished when cardiac papillary muscle was 
incubated with the Mas antagonist A779.  
1.4.5 Cardiac Hypertrophy 
Hypertrophy is defined as “the enlargement or overgrowth of an organ due to an 
increase in size of its constituent cells”(Dorn et al., 2003).  By definition cardiac 
hypertrophy is an increase in size of the walls or interventricular septum of the heart 
(Carreno et al., 2006). The heart has the ability to increase its productivity when 
there is an increase on physiological demands by augmenting the capacity of single 
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cardiomyocytes. This increase in heart size is termed physiological hypertrophy, as it 
is an initial compensatory response to stress and examples of these are cardiac 
growth in athletes or pregnancy (Chien, 1999, Carreno et al., 2006). However, if the 
stress signal continues compensatory hypertrophy switches to pathological 
hypertrophy with implications for cardiac function. Cardiac hypertrophy is one of 
the main risk factors for ischaemic heart disease, arrhythmias, HF and sudden death 
(Komuro, 2001, Frey and Olson, 2003). The mechanisms by which physiological 
and pathological hypertrophy differentiate are still unclear. Pathological hypertrophy 
is accompanied by fibrosis, abnormalities in contraction and electrophysiology, 
changes in energy consumption and altered gene expression profiles (Wang, 2001). 
Based on phenotype, pathological cardiac hypertrophy can be classified into two 
types: concentric or eccentric. Concentric hypertrophy is the result of an increase in 
the thickness of the heart walls (predominantly the left ventricular wall) and has been 
associated with chronic pressure overload. Eccentric hypertrophy is defined as the 
thinning of the heart wall and consequent dilatation of the heart cavities, usually due 
to volume overload (Dorn et al., 2003, Carreno et al., 2006, Chien, 1999) (Figure 1-
4). At a cellular level hypertrophy of the cardiomyocyte is established by four major 
characteristics, increases in cell size and protein synthesis, reorganization of 
sarcomeric units and re-entrance to the foetal gene programme (Chien, 1999, 
Carreno et al., 2006, Rajabi et al., 2007). Increases in cell size (by measuring cell 
area or volume) and reorganization of sarcomeres at the cellular level differentiates 
concentric and eccentric hypertrophy. Concentric hypertrophy induces an increase in 
cell width through addition of sarcomeres in parallel, whereas eccentric hypertrophy 
adds sarcomeres in series resulting in an increase in cell length (Satoh et al., 1996, 
Hwang et al., 2006, Frey et al., 2004).  
Although studies have demonstrated mitotic activity in cardiomyocytes (Beltrami et 
al., 2001, Datwyler et al., 2003, Engel et al., 2005, Novoyatleva et al., 2009), 
generally cardiomyocytes are considered non-dividing cells. When stress signals are 
applied to cardiomyocytes the normal mitotic pathway is not activated, instead a 
pattern of foetal metabolism, resulting in expression of molecular hypertrophy 
markers occurs. Hypertrophy results from the binding of different kinds of stimuli 
(such as AngII, endothelin-1 or growth factors) to specific receptors in 
cardiomyocytes which triggers signalling pathways that activate or inhibit gene 
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expression. Such genes include atrial natriuretic factor (ANF) or ANP, BNP, β 
isoforms of myosin heavy chain (β-MHC), skeletal α-actin, fos, c-jun, myc and junB. 
The hypertrophy-inducing factors in cardiomyocytes can be broadly divided into two 
groups, mechanical stretch and neurohumoral factors, although the actual mechanism 
of how cardiomyocytes transform mechanical stimuli to a hypertrophic response is 
still unclear. There are several studies that show the involvement of ion channels in 
the response of cardiomyocytes to stretch, especially the transient receptor potential 
channel (TRPC) family (Sharif-Naeini et al., 2009, Stiber et al., 2009).  
These mechanoreceptors are activated directly by tension and then may interact with 
G-protein coupled receptors such as the AT1R (Yamazaki and Yazaki, 1999, 
Nishimura et al., 2008). It has been described that coactivation of the AT1R and 
TRPC can be AngII-independent (Zuo et al., 2005, Onohara et al., 2006). Signalling 
through these receptors is thought to be via the interaction with the cytoskeleton. 
Cytoskeletal re-arrangement transforms and activates signalling proteins, such as 
calcineurin, which then activate developmental cell signalling pathways (Bush et al., 
2006, Kuwahara et al., 2006, Zobel et al., 2007). Mechanical stretch of 
cardiomyocytes has also been demonstrated to release preformed AngII from 
cytosolic granules (Cingolani et al., 2005). 
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Figure 1-4.  Type of cardiac hypertrophy. 
Schematic showing the different types of hypertrophy that can develop in cardiomyocytes. The 
proportionate increase of cell width and length lead to physiological hypertrophy. Increases in width 
only result in concentric hypertrophy, while increases in length result in eccentric hypertrophy. Both 
concentric and eccentric hypertrophy are developed as a result of pathological stimuli and lead to re- 
expression of the foetal gene program. [Diagram modified from (Hunter and Chien, 1999) Copyright 
© [1999] Massachusetts Medical Society. All rights reserved]. 
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 Neurohumoral factor-mediated stimulation of cardiomyocyte hypertrophy is 
complex and includes molecules acting in an endocrine, paracrine and/or autocrine 
manner leading to activation of different pathways. Growth factors including TGF-β, 
fibroblast growth factor (FGF) and insulin-like growth factor (IGF) have been 
studied in cardiac hypertrophy (Molkentin and Dorn, 2001). IGF is a single chain 
peptide that induces cell proliferation or differentiation through binding to the 
tyrosine kinase transmembrane receptor IGFR (Ren et al., 1999). IGF induces 
hypertrophy in skeletal muscle by increasing myotubule diameter through 
phosphorylation and activation of Akt (Morissette et al., 2009). In myocardium IGF 
increases transcription of myocyte enhancer factor 2C (MEF-2C) [a key transcription 
factor that stimulates activation of genes that promote cardiac hypertrophy (Xu et al., 
2006)], including ANP, BNP and skeletal alpha-actin genes (Munoz et al., 2009, Chu 
et al., 2008). TGF-β1 is a polypeptide that regulates cell growth, proliferation and 
differentiation by binding to the transmembrane receptors TGFβIR and TGFβIIR 
(Moustakas et al., 2002, ten Dijke and Arthur, 2007). TGF-β1 is present throughout 
development of the heart and also promotes cardiac differentiation of embryonic 
stem cells (Gwak et al., 2009, Lim et al., 2007). TGF-β1 has also been implicated in 
cardiac fibrosis and hypertrophy in the heart (Khan and Sheppard, 2006). TGF-β1 
interaction with its receptors leads to phosphorylation of the conserved transcription 
factor family Smad (Schiller et al., 2004). In the heart Smad2 predominantly 
mediates TGF-β1 actions (Pokharel et al., 2002) and Smad proteins then bind to 
specific nucleotides sequences in the regulatory regions of genes essential for matrix 
remodelling, such as collagen and gelatinase A and B (Greene et al., 2003, Tsuchida 
et al., 2003). TGF-β1 expression is increased in the scar tissue in rats which have 
undergone myocardial infarction suggesting that TGF-β1 regulates scar remodelling 
via matrix deposition (Hao et al., 1999, Ellmers et al., 2008). Expression of TGF-β1 
in myocardial infarction is of special importance as it has also been associated with 
decompensated hypertrophy and HF (Li et al., 2009b). There is also evidence of a 
crosstalk between TGF-β1 and AngII signalling in the heart. Several studies have 
shown that AngII regulates messenger ribonucleic acid (mRNA) expression of TGF-
β1 in cardiac and vascular tissue (Kupfahl et al., 2000), and furthermore secretion of 
TGF-β1 from cardiofibroblasts mediates AngII-induced hypertrophy in 
cardiomyocytes (Gray et al., 1998).  
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Cytokines also form part of the neurohumoral signalling network. Although 
cytokines have been strongly related to the development of the atherosclerotic 
plaque, there is also evidence of a direct effect of cytokines [especially those from 
the IL-6 family including cardiotropin 1 (CT-1)] in cardiac hypertrophy. CT-1 
activates the IL-6 receptor and in conjunction with the glycoprotein 130 (gp130) is a 
potent prohypertrophic agent through increasing cell length and expression of 
hypertrophy markers (Wang, 2001)(Calabro et al., 2009). Fredj et al. demonstrated 
that IL-6 also increased the expression of ANP and β-MHC in co-cultures of murine 
cardiomyocytes and cardiofibroblasts (Fredj et al., 2005). Other cytokines involved 
in cardiac hypertrophy are IL-1 and TNF-α. (for more detail see section 1.4.5.1).  
The final remaining group of hypertrophic stimuli include agonists which bind to 
GPCR. Among these the most studied are arg-vasopressin, endothelin-1, 
norepinephrine and AngII. GPCRs are one of the largest family of receptors. These 
are 7-transmembrane-spanning receptors which bind to G-proteins interconnected to 
intracellular signalling pathways. G-proteins are localized on the inner side of the 
cell membrane and are responsible for signal transduction. They are present in an 
inactive form consisting of 3 subunits, α [bound to guanosine diphosphate (GDP)], β 
and γ (Marinissen and Gutkind, 2001). G-proteins are freely scattered in the cell 
membrane, enabling them to interact with several receptors. Once an agonist is 
bound to the transmembrane receptor it induces a conformational change in the 
receptor enabling it to bind the αβγ complex. When the protein complex attaches to 
the receptor the GDP bound to the α-subunit is exchanged for guanosine triphosphate 
(GTP). This change causes a disassociation of the α-GTP from the βγ-subunits and 
the release of two new active complexes. The G-protein returns to its inactive form 
through interchanging GTP for GDP in the α-subunit and re-forming the αβγ 
complex. (Rang, 2007, Kroeze et al., 2003, Fredholm et al., 2007) (Figure 1-5). As 
one GPCR can activate several G-protein complexes, the specificity of the signal is 
given by the molecular variation of the α-subunit. In the heart there are 4 main 
classes of α-subunits, Gαs, Gαi, Gαq/11 and Gα12/13 (Fredholm et al., 2007). These 
variants show specificity in the receptors they bind and the pathways they activate.  
Although, many of the signalling pathways that individual G-protein subunits are 
coupled to have been identified, many are still not well understood, particularly in 
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cardiomyocyte hypertrophy. For example, some studies of the Gαi-subunit have 
shown that it inhibits adenylyl cyclase, and consequently cAMP decreases, resulting 
in impaired Ca
2+
 handling leading to hypertrophy and alterations in cardiac rhythm 
(McCloskey et al., 2008, Ruan et al., 2007). However, activation of the Gαi-subunit 
stimulates Akt and inhibits cardiomyocyte hypertrophy (Moore et al., 2007). 
Furthermore, Gαs has been proposed to activate adenylyl cyclase, while Gαi inhibits 
it, activating potassium channels and cGMP phosphodiesterases (Rang, 2007). 
Gα12/13 regulates the Na
+
/H
+
 exchanger, and Gαq/11 activates PLC β and increases IP3 
and DAG (Jalili et al., 1999b, Rang, 2007).  
1.4.5.1 Cell signalling in Hypertrophy 
To stimulate hypertrophy AngII acts mainly through the Gαq/11-subunit (Sadoshima 
and Izumo, 1993, Bai et al., 2004). The initial response of a G-protein coupled 
receptor to activation by an agonist is a transient increase in cytoplasmic Ca
2+
 
(Thomas et al., 1996, Emkey and Rankl, 2009) which leads to downstream 
signalling effects through specific pathways and molecules. 
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Figure 1-5. G-protein coupled receptor activation.  
(1-2) Binding of an agonist to a G-protein coupled receptor results in conformational changes that 
bind the receptor to the G-protein subunits α, β and/or γ. (3-4) Once a G-protein is bound to the 
receptor the α-subunit interchanges GDP for GTP, (5) this causes disassociation of the α-subunit. (6) 
G-proteins are inactivated via the interchange of GTP for GDP in the α-subunit and reassociation with 
subunits β and γ. Imaged modified from:  
http://www.scientificblogging.com/adaptive_complexity/blog/surprise_gprotein_coupled_receptor_af
icionado 
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The PLC/PKC Pathway 
Cardiomyocyte hypertrophy induced via Gαq is classically through activation of the 
PLC pathway (Figure 1-6). PLC is a membrane bound enzyme that cleaves the cell 
membrane component phosphatidylinositol bisphosphate (PIP2) (Jalili et al., 1999a). 
This phospholipid is then split into IP3 and DAG second messengers. IP3 is water 
soluble and is released to the cytosol where it act as a second messenger and binds to 
its receptor present in the endoplasmic reticulum and sarcoplasmic reticulum, 
opening Ca
2+
 channels and increasing cytoplasmic Ca
2+
 (Putney et al., 1986, Taylor 
et al., 2009). The increase in cytoplasmic Ca
2+ 
promotes migration of PKC from the 
cytoplasm to the cell membrane by binding to the C2 domain of PKC (Disatnik et 
al., 1994). Once in the membrane DAG binds to the C1 domain of PKC and 
activates the enzyme (Jalili et al., 1999a, Kim and Iwao, 2000, Rang, 2007). There 
are several isoforms of PKC and they are grouped into three categories: the classical 
PKC are activated by Ca
2+
 and DAG, novel PKC require DAG but not Ca
2+
 to be 
activated and the atypical PKC which are independent of both DAG and Ca
2+ 
(Palaniyandi et al., 2009). 
Not all PKC isoforms are translocated to the membrane as this process depends on 
the isoform of the Receptor for Activated C-Kinase (RACK) PKC binds. RACKs are 
specific for each PKC subtype and help determine their compartmentalization, so 
while PKCα, βII and δ are translocated from the cytosol to the membrane, PKCє 
translocates from the nucleus to myofibrils (Jalili et al., 1999b). This family of 
enzymes is implicated in regulating transcription factor activity, activating immune 
responses as well as cell growth, among other functions (Churchill et al., 2008, 
Malhotra et al., 2001). In cardiomyocyte hypertrophy it has been demonstrated that 
PKC isoforms cause an increase in the transcription factors c-jun and fos as well as 
activating MEK pathways through activation of Raf (Liao et al., 1997, Mehta and 
Griendling, 2007)(Dostal et al., 1997). Recently it has also been observed that the 
distribution of PKC isoforms is different, for example the Ca
2+
-dependent isoforms 
(α, βI and βII) are mainly found in the ventricle while PKC δ and δ are found mainly 
in the atria. However, different isoforms are also activated through different stimuli 
and induce different features of hypertrophy (Churchill et al., 2008). Furthermore, 
studies have shown that PKCα increases α-actin mRNA levels and ANP secretion 
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(Church et al., 1994); conversely other studies have shown that PKC ε activation 
leads to increased levels of β-MHC and skeletal α-actin while no induction of ANP 
was observed (Takeishi et al., 2000). Although its role is not completely understood 
it is clear that PKC activity is integrally linked to the development of cardiac 
hypertrophy. 
The MAPK pathway 
As well as G-protein coupled receptors, an alternative class of small G-proteins exist 
which reside in the cytosol and act independently of agonist-mediated receptor 
activation. The Ras superfamily represents this group and their activation by AngII 
leads to phosphorylation of the MAPK pathway. This pathway has four branches of 
downstream activation: ERK 1 and 2, JNKs, p38 and ERK 5 (Figure 1-7) (Molkentin 
and Dorn, 2001).  
The ERK1/2 branch initiates with the translocation of Raf1 to the cell membrane 
which is promoted by Ras, and is related to activation of Gαq (Molkentin and Dorn, 
2001). Also there is evidence of Raf1 activation through PKC (Liao et al., 
1997)(Liebmann, 2001). Raf phosphorylates MEK1/2 and activates ERK1/2 by dual 
phosphorylation of the threonine and tyrosine residues (Thr183 and Tyr185) 
(Muslin, 2005, Rang, 2007, Lorenz et al., 2009a). It has been shown that this dual 
phosphorylation of ERK1/2 is essential for its activation (Muslin, 2005). ERK1/2 
then, phosphorylates different substrates in the cytoplasm and nucleus including the 
transcription factors GATA binding protein 4 (GATA-4) and Elk-1 which are 
integrally involved in cardiac hypertrophy (Pikkarainen et al., 2004, Aplin et al., 
2007). GATA-4 has been shown to bind to motifs in promoter regions of 
hypertrophic genes such as α-MHC, ANP, BNP and myosin light chain-3 (Grepin et 
al., 1994, McGrew et al., 1996, Thuerauf et al., 1994), whereas Elk-1 activates 
transcription of the early gene c-fos (Babu et al., 2000).  
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Figure 1-6. Intracellular PLC/PKC and calcium cell signalling pathways in cardiac 
hypertrophy  
Schematic showing the PLC/PKC intracellular signalling pathway that leads to cardiomyocyte 
hypertrophy. AngII binds to the AT1-GPCR which leads to activation of PLC. PLC promotes 
membrane translocation of PKC. Also PLC increases intracellular Ca
2+
 levels activating 
calmodulin/calcineurin/NFAT signalling pathway (taken from Heineke, J and Molkentin, J. Molecular 
Cell Biology. 2006). 
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ERK1/2 stays in the cytoplasm by interacting with G-protein coupled receptor-β-
arrestin complexes (Aplin et al., 2007). Interestingly Alpin et al. showed that when 
ERK1/2 is activated by this pathway and retained in the cytoplasm, it does not 
phosphorylate any of the transcription factors already described (Elk-1, c-fos), and 
does not cause cardiomyocyte hypertrophy, showing a differential phenotype 
between activation of ERK1/2 by the Gαq-subunit and the receptor-β-arrestin 
complex (Aplin et al., 2007). The mechanisms that target ERK1/2 to the nucleus are 
unclear. Recently, Lorenz et al showed a direct interaction of ERK1/2 with the Gβγ-
subunit, which led to an autophosphorylation of ERK1/2 in the threonine residue 188 
(Thr188) (Lorenz et al., 2009a). This led to translocation of ERK1/2 to the nucleus 
and promotion of cardiac hypertrophy. Importantly, in order for the Gβγ-subunit to 
interact with ERK1/2, the complex Raf/MEK/ERK1/2 has to be formed. 
JNK are kinases that phosphorylate c-Jun. The initiation of the pathway for JNK is 
less characterised. Ras phosphorylates mitogen-activated protein kinase kinase 
kinase (MEKK) which in turn MEK, in this case MEK 4/7 (Molkentin and Dorn, 
2001). MEK 4 /7 then activates JNK at a dual motif formed by threonine, proline and 
tyrosine amino acids (Ito et al., 1999). Of the 3 isoforms of JNK, JNK3 is expressed 
mainly in brain while JNK1 and 2 are expressed ubiquitously, including in the heart 
(Ito et al., 1999, Molkentin and Dorn, 2001, Liang and Molkentin, 2003). Activated 
JNK phosphorylates AP-1 which is stimulated by c-Jun and c-fos proteins (Liang 
and Molkentin, 2003) and AP-1 increases transcription of genes, for example ANP, 
skeletal α-actin and TGF-β1 (Kim and Iwao, 2000). Conversely, JNK also has an 
antihypertrophic effect by inhibiting NFAT, demonstrating an overlapping effect of 
this kinase (Liang and Molkentin, 2003). This illustrates the complexity of JNK 
signalling as it is part of 2 counter-regulatory signalling pathways. 
P38 is a stress-stimulated kinase activated through MEKK (Molkentin and Dorn, 
2001). Activated MEK 3/6 phosphorylates p38 in the motif formed by threonine-
glycine-tyrosine (Park et al., 2001, Tanno et al., 2003) leading to its activation. 
There are four isoforms of this kinase, α, β, γ and δ, but p38α is the most abundant 
isoform in heart tissue (Gum et al., 1998, Wilson et al., 1996). Once activated, p38 
regulates several transcription factors including MEF2, MAPK2 and 3, Elk-1, among 
others (Molkentin and Dorn, 2001, Muslin, 2008). Although p38 is a stress-
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stimulated kinase, it has been demonstrated that AngII increases p38 
phosphorylation in neonatal rat ventricular cardiomyocytes (Li et al., 2009a) and 
transgenic hypertensive mice (Pellieux et al., 2000).  
Calcium mediated pathways 
The Ca
2+
/calmodulin/calcineurin/NFAT pathways have also been implicated in 
cardiac hypertrophy (Figure 1-6). Calcineurin is a serine/threonine protein-
phosphatase consisting of a catalytic subunit of 59 to 61 kDa (CnA) and a regulatory 
subunit of 19 kDa (CnB) (Klee et al., 1998). Calcineurin becomes activated when 
the Ca2
+
-binding adaptor protein calmodulin, saturated with Ca
2+
, binds to it 
(Heineke and Molkentin, 2006). Calcineurin, then, binds directly to the transcription 
factor NFAT in the cytoplasm and promotes its translocation to the nucleus, where it 
regulates expression of hypertrophy-related genes such as GATA-4, MEF-2, ANP 
and BNP (Diez et al., 2001, Heineke and Molkentin, 2006, Liu et al., 2008).  
1.4.5.2 Regulation of hypertrophy-associated cell signalling 
pathways by the RAS 
Within the development of cardiac hypertrophy the role of individual RAS 
components in cell signalling pathways in the heart have been studied. ACE 2 
knockout mice developed severe cardiac dysfunction characterized by decreased 
myocardial contractility, but however with no signs of cardiac hypertrophy or 
fibrosis (Crackower et al., 2002). However, in an independent study in ACE 2 
knockout mice no effect on cardiac function or size was observed (Gurley et al., 
2006). In myocardial infarction the loss of ACE 2 promotes fibroblast proliferation 
by activating ERK1/2 and JNK1/2, as well as inflammation by increasing 
neoutrophil infiltration to the infarct zone, leading to an increase in inflammatory 
components such as cytokines including IL-6, and a deficiency in MMP2 which 
leads to disruption of the extracellular matrix (Kassiri et al., 2009). It was also found 
that in these mice the lack of ACE 2 induced the upregulation of hypoxic genes and 
levels of AngII were increased. In a rat model of myocardial infarction, lentiviral 
overexpression of ACE 2 also had a protective role by rescuing cardiac function 
through improved cardiac output, ejection fraction and contractility,  
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Figure 1-7. Intracellular MAPK signalling pathway in cardiac hypertrophy 
Schematic showing the MAPK signalling pathway that leads to cardiomyocyte hypertrophy. GPCR 
activation leads to activation of Ras/Raf. Raf activates 3 different branches, 1. MEK1/2 that 
phosphorylates ERK1/2. ERK1/2 is translocated to the nucleus where it activates different 
transcription factors. ERK1/2 association with Β-arrestins leads to ERK1/2 retention in the cytoplasm. 
2. Raf phosphorylates MEK which activates MEK4/7-JNK pathway. 3. MEK is also phosphorylated 
by stress, in this case MEK phosphorylates MEK3/6 which further phosphorylates p38. 
Chapter 1  
45 
as well as reducing left ventricular wall thinning (Der Sarkissian et al., 2008). 
Furthermore, transfection of fibroblasts with an ACE 2 expression plasmid 
attenuated collagen and cytokine production (Grobe et al., 2007a). In similarity to 
these findings, ACE 2 knockout mice develop defects in conduction and contraction 
(Crackower et al., 2002). These studies suggest a protective role for ACE 2 in heart 
failure.  However studies have also shown a negative role. Donoghue et al. showed 
that cardiac specific overexpression of ACE 2 in transgenic mice caused severe and 
progressive malfunction of rhythm and conduction leading to ventricular tachycardia 
and sudden death (Donoghue et al., 2003). This group also showed that ACE 2 
overexpressing transgenic mice had mild interstitial fibrosis. Masson et al. also 
showed cardiac fibrosis and deficits in ejection fraction and fractional shortening in 
SHRSP overexpressing ACE 2 mediated by adeno-associated virus serotype 6 
delivery (Masson et al., 2009). In this study ACE 2 increased the expression of 
collagen type IIIα1, fibronectin and lysyl oxidase genes, suggesting a profibrotic 
action of ACE 2. In accordance expression of genes involved in cardiac maintenance 
(apelin, myosin heavy chain II and GATA6) were diminished. Therefore further 
research is required to address the true role of ACE 2 in cardiovascular physiology 
and pathophysiology. 
In the heart it has been shown that Ang1-7 regulates many growth cell signalling 
pathways (Ferreira and Santos, 2005). In Sprague-Dawley rats coinfusion of AngII 
and Ang1-7 blocks the cardiac phosphorylation of ERK1/2 and Rho kinases induced 
by AngII alone and furthermore the effects of Ang1-7 were abolished in the presence 
of the Mas antagonist A779 (Giani et al., 2007). Interestingly, Ang1-7 also activated 
STAT3 and STAT5a/b in the heart, however this effect was not abolished by A779, 
but was by an AT1R antagonist suggesting its involvement. Ang1-7 has also been 
shown to have a role in recovery following ischaemia/reperfusion injury (Zhang et 
al., 2008, Al-Maghrebi et al., 2009, Castro et al., 2006). In rat models of myocardial 
infarction, treatment with Ang1-7 has been demonstrated to prevent left ventricular 
deterioration (Loot et al., 2002). In this same study Ang1-7 blocked the deterioration 
in aorta relaxation by preserving endothelial function. Al-Maghrebi et al treated 
diabetic rats with Ang1-7 before inducing ischemia and demonstrated recovery of 
left ventricular function after ischemia an effect that was abolished by the co-
infusion of A779 (Al-Maghrebi et al., 2009). At the molecular level Ang1-7 
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decreased the levels of NF-κB and the expression of genes needed for activation of 
NF-κB; including toll-like receptor 2, IL-1 receptor associated kinase 1 and inhibitor 
of kappa B kinase (Al-Maghrebi et al., 2009). Furthermore an inhibitory effect for 
Ang1-7 in inflammatory pathways was demonstrated as it reduced expression of 
complement component C3, IL-1β, IL-6 and caspase 1.  
One of the most studied actions of Ang1-7 is in cardiac remodelling. Many authors 
have confirmed that Ang1-7 has some effect in at least one of the components of 
cardiac remodelling. Grobe et al. demonstrated reduced myocyte hypertrophy, 
interstitial fibrosis and TGF-β levels in response to Ang1-7 in an Ang II induced rat 
model of hypertension and cardiac remodelling (Grobe et al., 2007b). These effects 
of Ang1-7 were also blocked in the presence of A779, and were independent of 
effects on blood pressure. Studies with transgenic mice overexpressing Ang1-7 in 
the heart have shown that in the presence of AngII hypertrophy and fibrosis of the 
left ventricle is reduced, as well as expression of the hypertrophy markers ANP and 
BNP, and TGF-β1 (Mercure et al., 2008). In these mice Ang1-7 had no effect on 
AngII-induced ERK1/2 phosphorylation but reduced AngII-induced phosphorylation 
of c-Src and p38 kinases. One important finding was the fact that Ang1-7, both in the 
presence or absence of AngII, increased the levels of SHP-1 protein (Mercure et al., 
2008). Dias-Peixoto et al. investigated the molecular mechanisms of the actions of 
Ang1-7 in cardiac hypertrophy (Dias-Peixoto et al., 2008). An increase in NO 
phosphorylation due to Ang1-7-mediated activation of the PI3K/Akt signalling 
pathway was observed and these actions were blocked by co-treatment with A779, 
confirming the importance of Mas. Ang1-7 also promoted the phosphorylation of 
eNOS at Ser177 which augmented enzyme activity. Furthermore, this study showed 
that in cardiomyocytes of Mas knockout mice a lack of nitric oxide production due 
to decreased Akt activity, led to decreased phosphorylation of eNOS at Ser177 and 
therefore decreased activation (Dias-Peixoto et al., 2008). Caveolin-3 expression, 
which inhibits basal activity of eNOS, was also increased; and heat shock protein 90 
(Hsp90) (a scaffold protein which recruits Akt) was also decreased. Furthermore in 
normal cardiomyocytes Ang1-7 was not able to produce changes in Ca
2+
 transient 
parameters but curiously in Mas knockout (Mas
-/-
) cardiomyocytes Ang1-7 showed a 
smaller peak in the intracellular Ca
2+
 transient and slower Ca
2+
 kinetics, which was 
explained by a decreased expression of the sarcoplasmic reticulum Ca
2+
 ATPase 
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(SERCA2a) (Dias-Peixoto et al., 2008). This suggests that Ang1-7 modulates Ca
2+
 
handling by increasing nitric oxide and eNOS activity leading to activation of 
SERCA2a. 
In cardiac fibrosis, exposure of AngII-stimulated cardiac fibroblasts to Ang1-7 
inhibited collagen synthesis and expression of the growth factors endothelin-1 and 
leukaemia inhibitory factor (Iwata et al., 2005). It has also been described that Ang1-
7 normalises the decreased levels of matrix metalloproteinases (MMP) in AngII-
stimulated cardiac fibroblasts and myocytes (Pan et al., 2008). In addition, Grobe et 
al. showed that Ang1-7 was able to prevent interstitial fibrosis by decreasing 
collagen deposition in the deoxycorticosterone acetate (DOCA) salt hypertensive rat 
model (Grobe et al., 2006). In this model Ang1-7 did not prevent the increase in 
ventricular mass or myocyte diameter or have any effect on blood pressure. In 
nephrectomised mice Ang1-7 prevented left ventricular remodelling and preservation 
of cardiac function, and also diminished interstitial fibrosis by reducing the levels of 
TGF-β and increasing MMP2 and 9 (Li et al., 2009c). Ang1-7 also decreased the 
expression levels of inflammatory cytokines and suppressed oxidative damage (Li et 
al., 2009c). 
In the cardiovascular system Mas
-/-
 mice have been widely used and the results of 
these studies have contributed to the knowledge of Ang1-7 actions (Lemos et al., 
2005). Mas
-/- 
mice have been used to show the involvement of Mas in heart function. 
For example, Santos et al. characterized the phenotype of Mas
-/-
 mice and showed 
lower global ventricular function (Santos et al., 2006). Lack of Mas caused a 
decrease in systolic tension and heart rate, as well as left ventricular posterior wall 
thickness and decreased fractional shortening. At a molecular level, Mas
-/-
 mice have 
increased expression of type I and III collagen and fibronectin, while type IV 
collagen expression is decreased. In accordance with these findings, Castro et al 
showed a decrease in cardiac contractility in Mas
-/-
 mice (Castro et al., 2006).  
The RAS is integral to the normal physiology of the cardiovascular system and 
furthermore its dysregulation is important in the development of many CVDs. A 
clear role for AngII acting via the AT1R to activate downstream cell signalling 
pathways has been established. These downstream effects are pleiotropic and occur 
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in many different cells and tissues including smooth muscle cells, endothelial cells, 
fibroblast and cardiomyocytes. However, there still remain many unanswered 
questions on the integrated function of the RAS. The true role of the AT2R and 
whether it does antagonise the AT1R signalling is controversial. Other peptide 
metabolites of the RAS also play a role in CVD development. This is particularly 
evident for Ang1-7 which appears to antagonize the effects of AngII in many cells 
and tissues in CVD models via the receptor Mas. The role of other angiotensin 
metabolites, e.g. Ang1-9, AngIV, in the development of CVD phenotypes is less 
clear. 
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1.5 Aims 
Investigate Ang1-9 and Ang1-7 function in cardiomyocyte hypertrophy in rat 
neonatal (H9c2) and primary adult rabbit left ventricular cardiomyocytes in vitro. 
Assess the effects of Ang1-7 and Ang1-9 in vivo in the stroke prone spontaneously 
hypertensive rat model. 
Develop vectors for expression of RAS peptides that will be useful for probing RAS 
pathways in vitro following delivery to individual cells and tissues. Assess the effect 
of gene transfer from these vectors on cardiac hypertrophy in an in vitro model. 
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C H A P T E R   2 
 
Materials and Methods 
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2.1 Chemicals  
All chemicals unless otherwise indicated were obtained from Sigma Chemical 
Company (Dorset, UK). Angiotensin peptides were purchased from Sigma or 
Phoenix Pharmaceuticals (Karlsruhe, Germany). Pharmacological receptor 
antagonists were purchased from Sigma (Losartan, Captopril, PD123,319) or 
Bachem (Rhein, Germany) (A779).  
2.2  Tissue culture 
All tissue culture reagents were purchased from Lonza, (Braine-L’Alleud, Belgium) 
unless otherwise indicated. H9c2, an immortalized cardiomyocyte cell line derived 
from neonatal rat cardiomyocytes and HeLa cells (an immortalized cell line derived 
from cervical cancer) cell lines were purchased from the European Collection of 
Animal Cell Cultures (Porton Down, Wiltshire, UK). The 293 cell line (adenovirus 
type 5 transformed human embryonic kidney cells) was purchased from Microbix 
Biosystems (Toronto, Canada). Adult rabbit heart tissue was a gift from Dr. Anthony 
Workman (BHF Glasgow Cardiovascular Centre, University of Glasgow, UK). 
2.3 Cell culture 
All tissue culture involving primary, transformed, genetically manipulated or other 
animal tissue was performed under containment level 2, in sterile conditions, using a 
vertical laminar flow hood. H9c2 cardiomyocytes, HeLa and 293 cell lines were 
cultured in a humidified chamber at 37ºC in 5% CO2/95% air in Dulbecco´s 
Modified Eagle’s medium supplemented with 10% (v/v) foetal calf serum (FCS), 2 
mM L-glutamine and 1 IU penicillin, 100 µg/mL streptomycin (Invitrogen, Paisley, 
UK). H9c2 cells were passaged by trypsin-ethylenediamine tetra-acetic acid (trypsin-
EDTA) when the culture reached 50% confluence. HeLa and 293 cells were 
passaged upon reaching 90% confluence. Briefly, cells were washed twice with 
sterile Dulbecco´s calcium and magnesium free phosphate buffered saline (PBS), 
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and incubated with 2 ml of trypsin- EDTA (H9c2 and HeLa cells) or citric acid (293 
cells) at 37°C for approximately 5 minutes. Once the majority of the cells were 
detached the action of the trypsin-EDTA were blocked with an equal volume of 
100% FCS. Cells were harvested by centrifugation at 500 g and re-suspended in 
fresh media before plating. 
2.4 Cryopreservation 
For cryopreservation cells where collected as described in section 2.3. After 
centrifugation, cells were resuspended in complete cell culture media supplemented 
with 10% volume/volume (v/v) dimethyl sulphoxide (DMSO) at an approximate 
density of 1-2 x 10
6
 cells/mL and aliquoted into cryo-preservation tubes. Tubes were 
cooled at a constant -1ºC / minute to -80ºC using isopropanol, for long term storage 
in the vapour phase of liquid nitrogen. 
To resuscitate cells from cryo-preservation, vials were thawed at 37ºC. The cell 
suspension was carefully transferred to a universal container. 10 mL of complete cell 
culture was added drop by drop and the cell suspension subjected to centrifugation at 
500g to pellet the cells and discard the DMSO. The cell pellet was resuspended in 
1mL of complete culture media and cells were transferred to a T-150 flask 
containing 25 mL of pre-warmed cell culture media and then incubated at 37ºC / 5% 
CO2 / 95%. 
2.5 Primary cardiomyocyte isolation 
Adult rabbit left ventricular cardiomyocytes were used as the primary cell model due 
to lack of availability of rat primary cardiomyocytes. Twenty weeks of age adult 
rabbit left ventricular cardiomyocytes were isolated by cardiac retrograde aortic 
reperfusion. The full heart was digested with collagenase type I (400 U/ml) at 37ºC. 
The left ventricle was chopped into small pieces and placed into a sterile tube 
containing Kreb’s solution (20 mM NaCl, 20 mM HEPES, 5.4 mM KCl, 0.52 mM 
NaH2PO4, 3.5 mM MgCl2, 20 mM taurine, 10 mM creatine, glucose and bovine 
serum albumin (BSA) at 37°C, pH 7.4, at 37ºC). Cells were isolated by cycles of: 
inverting the tube constantly for ten minutes to enable the tissue to sink to the bottom 
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of the tube and then the supernatant was transferred into a fresh sterile tube, until the 
supernatant turned clear. Cells were then allowed to pellet by gravity over a period 
of approximately 30 minutes and the supernatant discarded carefully with a sterile 
pasteur pipette. Cells were resuspended in Kreb’s solution and washed 4 consecutive 
times with Kreb’s supplemented with CaCl2 at 100 μM, 400 μM, 700 μM and 1 mM, 
respectively. Between washes cells were allowed to pellet by gravity and the Kreb's 
discarded carefully. Following the final wash cells were gently resuspended in M199 
medium supplemented with 5 mM taurine, 5 mM carnitine, 5 mM creatine and 1 IU 
penicillin, 100 µg/mL streptomycin pre-heated at 37ºC. Cells were then plated in 6 
well plates at a density of 3x10
4
 cells/well in supplemented M199 medium and used 
immediately for experiments. 
2.6 Hypertrophy model 
A hypertrophy model was established in H9c2 cells and adult rabbit left ventricular 
primary cardiomyocytes. 
H9c2 cells were seeded at a density of 3x10
4
 cells per well and maintained at 37ºC in 
a humidified chamber 24 hours prior to initiation of experiments. Cells were then 
changed to serum free media for 1 hours, followed by stimulation with 100 nM 
AngII and cells incubated for 96 hours at 37°C in order to induce hypertrophy. After 
96 hours of incubation, cells were washed twice with PBS and fixed with 2% (w/v) 
paraformaldehyde (PFA) for 15 minutes on ice. PFA was removed with 2 washes of 
PBS and 2% (v/v) crystal violet added overnight to stain the cells. Cell size was 
measured with ImageProPlus 4.1 software (Media Cybernetics, USA). Alternatively, 
cells were stimulated with 1 µM arg-vasopressin in a similar manner to that 
described above. Cell size was assessed by measurement of cell length. For each 
condition 100 cells were measured (ten fields of view in each condition) and each 
experiment was repeated 3 times.  
To investigate the role of Ang1-7 and Ang1-9 in hypertrophy H9c2 or adult rabbit 
primary left ventricular cardiomyocytes were incubated with either Ang1-7 or Ang1-
9 30 min before addition of AngII or arg-vasopressin. Alternatively, agonists for 
Mas (MBP7 10 µM and 100 µM) and AT2R (CGP42112A 10 nM, 100 nM and 1 
Chapter 2  
54 
µM) at the indicated concentrations were added 30 minutes before adding AngII. To 
assess receptor use the following antagonists were used at the indicated 
concentrations: ATR1 (Losartan 1 µM, 10 µM), ATR2 (PD123,319 100 nM, 500 
nM, 1 µM) Mas receptor (A779 10 µM), B2 bradykinin receptor (HOE 140 1 µM) 
and the ACE inhibitor (Captopril, 1 mM). Antagonists were added 15 minutes before 
addition of Ang1-7 or Ang1-9.  
Left ventricular rabbit cardiomyocytes were seeded as above following extraction 
and then stimulated with AngII (500 nM) or arg-vasopressin (1 µM), followed by 
incubation for 24 hours at 37°C. In primary cardiomyocytes length and midpoint 
width was measured to calculate volume of the cell. Cell volume was determined via 
a modified calculation as first described by Satoh et al. (Satoh et al., 1996). Using 
confocal microscopy, Satoh et al. reconstructed the volume of spherical latex beads. 
Based on this data they were able to calculate a correction factor for spherical 
aberration of 0.68. Assuming cardiomyocytes as an ellipsoid and applying the 
correction factor, volume was calculated as:  
Volume = (Width x Length x π) x 0.68 
Ang1-7 (500 nM) and Ang1-9 (500 nM) were added 30 minutes before the addition 
of the prohypertrophic peptide (AngII or arg-vasopressin). Losartan (1 µM), 
PD123,319 (500 nM) and Captopril (10 µM) were added 15 minutes before Ang1-7 
or Ang1-9. 
For pertussis toxin (PTX), cells were seeded in 6 well plates at 3x10
4
 cells per well 
and incubated for 8 hours. Media was exchanged for culture media (DMEM, 10% 
(v/v) FCS, 2 mM L-glutamine, 1 IU penicillin, 100 µg/mL streptomycin, 1% (v/v) 
sodium pyruvate) supplemented with PTX (25 ng/ml) and cells incubated overnight. 
Media was exchanged for serum free media supplemented with PTX (25 ng/ml), and 
Ang1-7, Ang1-9 and AngII stimulation was performed as described above. 
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2.7 Protein extraction 
Protein was extracted from unstimulated and AngII and/or Ang1-7 or Ang1-9 
stimulated H9c2 cardiomyocytes seeded in 6 well plates by washing twice with PBS 
and adding 300 µl of lysis buffer containing 50 mM tris(hydroxymethyl) 
aminomethane (Tris)-HCl, 150 mM NaCl, 2 mM EDTA, 2 mM ethylene glycol 
tetraacetic acid (EGTA), 0.2% (v/v) Triton-X, 0.3% (v/v) nonyl 
phenoxylpolyethoxylethanol (NP-40), 100 mM phenylmethanesulfonyl fluoride, 1 M 
sodium fluoride (NaF) and 1 x proteinase and phosphatase cocktail (Sigma, Dorset, 
UK) to each well. Each well was scraped, the lysed cells collected in a 
microcentrifuge tube and then incubated on ice for 1 hour, with agitation every 15 
minutes. Samples were subjected to centrifugation at 12,000 g to pellet the cell 
debris. Protein containing supernatant was transferred to a new microcentrifuge tube 
and the pellet discarded. 
2.7.1 Determination of protein concentration 
Protein concentration in samples was determined using the bicinchoninic acid (BCA) 
Protein Assay Kit (Pierce, Rockford, Illinois, USA), a colorimetric detection and 
quantification protocol, following manufacturer’s instructions. Briefly, a standard 
curve was generated using the following BSA dilutions: 2000 µg/mL, 1500 µg/mL, 
1000 µg/mL, 750 µg/mL, 500 µg/mL, 250 µg/mL, 125 µg/mL and 25 µg/mL. 200 
µL of working reagent was added to 25 µL of sample or standard in duplicate in a 96 
well plate, and incubated for 30 minutes at 37ºC in the dark. The plate was then 
analysed on a Wallac Victor
2
 plate reader (Wallac, Turku, Finland) with absorbance 
at 570 nm. Results were then calculated according to the linear equation based on the 
standard curve generated. 
2.8 Electrophoresis  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western immunoblotting was used to detect specific proteins. First, samples were 
prepared at the appropriate concentration with 5x loading buffer containing: 10% 
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weight/volume (w/v) SDS, 30% (v/v) glycerol, 10% (v/v) Tris-HCl pH 6.8, 0.01% 
(w/v) bromophenol blue and 2% (v/v) β-mercaptoethanol. Samples were heated at 
95ºC for 5 minutes to denature the protein, mildly cooled and loaded into the well.  
The polyacrylamide (PA) gel consisted of a 4% stacking gel containing 13.3% (v/v) 
N,N’-methylene-bis-acrylamide (polyacrylamide 30%), 25% (v/v) Tris pH 6.8 (3.75 
mM), 0.1% (v/v) SDS, 1% (v/v) ammonium persulphate (APS) and 0.1% (v/v) of 
N,N,N’,N’-Tetramethylethylenediamine (TEMED). Depending on the molecular 
mass of the protein to be detected different percentage resolving gels were used: To 
detect the Ang1-7 and Ang1-9 fusion protein (32 kDa) (section5.1) following 
adenoviral gene transfer a 12% resolving gel which contained 40% (v/v) of PA 
(30%), 25% (v/v) of Tris pH 8.8 (11.25 mM), 0.1% (v/v) SDS, 1% (v/v) APS and 
0.1% (v/v) TEMED was used. 
Following sample loading, gels were electrophoresed at 100 V through the stacking 
gel, then switched to 200 V for electrophoresis through the resolving gel in running 
buffer (0.025 M Tris-HCl, 0.2 M glycine, 0.001 M SDS) for approximately 3 hours. 
Protein was then transferred to Hybond-P polyvinylidene difluoride membrane 
(Amersham Bioscience UK Limited, Buckingham, UK), to enable antibody binding 
and detection. Protein transfer was performed using an electric current which 
promotes protein migration from the gel to the membrane. Protein transfer was 
performed overnight at 80 mV in transfer buffer [0.025 M Tris, 0.2 M  glycine, 20% 
(v/v) methanol, 0.01M SDS] at 4ºC. To confirm the samples had transferred 
correctly, the gel was stained with Coomassie brilliant blue stain [0.5% (w/v) 
Coomassie Brilliant Blue R-250 (Biorad, Hemel Hempstead, UK), 50% (v/v) 
methanol and 10% (v/v) glacial acetic acid) for 30 minutes and then destained with 
destaining solution containing 40% (v/v) methanol and 10% (v/v) glacial acetic acid 
for another 30 minutes. 
2.9 Western immunoblotting 
Once proteins were transferred to the membrane, antibody detection was performed. 
The membranes were first blocked in TBS-T [150 mM NaCl, 50 mM Tris, 0.1% 
(v/v) Tween-20] + 10% (w/v) fat-free milk powder (blocking buffer) for 8 hours at 
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4ºC. Membranes were incubated with the primary antibody diluted in blocking 
buffer at the recommended dilution (Table 2) overnight at 4ºC with shaking. 
Following overnight incubation the membrane was washed twice in blocking 
solution for five minutes each at room temperature, followed by incubation with an 
1:2000 dilution of the appropriate secondary antibody, rabbit anti-mouse or swine 
anti-rabbit horseradish peroxidase (HRP) (Neomarkers, Fremont, CA, USA) for 1 
hour at room temperature with shaking. The membrane was then washed six times 
for 15 minutes each at room temperature with shaking, four times with blocking 
solution and two times with tris buffered saline-tween (TBS-T). Proteins were 
visualized using Enhanced Chemiluminescent (ECL) Detection System (Amersham 
Biosciences UK Limited, Buckingham, UK) following the manufacturer’s 
instructions. Films were exposed for various lengths of time, ranging from 10 
seconds to overnight. 
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Antibody Dilution Stock 
Concentration Name Specie Clone # Company 
Anti-Mouse 
IgG2b 
Rabbit 
polyclonal 
Ab9171 Abcam 1:250 4 µg/mL 
Anti-PKC Mouse 
monoclonal 
MC5 Abcam 1:100 2.70 mg/mL 
FITC-
labelled 
Rabbit anti-
mouse 
polyclonal 
F0232 Dako 1:40 400 mg/L 
 
Table 2.  Primary antibodies and conditions used in western blot protein detection. 
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2.10 Immunocytochemistry 
H9c2 cardiomyocytes were plated on to silane-coated coverslips at 3x10
5
 cells per 
coverslip. 24 hours later cells were stimulated for different times and then fixed with 
4% (w/v) paraformaldehyde for 15 minutes on ice. PFA was removed following two 
washes in PBS and the cells permeabilised with 0.1% (v/v) Triton-X-100 for 30 
minutes at room temperature. Cells were washed 3 times in PBS, and incubated for 1 
hour with the primary antibody, mouse monoclonal anti-PKC (diluted 1:100 in PBS 
and 20% (v/v) rabbit serum; 22 µg/mL). The primary antibody was removed by 
washing the cells 3 times with PBS, for 5 minutes. Next, cells were incubated with 
secondary fluorescein isothiocyanate (FITC)-labelled antibody (Dako, Ely, UK) 
(rabbit anti-mouse antibody diluted 1:40 in PBS and 20% (v/v) rabbit serum) for 30 
minutes in the dark. Next, cells were washed 3 times for 5 minutes each with PBS to 
remove secondary antibody and then mounted onto a glass slide using Vectashield 
(Vector laboratories, Peterborough, UK) with propidium iodide as nuclear 
counterstain. 
2.11 Phalloidin staining 
Phalloidin (Sigma, Dorset, UK) is a fungal toxin able to bind to the F-actin subunit 
of actin filaments in cells. Phalloidin was used to stain actin filaments and image 
changes in their organization in H9c2 cardiomyocytes stimulated with AngII and/or 
Ang1-9 or Ang1-7. H9c2 cardiomyocytes were seeded at 3x10
4
 cells per well on 
coverslips. Hypertrophy was stimulated as described previously (section 2.6). After 4 
days cells were washed twice with PBS, fixed with 4% (w/v) PFA for 20 minutes at 
room temperature, followed by two washes in PBS before permeabilization with 
0.1% (v/v) Triton X-100 for 20 minutes. Cells were washed in PBS and stained with 
phalloidin solution [5 µg/ml (v/v) Phalloidin-FITC, 1% (w/v) BSA in PBS] for 1 
hour at room temperature protected from light. Unbound phalloidin was removed by 
washing in PBS and coverslips mounted onto a glass slide using Vectashield 
containing 4',6-diamidino-2-phenylindole (DAPI).  
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2.12 RNA extractions 
To extract RNA from H9c2 cardiomyocytes, cells were plated at 3x10
5
 cells per well 
in 6 well plates. RNA was extracted using the RNeasy mini kit (Qiagen, Crawley, 
West Sussex, UK). Briefly, cells were lysed and homogenized with RLT buffer 
which contains denaturing guanidine isothiocyanate. RLT buffer immediately 
inactivates RNases and ensures the extraction of the intact RNA. 70% (v/v) ethanol 
was then added to facilitate binding to the spin column and sample was loaded to an 
RNeasy spin column and subjected to centrifugation at 8,000 g for 15 seconds in 
order to bind the RNA onto the membrane. Once bound, the RNA sample was 
washed 3 times (700 µL of RW1 buffer x 1 and 500 µL of RPE buffer x 2) and 
subjected to centrifugation at 8,000 g for 15 seconds to eliminate contaminates. To 
elute purified RNA 30 µL of dH2O was added to the column and spun at 8000g for 1 
minute. Samples were stored at -80ºC. 
2.13 DNase treatment 
In order to remove the contaminating DNA from RNA extractions Turbo DNA-free 
kit (Applied Biosystems, Warrington, UK) was used. Following the manufacturer’s 
instructions a 50 µL reaction was generated consisting of 40 µL RNA, 0.5 µL 10x 
buffer and 1 µL DNase. The reaction was incubated for 30 minutes at 37ºC in a 
water bath. DNase activity was suspended by adding DNase inactivation reagent 
(0.1% volume) and followed by incubation for 2 minutes at room temperature. To 
pellet the DNase inactivation reagent the reaction was subjected to centrifugation at 
10,000 g for 1.5 minutes and the RNA transferred to a fresh Eppendorf.  
2.14 Quantification of nucleic acids 
Nucleic acids (DNA and RNA) were quantified using a Nanodrop Spectophotometer 
(Thermo Scientific, Loughborough, UK). This apparatus measures the pulse light 
produced by a xenon flash lamp that passes through the sample, using a linear 
charged-coupled device (CCD) array. Calculation of the amount of nucleic acid is 
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based on a modified Beer-Lambert equation with ng/µL as units. The equation is as 
follows: 
    c = (A * ε)/b 
c = the nucleic acid concentration in ng/µL 
A = the absorbance in arbitrary units (AU) 
ε = the wavelength-dependent extinction coefficient in ng / µL 
b= the pathlength in cm 
 
The extinction coefficients used for nucleic acids are: 
• Double-stranded DNA: 50 ng/μL 
• Single-stranded DNA: 33 ng/μL 
• RNA: 40 ng/μL 
The purity of the sample was assessed by calculating the A260:A280 ratio. A ratio of ≥ 
1.8 was considered pure. 
2.15 Complementary deoxyribonucleic acid (cDNA) 
synthesis 
mRNA extracted from cells was reverse transcribed into complementary DNA 
(cDNA). The Reverse Transcription Kit (Applied Biosystems, Warrington, UK) was 
used following the manufacturer’s instructions to reverse transcribe 1 µg of mRNA 
in a 20 µL reaction. The reaction contained: 5.5 mM MgCl2, 2 mM total 
deoxyribonucleotide triphosphates (dNTPs) mix (0.5 mM each), 8 U random 
hexamers, 25 U Multiscribe, and 1µg of RNA. Cycling conditions were as follow: 
25ºC for 10 minutes for preannealing, 48ºC for 30 minutes to enable reverse 
transcription and 95ºC for 5 minutes for reverse transcription inactivation. CDNA 
was stored at -20ºC. 
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2.16 Polymerase chain reaction (PCR) 
PCR is a technique used to amplify at a large scale a specific DNA sequence 
generating millions of copies. This method utilises differential thermal cycling 
conditions, where double stranded DNA is heated to separate the DNA strands 
through breaking the hydrogen bonds, then cooled to facilitate primer annealing 
followed by re-heating to elongate the DNA by the action of a thermostable DNA 
polymerase. This is followed by a final step of re-annealing of the new DNA strands. 
These steps are repeated to exponentially increase the amount of the DNA template. 
PCR was used to detect expression of Mas and AT2R in H9c2 cardiomyocytes. 
Primers were designed based on the Genebank sequences (Table 3). PCR reactions 
were as follows: 10 ng of cDNA in a 25 µL reaction containing 200 µM of each 
dNTP, 2 mM MgCl2, 200 nM forward and reverse primers and 1 U Taq® DNA 
polymerase (Promega, Southampton, UK) in 1x PCR reaction buffer. Samples were 
submitted to 35 thermal cycles of denaturing at 95ºC for 1 minute, annealing at 
primer-specific temperatures (for details see table 3) for 1 minute and extension at 
72ºC for 1 minute. PCR products were analysed following electrophoresis in an 
agarose gel (section 2.22.2.1). 
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PCR Primers Sequence Melting Point 
Mas 
receptor 
 Forward     5’-CCATCAGTGTGGAGAGATGCCT-3’ 68ºC 
 Reverse     5’-CAGTAGTACCAGTGGTAATAGT-3’ 62ºC 
AT2 
receptor 
 Forward     5’-CCCTGGCAAGCATCTTATGTAG-3’ 66ºC 
 Reverse     5’-GTCTTAATGGGCACTGGTTCAG-3’ 66ºC 
BNP 
 Forward     5’-CAGAACAATCCACGATGCAG-3’ 57ºC 
 Reverse     5’-CCTTTACCGAGTCTCTGTCG-3’ 59ºC 
 
Table 3.  Primers used for gene expression detection. 
Primers sequences used in PCR to detect gene expression of Mas, AT2R and BNP (brain natriuretic 
peptide). 
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2.17 Quantitative real-time polymerase chain reaction 
(QPCR) 
QPCR is a laboratory technique used to amplify and quantify a target DNA 
sequence. This technique follows the same DNA amplification principle of standard 
PCR but with the production of a fluorescence signal that is proportional to the 
amount of product generated in each cycle. The fluorescence signal can be measured 
directly to give either an absolute number of copies or a relative amount when it is 
normalized to control DNA. There are two methods of quantification: using dyes that 
bind to double stranded DNA (dsDNA) or using fluorescent oligonucleotide probes. 
To quantify the expression of BNP the SYBR Green Detection System (Applied 
Biosystems, Warrington, UK) was used in which SYBR Green binds dsDNA. 
Reactions consisted of 1 µg cDNA, the SYBR Green PCR core reagents kit (6.25 µl 
v/v) and 400 nM of each specific primer (Table 3). QPCR was performed using a 
7900HT Fast Real-Time PCR System (Applied Biosystems, Warrington, UK) using 
the following conditions: 50 cycles at 95ºC for 10 minutes to denature DNA, 95ºC 
for 15 seconds to denature, 60ºC for 1 minute for annealing and elongation. This was 
followed by 95ºC for 15 seconds to dissociate, 60ºC for 15 seconds and 95ºC for 15 
seconds. 
BNP quantification was calculated relative to the expression of a control 
housekeeping gene 18S (Applied Biosystems, Warrington, UK). All samples were 
analysed in duplicate using TaqMan data analysis software. 
2.18 Analysing calcium transients in single cells 
Ca
2+
 stored in the endoplasmic reticulum is mobilized to the cytoplasm through a 
receptor mediated event, such as activation of a GPCR. To study calcium transient 
activation a single cell calcium assay was performed. Fura-2 Calcium Indicator 
(Invitrogen, Paisley, UK) is a fluorescent reagent that binds to intracellular calcium, 
changing its emission wavelength proportionally to the amount of Ca
2+
 bound 
enabling quantification. Based on this, intracellular Ca
2+
 can be estimated 
independently of dye concentration or cell thickness. H9c2 cardiomyocytes were 
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seeded on coverslips at 1x10
5 
cells per well, for 70% confluence the following day. 
Cells were loaded 1.5 µM Fura-2 in standard cell culture media, and incubated for 30 
minutes at 37ºC. Coverslips were placed into a microscope chamber in a Nikon 
Diaphot inverted microscope equipped with a Nikon ×40 oil immersion Fluor 
objective lens (NA = 1.3) containing microscope buffer (130 mM NaCl, 5 mM KCl, 
20 mM HEPES, 10 mM Glucose, 1 mM MgCl2, 1 mM CaCl2, pH 7.4) connected to a 
perfusion system and the microscope chamber was illuminated with an ultrahigh 
point intensity 75-W xenon arc lamp (Optosource, Cairn Research, Faversham, Kent, 
UK). A monochromator (Optoscan, Cairn Research) was used to alternate the 
excitation wavelength between 340/380 nm and control the excitation band pass (10 
nm for 340 nm and 8 nm for 380 nm). Sequential images (2 x 2 binding) were taken 
every 60 ms, with exposure to excitation light for 100 ms / image. AngII, Ang1-7, 
Ang1-9 and ionomycin agonists (Sigma, Dorset, UK) were diluted to a concentration 
of 1 µM in microscope buffer, while vasopressin was diluted to 10 µM. Cells were 
perfused with agonists after 60 basal images were recorded and further 140 images 
recorded following stimulation. Agonist was then removed, 200 images recorded and 
cells then perfused with the positive control agonist (ionomycin 1 µM or vasopressin 
10 µM). Cell images were obtained using a Nikon Diaphot inverted microscope 
coupled to a Nikon (Tokyo, Japan) 40x oil immersion Fluor objective lens. To 
monitor Fura-2 fluorescence emission at 510 nm, a high-resolution interline-transfer 
cooled digital camera (Cool Snap-HQ, Roper Scientific/Photometrics, Tucson, AZ, 
USA) was used. MetaFluor imaging software (Universal Imaging Corp., Downing, 
PA) was used for control of the monochromator, charge-coupled device camera, and 
for processing of the data. 
2.19 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) Assay 
CellTiter 96® Non-radioactive Cell Proliferation Assay (Promega, Southampton, 
UK) was used to determine viable cell number in the hypertrophy assay. This assay 
is based on the conversion of a tetrazolium salt to a formazan product by viable cells. 
H9c2 cardiomyocytes were plated at a seeding density of 3x10
4
 cells per well and 
the hypertrophy assay protocol followed (section 2.6). After the 96 hours incubation 
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period, dye solution containing tetrazolium was added to the culture medium of each 
well in a 15:100 ratio and incubated for 4 hours at 37°C in 5% CO2 / 95% air. After 
incubation 1 mL of Solubilization Solution/Stop Mix was added to each well to 
solubilize the formazan product. Absorbance was recorded at 570 nm using a Wallac 
Victor
2
 plate reader (Wallac. Turku, Finland). 
2.20 Animal husbandry and in vivo experimentation 
To study the role of Ang1-9 the SHRSP was used (Figure 2-1). SHRSP are 
maintained “in-house” by brother-sister mating. Routine in lab microsatellite 
screening is performed to confirm homozygosity of all loci within a random group of 
the strain. All animals are housed under controlled environmental conditions, 
maintained with a 12 hours light/dark cycles at ambient temperature. Rats were fed 
standard rat chow (rat and mouse No.1 maintenance diet, Special Diet Services) and 
water provided ad libitum. Male rats were used in all experiments. Work with 
experimental animals was in accordance with the Animals Scientific Procedures Act 
1986 under the project license 60/2874 held by Professor A.F. Dominiczak. At 11 
weeks of age an exploratory transthoracic echocardiography was performed followed 
by implantation of the radio-telemetry probe to monitor blood pressure. 10 days after 
telemetry probe implantation (13 weeks of age), osmotic minipumps were implanted 
subcutaneously to secrete peptides/pharmacological reagents for 4 weeks. Two 
weeks following implantation of the minipump (15
 
weeks of age) a second 
echocardiogram was performed. At 17
 
weeks of age the third echocardiogram was 
performed before SHRSP were sacrificed and organs processed for analysis.  
2.20.1 Radiotelemetry 
Hemodynamics of SHRSP were monitored through the study from one week prior to 
implantation of the osmotic minipumps using the Radio-Telemetry Monitoring of 
Blood Pressure and Heart Rate Dataquest IV Telemetry System (Data Science 
International, Minneapolis, USA). Radiotelemetry provides 24 hours monitoring and 
data records of systolic and diastolic blood pressure, mean arterial pressure, heart 
rate and motor activity, as previously described (Davidson et al., 1995). Briefly, 
before the transmitter (radio frequency transducer model TA11PA) was implanted, 
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calibration was performed to verify accuracy to within 3 mmHg. 11 week old 
SHRSP were anesthetised with 5% isofluorane and the flexible catheter of the 
transmitter was inserted in the abdominal aorta below the renal arteries, orientated 
against flow and sutured to the abdominal wall. Rats were housed in individual cages 
following the procedure. Each cage was placed on a receiver panel connected to a 
computer for data acquisition. Rats were unrestrained and free to move within their 
cages. Data was sampled every 5 minutes for 10 seconds. Following the procedure a 
recovery period of 7 days for blood pressure and heart rate return to normal was 
allowed (Davidson et al., 1995) before interventions were initiated. 
2.20.2 Osmotic minipump studies 
Osmotic minipump secretion (Alzet, CA, USA) was used to assess the systemic 
effects of Ang1-9 in the SHRSP in the presence and absence of the AT2R blocker 
PD123,319 for 4 weeks. Control animals were implanted with a minipump secreting 
water. The osmotic minipump operates through an osmotic pressure difference 
between a compartment of the pump and the tissue where it is set (Figure 2-2). The 
compartment has a high osmolality causing water to enter, compressing the peptide 
reservoir and ejecting at a controlled and predetermined rate the agent inside. The 
secretion rate depends on the model and varies between 0.11 and 10 µL/h. 
Osmotic minipumps secreted 100 ng/kg
-1
/min
-1
 Ang1-9 or PD123,319 for 4 weeks 
following implantation. In order to determine the stock concentration of Ang1-9 
required prior to filling the minipumps the following equation was used: 
     C = K/Q 
C = concentration of solution (µg/µL) 
K = peptide delivered per day (µg/kg) 
Q = release rate of the pump (µL/h) 
The flow rate of the osmotic minipump used (Azlet # 2004) was 0.25 µL/h so the 
concentration required was: 
C = (144 µg/kg) / (0.25 µL/h) = 5.76 µg/µL. 
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The maximum reservoir of the 2004 model is 200 µL, so to achieve a concentration 
of 5.76µg/µl, the amount of peptide that should be dissolved in 200 µL is:  
(5.76 µg/µL) x 200 µL = 1.2 µg 
Minipumps were filled the day before implantation and left overnight in isotonic 
solution at 37ºC to allow equilibration to be reached. Minipumps were 
subcutaneously implanted under anaesthesia 10 days after the surgical placement of 
the telemetry radio transducer. For double pump implantation, minipumps were 
implanted back to back in the same site. 
2.20.3 Echocardiography (ECHO) 
SHRSP were mildly anesthetized with 1.25% to 1.5% isofluorane in 1.5 L/min O2 
before image acquisition and were positioned in left lateral decubitus on a heated 
pad. An Acuson Sequoia c512 ultrasound system was used to acquire non-invasive 
2-D guided M-mode images at a depth of 20 mm and at the tip of the papillary 
muscles. Left ventricle anterior and posterior wall thickness as well as chamber 
diameter were measured in a short axis view using the leading edge-to-lead edge 
convention during both systole and diastole. The velocity of blood passing through 
the mitral valve was measured with colour Doppler and pulse wave. The sample 
volume was placed at the tip of the mitral leaflets and adjusted to the maximal 
velocity position. The sample volume was set at 2.5 mm. This method was also used 
to qualitatively examine the valve for evidence of mitral regurgitation. All ECHO 
data was measured over at least three consecutive cardiac cycles, except for Doppler 
spectra which were recorded over 5 to 10 cardiac cycles at a sweep speed of 150 
mm/s. 
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Figure 2-1. Experimental protocol diagram for SHRSP.  
At 13 weeks of age SHRSP were infused with Ang1-9 peptide for 4 weeks. During this time blood 
pressure was monitored with a radiotelemetry probe implanted at the 11
th
 week of age. Cardiac 
function was monitored with echocardiogram performed 3 times: pretreatment (11 weeks of age), 
during treatment (15
 
weeks of age) and at the end of the study (17 weeks of age). After SHRSP were 
sacrificed organs were collected for myography and histology analysis. 
Chapter 2  
70 
 
 
 
H20
Flow moderator
Test agent
Collapsable
reservoir
Osmotic layer
Semipermeable
membrane
A B
 
Figure 2-2. Schematic of osmotic minipump.  
Osmotic minipumps function based on the difference in osmolarity between compartments. These 
pumps have a semipermeable membrane which allows water to enter the osmotic layer driven by its 
high osmolarity. (A) This osmotic layer surrounds the cylindrical collapsible reservoir containing the 
reagent for secretion. (B) When the pump is in an aqueous location the osmotic layer absorbs water 
collapsing the reservoir due to the hydrostatic pressure generated, resulting in secretion of the stored 
reagent [modified from Theeuwes et al. (Theeuwes and Yum, 1976)].  
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2.20.3.1 Formulae used in ECHO assessments 
• Ejection fraction was defined as follows:  
EF = [(LVEDV – LVESV) / LVESD x 100] 
LVEDV = left ventricular end diastolic volume  
LVESV = left ventricular end systolic volume  
• Fractional shortening was derived from:  
FS = [(LVEDD – LVESD) / LVEDD x 100] 
LVEDD = left ventricular end diastolic diameter 
LVESD = left ventricular end systolic diameter  
• Cardiac output was derived from:  
CO = [(ESV – EDV) x HR] 
ESV = end systolic volume 
EDV = end diastolic volume  
HR = heart rate 
• Stroke volume was calculated as follows: 
SV = ESV - EDV 
ESV = end systolic volume 
EDV = end diastolic volume  
 
• Left ventricular mass index was calculates as follows: 
LVMI  = 0.8 (1.04 (LVAWd + LVIDd + LVPWd)
3
 - (LVIDd)
3
) + 0.6) 
LVAWd = left ventricular anterior wall in diastole 
LVIDd = left ventricular internal diameter in diastole 
LVPWd = left ventricular posterior wall in diastole 
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• Relative wall thickness was calculated as follows: 
RWT = (AWTd + PWTd) / EDD 
AWTd = anterior wall thickness in diastole 
PWTd = posterior wall thickness in diastole 
EDD = end diastolic diameter 
• Change in interventricular septal wall thickness was measured using the 
formula:  
ISWT = [(AWTs – AWTd) / AWTs x 100] 
AWTs = anterior wall thickness in systole  
AWTd = anterior wall thickness in diastole  
2.20.4 Tissue collection 
SHRSP were sacrificed after 4 weeks of implantation of the minipump. Rats were 
deeply anesthetized with isofluorane and the thoracic cavity opened to expose heart 
and lungs. Thoracic aorta was excised from its insertion into the diaphragm and the 
aorta, lungs and heart isolated. Carotid arteries, kidneys, liver, spleen, muscle and 
brain were collected and either snap frozen in liquid nitrogen, embedded in optimal 
cutting temperature compound (OCT) (VWR, Lutterworth, UK) or fixed in 10% 
(v/v) formalin overnight for embedding in paraffin for histological analysis. A fresh 
section of the thoracic aorta was retained to perform large vessel pressure 
myography. 
2.20.5 Large vessel pressure myography 
Pressure myography is used to measure the physiological function of large vessels. 
In this technique, small segments of the vessel are mounted between two wire 
cannulae and a suitable transmural tension applied thereby enabling a study of the 
effects on myogenic response to certain vasoactive compounds.  
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Pressure myography was used to assess the thoracic aortic endothelial function of 
SHRSP in each group. To prepare thoracic aortas, vessels were cleaned from 
connective tissue (Figure 2-3 A and B), 2 mm rings cut and then mounted in a large 
vessel myograph baths containing Kreb’s buffer (0.25 M NaCl; 0.001 M KCl; 2 mM 
MgSO4; 50 mM NaHCO3; 2 mM KH2PO4; 1 mM glucose; 2.5 mM CaCl2) 
maintained at 37ºC, oxygenated with 95% O2, 5% CO2 (Figure 2-3 C and D). The 
vessel was pre-treated with potassium-buffered Kreb’s (0.6 M KCl; 0.13 M MgSO4; 
0.25 M NaHCO3; 11 mM KH2PO4; 0.1 M glucose; 0.025 M CaCl2) followed by 
stimulation with PE and carbachol (1µM). Drugs were washed from the aortic rings 
and then rested for 30 minutes before cumulative concentration-response curves to 
PE (for contraction) and carbachol (for relaxation) (1 nM to 10 µM) were 
constructed. Aortic rings were then washed to remove drugs, rested for 30 minutes 
before treating the vessel with L-NAME (100 mM). After 20 minutes incubation 
period a concentration-response curve to PE (1 nM to 10 µM) was constructed.  
2.20.6 Histology 
Slides were coated with aminoalkylsilanes by placing blank slides in 2% (v/v) 3-
aminopropyltriethoxysaline (APES) and acetone solution for 30 seconds. Slides were 
washed twice with acetone for 10 seconds followed by 2 washes with dH2O for 5 
minutes each. Slides were then dried at 37ºC overnight. Five µm sections were cut 
and mounted onto slides. Slides were baked for 3 hours at 65ºC and then at 40ºC 
overnight. Paraffin was removed from the tissue sample by 2 x 7 minute washes in 
Histoclear (Fisher Scientific, Leicestershire, UK). Samples were then rehydrated by 
passing through an ethanol concentration gradient (100%, 95%, and 75%) for 7 
minutes each, followed by a final wash in dH2O for 7 minutes. 
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Figure 2-3. Pressure myograph. 
(A) Thoracic aortas from each group were cleaned from connective tissue and (B) 2 mm aortic rings 
were cut to perform large vessel myography. (C and D) Aortic rings were placed in the heads of the 
bath to enable transmural tension on the vessel to be applied and controlled by the micrometer. The 
bath was filled with Kreb’s buffer at 95% O2/5% CO2 pumped through the gas tube. Vessel 
contraction was recorded by the transducer and data collected. 
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2.20.6.1 Haematoxylin and eosin 
Deparaffinised sections were stained with haematoxylin for 2 minutes, washed in 
running tap water for 10 minutes, and excess haematoxylin removed by dipping 
slides in 95% ethanol 10 times. Nuclei were counterstained in eosin for 2 minutes 
followed by a further 5 minutes wash in running tap water. Slides were dehydrated 
through increasing concentrations of ethanol (75%, 95% and 100%) for 7 minutes 
each. Sections were then cleared by 2 washes in histoclear (7 minutes each) and 
mounted in DPX (non-aqueous xylene based mounting media) (Sigma, Dorset, UK) 
for analysing. The nuclei stained blue while the cytoplasm stained pink.  
2.20.6.2 Masson’s trichrome staining 
The Masson’s Trichrome kit (Sigma, Dorset, UK) was used as per the 
manufacturer’s instructions. Briefly, deparaffinised sections were incubated in 
Bouin’s solution overnight at room temperature and the following day slides were 
washed under running water. Next, Weigert’s Iron Haematoxylin solution was 
prepared by mixing equal parts of solution A (1% (v/v) haematoxylin in ethanol) and 
solution B [1.2% (w/v) ferric chloride and 1% (v/v) hydrochloric acid] and slides 
incubated for 5 minutes, followed by a 5 minutes wash under running dH2O. 
Sections were incubated in Biebrich Scarlet-Acid Fuchsin (0.9% (v/v) Biebrich 
Scarlet, 0.1% (v/v) acid fuchsin, 0.1% (v/v) acetic acid) for 5 minutes, and then 
washed for 5 minutes in dH2O. Slides were then placed in working 
phosphotungstic/phosphomolybdic acid solution (1 volume 10% (v/v) 
phosphotungstic acid, 1 volume 10% (v/v) phosphomolydic acid, 2 volumes of 
dH2O) for 5 minutes and then in Aniline Blue solution (2.4% (v/v) aniline blue, 2% 
(v/v) acetic acid) for a further 5 minutes. Sections were then washed for 2 minutes in 
1% (v/v) acetic acid followed by dehydration and mounted in DPX as described in 
haematoxylin and eosin section. The procedure stains cell nuclei black, the 
cytoplasm and muscle fibres appear red and collagen stains blue. Quantification of 
collagen stain was measured by transforming pixel values to optical density units 
using the Area of Interest selection tool and Macro within ImageProPlus software. 
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2.20.6.3 Picrosirius red staining 
After deparaffinisation and rehydratation as described above, sections were 
incubated under dark conditions in 0.1% (v/v) picrosirius red solution (300 mg sirius 
red F3B, 300 ml saturated picric acid) for 90 minutes at room temperature. Sections 
were then washed twice for 5 minutes in 0.01 N HCl, followed by 2 washes of 5 
minutes each with dH2O. Sections were then dehydrated, cleared and mounted as 
described in haematoxylin and eosin section. Picrosirius red stains collagen bright 
red. Quantification of collagen stain was measured by transforming pixel values to 
optical density units using the Area of Interest selection tool and Macro within 
ImageProPlus software. 
2.21 Plasmid cloning  
2.21.1 Annealing of oligonucleotides 
Oligonucleotides were resuspended in dH2O to a concentration of 100 µM. To 
anneal the oligonucleotides 1 µL of each was added to 98 µL of dH2O to a final 
reaction volume of 100 µL (final concentration of oligonucleotide 1 µM). Reactions 
were heated at 98ºC for 10 minutes and then cooled to 50ºC over 1 hour. Samples 
were subjected to electrophoresis in a 16% PA gel to confirm annealing (Section 
2.22.2.2).  
2.21.2 Plasmid preparation 
A sample of glycerol stock of transformed bacteria containing the plasmid (see 
section 2.22.6) was streaked onto agar and incubated overnight at 37ºC to allow the 
bacteria to grow. Single bacterial colonies were picked to be amplified in 10 mL of 
Luria-Broth (LB) for 6 hours at 37ºC with shaking and then transferred to 500 mL of 
LB for overnight culture at 37ºC with shaking. 
Plasmid DNA extraction 
Plasmid DNA was isolated using either the QIAGEN® plasmid purification Maxi kit 
or the QIAprep® Miniprep kit (Qiagen, Crawley, West Sussex, UK).  
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● Small scale preparation of plasmid DNA (Miniprep)  
This protocol is based on alkaline lysis (NaOH/SDS) of bacterial cells and the 
binding of DNA to a silica membrane in the presence of a high salt buffer followed 
by elution in low salt buffer. Briefly, individual plaques of competent bacteria 
transformed with the plasmid were collected and amplified in 5 mL LB overnight. 
Bacteria were pelleted and resuspended in 250 µL of P1 buffer (RNase A), lysed by 
addition of 250 µL of buffer P2 (NaOH/SDS) (which breaks down components of 
the bacterial cell wall and denatures proteins and chromosomal and plasmid DNA). 
The lysis buffer was neutralized by addition of 350 µL of N3 buffer (guanidinium 
chloride and acetic acid), which adjusts the reaction conditions to high salt binding 
and causes SDS, cellular debris and chromosomal DNA to precipitate. Precipitated 
samples were subjected to centrifugation at 18,000 g for 10 minutes at 4ºC and the 
supernatant transferred to the column containing a silica membrane to bind the 
plasmid DNA, followed by centrifugation for 1 minute at 4ºC. The eluted DNA was 
washed with 500 µL buffer PB (guanidinium chloride and propan-2-ol) to remove 
endonucleases and salts were removed by a further wash in 750 µL of buffer PE. 
DNA was eluted by incubation of the membrane with 50 µL of TE (Tris-EDTA) 
buffer and centrifugation at 18,000 g for 1 minute. 
● Large scale preparation of plasmid DNA (Maxiprep) 
This technique is based on the same principles of alkaline lysis as the Miniprep 
protocol, but utilises DNA binding via an anion-charge membrane under low salt and 
appropriate pH conditions. Briefly, a single colony of transformed competent 
bacteria was grown in 10 mL of LB for 6 hours at 37ºC with shaking at mid-log 
phase. The culture was then transferred to a new culture of 500 mL LB for 
amplification overnight at 37ºC with shaking. Bacteria were harvested by 
centrifugation at 6,000 g for 15 minutes at 4ºC. To lyse the bacteria the resulting 
pellet was resuspend in 10 mL P1 buffer (containing RNase A) and 10 mL of P2 
buffer (NaOH-SDS), followed by incubation for 5 minutes in order to allow the SDS 
to disrupt the cell membrane and the NaOH to denature chromosomal DNA and 
proteins. The lysis step was then neutralized by the addition of P3 buffer (acidic 
potassium acetate) for 20 minutes incubation on ice. This incubation step triggers 
precipitation of potassium dodecyl sulphate, which traps denatured proteins and 
DNA. Samples were then subjected to centrifugation at 20,000 g for 30 minutes at 
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4ºC. The supernatant containing the plasmid DNA was transferred to the column 
allowing the solution to flow through the resin by gravity to permit binding of 
plasmid DNA to the resin. To completely remove residual RNA and cellular debris, 
the column was washed twice with 3 mL of buffer QC and plasmid DNA eluted via 
washing the column with 15 mL of buffer QF. Plasmid DNA was desalted and 
concentrated by precipitating with 10.5 mL isopropanol and subjected to 
centrifugation at 15,000 g for 30 minutes at 4ºC. DNA pellet was washed with 5 mL 
of 70% (v/v) ethanol, then subjected to a further step of centrifugation at 15,000 g 
for 10 minutes. Finally, the DNA pelleted was left to air dry for 30 minutes before 
resuspension in 200 µL 1x TE (pH 8.0).  
2.22 Nucleic acid analysis and manipulations 
2.22.1 Restriction endonuclease digestion 
Restriction endonuclease digestion is a procedure to cut double stranded DNA by the 
action of a restriction endonuclease. These enzymes were isolated from bacteria for 
their ability to digest foreign double-stranded DNA at specific nucleotide recognition 
sequences in both strands (restriction sites).  These restriction sites occur by chance 
in the DNA and are mainly palindromic, allowing the enzyme to cut the same 
sequence in both strands. Usually the restriction endonucleases leave an over-
hanging end on each strand, termed the “sticky” end, facilitating ligation of 
nucleotide sequences with complementary “sticky” ends to generate recombinant 
DNA molecules. This technique was used to confirm plasmid DNA integrity and to 
prepare plasmid vectors for cloning. To verify plasmid DNA integrity 0.5-1.0 µg of 
plasmid DNA was digested in a 10 µL reaction containing 10 U of the specific 
restriction endonuclease and 1x of the appropriate reaction buffer. Reactions were 
incubated at 37ºC for 1 to 2 hours. To prepare plasmid vectors for cloning 50 – 100 
µg of plasmid DNA was digested with 50 U of the restriction endonuclease and 1x 
reaction buffer in a 100 µl reaction at 37ºC overnight. Complete reactions were 
analysed via agarose gel electrophoresis (section 2.22.2.1).  
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2.22.2 Gel electrophoresis 
Gel electrophoresis is used to separate nucleic acids or proteins using a crosslinked 
polymer set in an electrical current. Because DNA molecules and proteins carry a 
negative charge, when applying the electrical current, samples migrate towards the 
anode. When migration is performed through the polymer, the pores of the gel allow 
the separation of the nucleic acids or proteins depending on their size. The two main 
types of gel are agarose and acrylamide. They differentiate in the porosity of the 
polymer; acrylamide has smaller pores, so it is used for separating smaller 
fragments. 
2.22.2.1 Agarose gel electrophoresis 
Agarose gel electrophoresis is typically used for analyzing PCR fragments or 
restriction endonuclease digest reactions. Products were electrophoresed through a 
1% (w/v) agarose gel in 1x Tris/Borate/EDTA (TBE) (10 mM Tris, 10 mM boric 
acid, 10 mM EDTA, pH 8.3) and ethidium bromide (10 ng/mL). Typically, samples 
and DNA size markers (100 bp or 1 kb, depending on the size of the fragment of 
interest) were loaded in 6x loading gel (0.02% (w/v) bromophenol blue, 0.02%  (v/v) 
xylene cyanole and 2.5% (v/v) glycerol) into pre-cast wells and current was applied. 
Gels were electrophoresed at a constant voltage of 90 to 100 V with TBE as a 
running buffer. Bands were visualised and photographed on a molecular imager 
ChemiDoc™ XRS+ Imaging System (Bio-Rad Laboratories, Hemel Hempstead, 
UK). 
2.22.2.2 Polyacrylamide gel electrophoresis  
In polyacrylamide gels the pores of the polymer are smaller, making it better suited 
to resolve small DNA fragments (up to a maximum of 1000 bp). PAGE was used to 
analyse single stranded oligonucleotides annealing efficiency. Oligonucleotides were 
analysed in 16% PA gels. Either 400 ng of annealed oligonucleotides or 200 ng of 
single stranded oligonucleotides were loaded in 6x loading gel (section 2.22.2.1). 
Gel was subjected to electrophoresis at a constant voltage of 100 V.  
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2.22.3 Gel extraction of DNA 
This technique was design to extract PCR products or excised DNA fragments 
following restriction endonuclease digestion to eliminate excess nucleotides, primers 
or enzyme reaction reagents. The Wizard® SV Gel and PCR Clean-Up System 
(Promega, Southampton, UK) was used to extract plasmid DNA following the 
manufacturer’s instructions. Briefly, following separation of plasmid DNA or PCR 
products by agarose gel electrophoresis, the gel portion containing the DNA segment 
of interest was cut with a clean scalpel blade and then transferred to a 
microcentrifuge tube containing membrane binding solution (4.5 M guanidine 
isothiocyanate, 0.5 M potassium acetate, pH 5) at a ratio of 10 µL of binding 
solution per 10 µg DNA. DNA was mixed well and incubated at 65ºC for 10 minutes 
(or until the gel was fully dissolved). The solution was then transferred to a 
minicolumn, incubated for 1 minute and then subjected to centrifugation at 16,000 g 
for 1 minute at 4ºC. The minicolumn was washed twice with Washing Solution (10 
mM potassium acetate pH 5, 16.7 µM EDTA pH 8, 80% (v/v) ethanol) with 700 µL 
and 500 µL, respectively. After each wash samples were subjected to centrifugation 
at 16,000 g for 1 minute and then 5 minutes at 4ºC. Gel-purified DNA was eluted 
with 50 µL of TE and centrifugation at 16,000 g for 1 minute. DNA was stored at -
20ºC. 
2.22.4 Dephosphorylation of plasmid DNA ends 
To avoid recircularization of digested plasmid DNA in ligation reaction the 5’ 
phosphates from digested plasmid DNA were removed. Briefly, 5 U Shrimp 
Alkaline Phosphatase (SAP) (Promega, Southampton, UK) was added per 2.5 µg of 
plasmid DNA and the samples incubated for 15 minutes at 37ºC followed by 
inactivation of the SAP by 15 minutes incubation at 65ºC. 
2.22.5 Ligation of oligonucleotides into digested plasmid 
DNA 
To ligate annealed oligonucleotides the dephosphorylated plasmid DNA T4 DNA 
ligase (Promega, Southampton, UK) was used. Ligation reactions were performed at 
Chapter 2  
81 
ratios of 5:1, 3:1, 1:1, 1:3 and 1:5 molar ratio of vector:insert were performed to 
maximize the chance of obtaining the correct colonies. To calculate ratios the 
following formula was used: 
          ng of insert  =  (ng of vector) x (kb size of insert)  x (molar ratio) 
                                                 kb size of vector 
for example: 
ng of vector = 50 ng 
kb size of insert = for Ang1-7 0.048 kb 
                    for Ang1-9 0.054 kb 
kb size of the insert = 1 kb 
 
1 U of T4 DNA ligase in a final reaction volume of 10 µL was added and samples 
incubated at 4ºC for 3 hours, before proceeding to transform mixture into competent 
bacteria to select ligated colonies (section 2.22.6). 
2.22.6 Transformation of competent bacteria 
DNA is a hydrophilic molecule and naturally repelled by cell membranes. In order 
for DNA to cross the cell membrane, bacteria have to be made “competent” by 
producing small holes in the bacteria cell membrane by suspending the cells in ice 
cold 50 mM CaCl2. We transformed ligation reactions into competent E.coli JM109 
(Promega, Southampton, UK). Briefly, 50 µL of competent bacteria were incubated 
with 5 µL ligation reaction for 30 minutes on ice allowing the DNA to bind to the 
membrane. Samples were then incubated for 1 minute at 42ºC in a water bath, heat-
shocked and immediately put back on ice for 2 minutes. 450 µL SOC media (20g/L 
bactotryptone, 5 g/L yeast extract, 10 mM NaCl, 2.5 mM KCl, 20 mM glucose) was 
added and samples placed in an orbital shaker at 180 rpm / 37ºC for 1 hour. 250 µL 
bacteria was then pipetted onto a LB agar plate (10 g/L bactotryptone, 5 g/L 
bactoyeast extract, 5 g/L NaCl, 15 g/L agar, pH7.5) with 100 µg/mL of ampicillin, 
and sample was spread over the agar surface and incubated at 37ºC overnight. 
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Ratio Ang1-7 Ang1-9 
1:5 10.2 ng 13.5 ng 
1:3 7.2 ng 8.1 ng 
1:1 2.4 ng 2.7 ng 
3:1 0.8 ng 0.9 ng 
5:1 0.48 ng 0.54 ng 
 
Table 4. Amount of Ang1-7 and Ang1-9 oligonucleotides duplexes used for plasmid 
ligation. 
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2.22.7 DNA sequencing 
The dideoxy sequencing technique was used. This procedure is based on the use of 
dideoxynuclotides labelled with different fluorophores which have a missing 
hydroxy group at the 3' position, making it impossible for another nucleotide to bind, 
resulting in a series of different size DNA fragments which are visualized through 
the last nucleotide incorporated as a fluorescent labelled dNTP. The DNA sequencer 
utilises a laser beam focused in a constant position on the electrophoresis gel, to 
excite the fluorescence caused by the different fluorophores and according to the 
different wavelength that each fluorophore emits the sequencer translates the 
information to the 4 different nucleotides and generates a DNA sequence. 
In order to confirm oligonucleotide sequence plasmid DNA was extracted from 
amplified single colonies of competent bacteria, see section 2.21.2. 300 ng DNA was 
used as a template for sequencing using a specific forward primer: 5’-
TGGATGAATATAAACTCT-3’; and individual reverse primers (Table 5). Each 
sequencing reaction contained 1.6 nM primer (forward or reverse), 0.5 µL v.3.1 
Ready reaction mix (Applied Biosystems, MA, USA), 3.5 µL v3.1 sequencing buffer 
(Applied Biosystems, MA, USA) in a 20 µL reaction. The cycle conditions were 25 
cycles of 96ºC for 50 seconds to denature, 50ºC for 20 seconds to anneal and 60ºC 
for 3 minutes to extend the DNA sequenced fragment. The sequencing reaction was 
cleaned with CleanSEQ (Agencourt Bioscience Corporation, MA, USA) following 
the manufacturer’s instructions. Results were then analysed using an ABI 3730 
automated sequencer using SeqScape v2.0 analysis software. 
2.22.8 Generation of glycerol stocks 
For archiving of plasmid colonies glycerol stocks were generated. 800 µL of the 
bacterial culture containing the plasmid DNA was transferred to a 1.5 µL Eppendorf 
and 200 µL of sterile glycerol added. Glycerol stocks were stored at -80ºC. 
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2.23 Production of recombinant adenoviruses 
RAdAng1-7 and RAdAng1-9 
Production of recombinant adenoviruses (RAd) was based on cotransfection of two 
plasmids via the method first described by McGrory et al. (McGrory et al., 1988). 
Very briefly, two plasmids (an adenovirus genome vector and a shuttle vector 
containing a transgene expression cassette) are cotransfected into the 293 cell line [a 
human embryonic kidney cell line transformed with the entire left-hand end of the 
adenovirus serotype 5 genome containing the E1 gene, essential for virus replication 
(Graham et al., 1977)] recombination between the 2 plasmids removes the early 
region 1 of the adenovirus and inserts the expression cassette encoding the transgene 
This produces replication deficient adenoviral vectors expressing the transgene that 
can be propagated in the 293 cell line. 
2.23.1 Co-transfection of genome vector and shuttle 
vector for generation of recombinant adenovirus 
Recombinant adenoviruses were generated in low passage 293 cells by 
recombination of pVQ-CMV-K-NpA shuttle vector (with the appropriate expression 
cassette in it) and the pacAd59.2-100 genome vector. Transfection of plasmid DNA 
was mediated by Ca
2+
/phosphate-mediated gene transfer. This technique is 
commonly used to transfer DNA into the cell, via the DNA forming a complex with 
Ca
2+
 phosphate facilitating its association with the cell membrane, allowing the 
uptake of this precipitate by the cell and passive transport to the nucleus. Low 
passage 293 cells were plated at 2x10
6
 cells per 25 cm
2
 tissue culture flask in order 
to reach 70-80% confluence next day. Cells were washed twice in PBS, and media 
replaced with 1.5 mL DMEM supplemented with 10% (v/v) FCS, 25 mM HEPES 
pH 7.9. Next, drop-wise addition of a solution containing 320 µL media (DMEM 
supplemented with 25 mM HEPES pH 7.1) 16 µL of 1 M CaCl2 and 21 µg plasmid 
DNA (14 µg pacAd5 9.2-100 plasmid and 7 µg of pVQ-CMV-K-NpA-Ang1-7 or 
pVQ-CMV-K-NpA-Ang1-9) was performed with rocking of the flask. Flasks were 
incubated at 37ºC for 16 hours before washing the cells gently with PBS and 
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changing the media to 7 mL standard cell culture media. Cell media was replaced 
every 2 to 3 days until cytopathic effect was apparent. 
2.23.2 Generation of crude adenovirus stock  
Once the cytopathic effect was evident cells were harvested to extract recombinant 
adenoviral vectors. Adenovirus were recovered by lysing the cells using Arklone P 
(trichlorotrifluoroethane) (ICI Ltd, Cheshire,UK) or 3 freeze/thawing cycles in dry 
ice and a 37ºC water bath. Briefly, cells were collected in 50 mL tubes and subjected 
to centrifugation at 250 g for 15 minutes at room temperature. The pellet was 
resuspended in 1 mL PBS and an equal volume of Arklone P added. The tube was 
inverted for 10 seconds followed by shaking for 5 seconds. This step was repeated 
for 1 minute. Samples were subjected to centrifugation at 750 g for 15 minutes to 
form 3 layers. The upper layer consists of an aqueous solution, containing the virus, 
while the middle and lower layers contain cellular debris and solvent, respectively. 
The top layer containing the adenovirus was transferred to a fresh tube and stored at 
-80ºC until purification via CsCl density gradient centrifugation. 
2.23.3 Plaque purification by end-point dilution of 
recombinant adenovirus 
Crude stocks of recombinant adenovirus may be the result of several recombination 
events during the plasmid cotransfection in 293 cells. In order to generate stocks of 
single recombinant adenoviral vectors we purified the crude stock via serial dilutions 
in 293 cells. 293 cells were plated in a 96 well plate (10 wells in a row, 8 rows) at 50 
to 60% confluence. Serial dilutions of crude adenovirus stocks were prepared at 
dilutions ranging from 10
-2
 to 10
-11
 in standard cell culture media. The media in each 
well of a row was replaced with 100 µL of sequential adenoviral dilutions (10 wells 
per row), leaving the bottom row for control cells (untransfected). The plate was then 
incubated in a humidified chamber at 37ºC in 5% CO2 overnight. Media in each well 
was then changed for 200 µL of fresh media and every 2-3 days onwards until the 8
th
 
day. Cells and media of 3 wells with a visible cytopathic effect at the highest dilution 
were collected for storage at -80ºC. For 1 well recombinant adenovirus was extracted 
by addition of an equal volume of Arklone P and a second round of plaque 
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purification performed. By the 8
th
 day of the second plate, plaques of the highest 
dilution were consider plaque pure and were extracted by Arklone P (described 
above) and stored at -80ºC as recombinant adenovirus stock.  
2.23.4 Generation of seed stocks of recombinant 
adenovirus 
To generate seed stocks of recombinant adenoviral vectors, 50 µL of plaque pure 
virus was added to a 1x T-150 flask of 293 cells. Transduced cells were incubated 
for 3 to 5 days for the cytopathic effect to be complete. Cells were collected and 
subjected to centrifugation to pellet. The cell pellet was resuspended with Arklone P 
as previously described (section 2.23.2). Virus was aliquoted and stored at -80ºC.  
2.23.5 Generation of high–titer stocks of recombinant 
adenovirus 
To generate high-titer stocks of recombinant adenoviral vectors 293 cells were 
subcultured in 20-30 150 cm
2 
tissue culture flasks. When cells were approximately 
80-90% confluent they were infected with 50 µL of seed stock of recombinant 
adenovirus. Media was changed every 3 days until the cytopathic effect initiated, and 
then cells were fed with 10 mL of fresh media and incubated until all cells were 
detached from the flask. Once detached, cells were collected immediately to avoid 
prolonged incubation periods of detached cells which cause loss of virus titer. Cells 
were pelleted at 250 g for 10 minutes at room temperature and the pellet resuspended 
in 8 mL PBS, before extraction with Arklone P as described above, mixing it well 
for 1 minute.  
2.23.6 CsCl density gradient purification  
Virus extraction with solvents such as Arklone P leaves contaminating cellular 
debris in the preparation which may be cytotoxic when using the virus in vitro and in 
vivo. For this reason a CsCl density gradient was used to separate these cellular 
proteins and produce pure virus stocks. This method is also a simple and efficient 
method to concentrate adenovirus stocks. First 14 mL cellulose-nitrate ultra-clear 
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centrifuge tubes (Beckman Coulter Ltd, Buckinghamshire, UK) were sterilized with 
70% (v/v) ethanol followed by rinsing in sterile dH2O. In these tubes a 3 layer 
gradient was formed by pipetting a lower layer of 2 mL CsCl density 1.45 g/cm
3
, 
followed by careful layering of 3 mL of CsCl density 1.32 g/cm
3 
and finally 2 mL of 
40% (v/v) glycerol. Next the crude adenovirus preparation was added drop-wise to 
the top layer and the tube topped up with PBS. Next tubes were loaded into a Sorvall 
Discovery 90 rotor bucket, placed in the rotor (RPS4OT-859) and subjected to 
ultracentrifugation at 90,000 g for 1.5 hours at room temperature with maximum 
acceleration and free deceleration. Following centrifugation a discrete white band is 
formed between the CsCl 1.45 and the CsCl 1.32 density layers containing the virus. 
To collect the band the tube was gently pierced with a 22 G needle and syringe just 
underneath the virus band, and the virus carefully collected into the syringe. The 
virus was then transferred to a Slide-A-Lyser dialysis cassette with a molecular 
weight cut off of 10,000 kDa (Perbio Science UK Ltd, Northumberland, UK) and 
dialysed for 2 hours against 2 L of 0.01 M Tris pH 8 / 0.001 M EDTA (dialysis 
buffer). After 2 hours the buffer was changed to 2 L of fresh dialysis buffer 
supplemented with 10% (v/v) glycerol and left overnight. Finally, the virus was 
removed from the dialysis cassette, aliquoted into 50 µL volumes and stored at -
80ºC. 
2.23.7 Titration of recombinant adenoviral stocks  
Titration of recombinant adenoviral vectors was performed via two methods, 
determining the number of physical virus particles or by calculating the plaque 
forming unit (biological titer) per mL (pfu/mL). 
2.23.7.1 Recombinant adenovirus particle titres 
Viral particles titers were calculated by measuring the protein content of the virus 
stock by MicroBCA assay kit (Pierce, Rockford, IL, USA). Following 
manufacturer’s instruction BSA standards ranging from 0.5 µg/mL to 200 µg/mL 
were prepared and 150 µL loaded in duplicate into wells of a clear 96 well plate. 
Next 1, 3 and 5 µL of virus stock in duplicate were added to the 96 well plate and the 
volume adjusted to 150 µL using PBS. Next, 150 µL of BCA working reagent was 
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added to all samples and standards and the plate incubated at 37ºC for 2 hours. 
Absorbance of each well at 570 nm was measured in a Wallac Victor
2
 plate reader 
(Wallac, Turku, Finland). To calculate the protein content the blank absorbance was 
subtracted from the gross readings for each sample and standard. The value of the 
unknowns was then exported to the plotted standard curve to generate the virus 
particle titre according to the following formula described by Von Seggern et al. 
(Von Seggern et al., 1998): 
1 µg protein = 1 x 10
9
 viral particles 
2.23.7.2 Titration of recombinant adenovirus by end-point 
dilution assay 
This form of titration quantifies only the virus particles that are capable of forming a 
plaque. This technique is based on end-point dilution, through serial dilutions of the 
virus in 293 cells was described in section 2.23.3. On the 8
th
 day of cell infection, 
pfu/ml was calculated according to the following equation (Nicklin, 1999): 
The proportionate distance (PD) =   
                 % positive wells above 50% -50                                  
             (% positive wells above 50%) – (% positive below 50%) 
and log ID50 (infectivity dose) =  
       log dilution above 50% + (proportionate distance x dilution factor) 
For example; for a plate with 6 positive well at 10
-10
 dilution and 1 positive well at 
10
-11
 dilution the calculation would be as follows: 
 
PD = 60% - 50%     = 0.2 
         60% - 10% 
 
logID50 = -10 + (0.2  x -1) = -10.2 
 
TCID50 (tissue culture infectivity dose) =     1 
             10
-10.2 
TCID50/100µl = 10
10.2 
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X dilution factor (= 10) 
 
TCID50/ml = 10
11.2 
= 1.584 x 10
11
 TCID50/mL 
 
1 TCID50 ≈ 0.7 pfu 
 
Final titer = (1.584 x 10
11
) x 0.7 = 1.11 x 10
11
 pfu/mL 
2.24 In vitro infections 
2.24.1 Optimization of virus infection dose with β-
galactosidase expression 
Different cell lines vary in the concentration of virus required for efficient 
transduction. In order to optimise adenoviral gene delivery to H9c2 cardiomyocytes 
a recombinant adenovirus containing a lacZ gene which expresses β-galactosidase 
(RAd35) (Wilkinson et al., 1998) was used. This assay uses X-gal as a substrate for 
β-galactosidase (β-gal), converting it into a blue insoluble product, visualizing cells 
producing β-gal as a result of virus transduction. 
H9c2 cardiomyocytes were seeded in 24 well plates at a density of 1x10
4
 cells per 
well and incubated overnight in a humidified chamber at 37ºC 5% CO2. Cells were 
transduced with 10, 50, 100, 300, 500 and 1000 pfu/cell of RAd35 and incubated for 
24 hours at 37ºC. Cells were then washed twice with PBS and fixed with 2% (w/v) 
PFA (Sigma, Dorset, UK) on ice for 15 minutes, the PFA removed by 2 washes in 
PBS, X-Gal stain (77mM Na2HPO4, 23 mM NaH2PO4, 1.3 mM MgCl2, 3 mM 
K3Fe(CN6), 3 mM K4Fe(CN6), 20 mg X-Gal) (Melford Laboratories Ltd, Ipswich, 
UK) added. Cells were incubated for 24 hours at 37ºC to facilitate staining. Cells 
were then visualized using light microscopy.  
To assess RAdAng1-7 and RAdAng1-9 in the hypertrophy assay H9c2 
cardiomyocytes were seeded in a 6 well plates at a density of 3x10
4
 cells per well 
and incubated overnight in a humidified chamber at 37ºC 5% CO2. Cells were 
transduced with 500 and 1000 pfu/cell of RAdAng1-7 or RAdAng1-9 and incubated 
for 24 hours at 37ºC. Cells were then changed to serum free media followed by 
stimulation with 100 nM AngII and cell incubated for 96 hours at 37°C. After 4 days 
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of incubation cells were fixed with 2% (w/v) PFA, stained with 2% (v/v) crystal 
violet and cell size measures using Image ProPlus software as described previously. 
To asses receptor use A779 (10 µM) and PD123,319 (500 nM) were added at the 
same time as addition of RAdAng1-7 or RAdAng1-9. 
To investigate RAdAng1-7 or RAdAng1-9 in adult rabbit primary left ventricular 
cardiomyocyte, these cells were seeded at 3x10
4
 cells per well and transduced with 
500 and 1000 pfu/cell of RAdAng1-7 or RAdAng1-9 1 hour before stimulation with 
AngII, followed by incubation for 24 hours at 37°C. Length and midpoint width was 
measured and volume calculated as described. 
2.25 Statistical analysis 
Experiments were performed in triplicate on 3 different occasions. Data are shown as 
mean ± standard error of the mean (ME ± SE) and representative of three 
independent experiments. Paired Student’s t test and one way ANOVA with 
Bonferroni’s correction for multiple comparisons were applied and statistical 
difference was considered with p values <0.05.  
In vivo experiments were performed with 6 animals per group. Comparison between 
groups for the myography data was performed by repeated measures ANOVA 
(analysis of variance) as described previously (Davidson et al., 1995). Data from 
radio-telemetry was analysed by two way ANOVA with Bonferrroni’s correction. 
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C H A P T E R   3 
 
Assessment of the effects of AngII, 
Ang1-7 and Ang1-9 on 
cardiomyocyte hypertrophy 
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3.1 Introduction 
The renin angiotensin system receptors AT1R, AT2R and Mas are all classified as 
GPCRs, however their mechanisms of action vary widely. Although, AngII is an 
agonist for the AT1R and AT2R, it is through the AT1R that AngII classically 
signals (Aplin et al., 2009). AngII binds to the AT1R and induces hypertrophy 
through the Gαq/11-subunit in vascular smooth muscle cells and by inducing 
transactivation of the epidermal growth factor receptor as well as phosphorylation of 
Rho-kinase (Ohtsu et al., 2008). AngII also activates PLC beta 3 and the Erk1/2 
pathway through Gαq/11-subunit to induce cardiomyocyte hypertrophy (Lorenz et al., 
2009b, Bai et al., 2004, Lorenz et al., 2009a). The function of the AT2R is less well 
understood. Although it is thought to act through the Gαi-subunit there is conflicting 
evidence. Mukoyama et al. showed that the AT2R retained a 5-amino acid motif 
which impaired the coupling of a G-protein (Mukoyama et al., 1993). However in 
2000, Hansen et al. demonstrated activation of the Gαi-subunit by stimulation of 
AT2R with AngII, AngIII or Ang1-7 (Hansen et al., 2000). Very few studies have 
linked the Mas receptor to G-protein subunit activation, although there is evidence 
that Gαq/11-subunit activation by Mas can lead to induction of AT1R expression 
(Canals et al., 2006).  
As well as the specificity in G-protein subunits in enabling coupling to specific cell 
signalling pathways homo and heterodimerization of GPCR has been shown to 
regulate activation of signalling pathways, adding further complexity to our 
understanding of cell signalling mechanisms (Milligan, 2007, Milligan, 2008, 
Schulte and Levy, 2007). Many studies have shown an interaction between the B2 
bradykinin receptor and Mas receptor, where by Ang1-7 potentiates bradykinin-
induced vasodilatation through the Mas receptor (Peiro et al., 2007, Ueda et al., 
2001). Furthermore, Castro et al., have shown an interaction between the AT1R, 
AT2R and Mas in murine hearts (Castro et al., 2005). 
Many cell signalling pathways converge on activation of sets of transcription factors. 
Transcription factors regulate the expression of certain genes and the primary 
response in many pathways is an increase in genes such as fos, c-jun, myc and junB 
within the first hour of stimulation. These genes are termed the immediate-early 
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genes and their expression is transitory, returning to normal levels after a couple of 
hours, independently of the presence of the stimuli (Kim and Iwao, 2000, Diez et al., 
2001, Rajabi et al., 2007). Sadoshima et al. demonstrated the expression of these 
immediate-early genes in cultured cardiac myocytes stimulated with AngII 
(Sadoshima and Izumo, 1993). Because of their early expression these genes are 
believed to be expressed as the cardiomyocyte adapts to the stimuli. After induction 
of the early genes AngII induces myocyte gene reprogramming to a foetal phenotype 
increasing the expression of ANP, BNP, β-MHC, skeletal α-actin and TGF-β among 
others (Chien et al., 1991). Concurrently the expression of genes related to 
intracellular Ca
2+
 metabolism such as phospholamban and Ca
2+
-ATPase are 
decreased (Chien et al., 1991).   
Several studies have shown that AngII induces cardiac hypertrophy through the 
AT1R (Lamas and Pfeffer, 1991, Kaneko et al., 1996) AngII promotes cardiac 
hypertrophy by activating several pathways, including activation of PKC and 
alterations in Ca
2+
 handling, to promote cardiomyocyte hypertrophy (Liao et al., 
1997, Qin et al., 2001, Heineke and Molkentin, 2006, Liu et al., 2008, Chintalgattu 
and Katwa, 2009). AngII also promotes cardiac hypertrophy and fibrosis by 
phosphorylation of ERKs (Liao et al., 1997, Min et al., 2005, Aplin et al., 2007, 
Olson et al., 2008). Activation of JNK and p38 phosphorylation by AngII has also 
been shown to increase the expression of hypertrophy markers (Kim and Iwao, 2000, 
Force et al., 1996). However, AngII also directly induces c-fos, jun B, Egr-1, c-myb 
and c-myc (Aaronson and Horvath, 2002, Kandalam and Clark, 2009, Mehta and 
Griendling, 2007). 
AngII is also important in extracellular remodelling. It has been shown that 
phosphorylation of c-Src tyrosine kinase leads to extracellular matrix remodelling 
and activation of cytoskeletal proteins to allow cardiomyocyte remodelling (Kodama 
et al., 1998, Taniyama et al., 2003, Mehta and Griendling, 2007). AngII also 
regulates extracellular matrix remodelling by increasing the synthesis of collagen, 
fibronectin, promoting the accumulation of proteoglycans and increasing expression 
of TGF-β (Ju and Dixon, 1996, Huang et al., 2008, Tiede et al., 2003, Brilla et al., 
1993, Schroder et al., 2006). 
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In cardiac hypertrophy the role of the AT2R is controversial. Blockade of AT2R in 
AngII-infused rats increased left ventricular growth (Bartunek et al., 1999). AT2R 
inhibition also increased protein synthesis and augmented PKC translocation to the 
membrane (Bartunek et al., 1999). Furthermore, lentivirus-mediated overexpression 
of the AT2R in SHRSP diminished left ventricular wall thickness and collagen 
without affecting blood pressure (Metcalfe et al., 2004). Aortic banding in transgenic 
mice overexpressing the AT2R reduced left ventricular myocyte diameter as well as 
decreasing collagen levels (Yan et al., 2008). Although the typical hypertrophy 
markers were not regulated, the expression of phospholamban (PLB), as well as the 
ratio between SERCA2 and iNOS were higher, indicating a role for the AT2R in 
hypertrophy regulation (Yan et al., 2008). However, there have been studies where 
the AT2R seems to have a prohypertrophic effect. D’Amore et al. showed that 
adenoviral mediated overexpression of AT2R in cardiomyocytes resulted in 
hypertrophy (D'Amore et al., 2005). Furthermore, this AT2R-mediated pro-
hypertrophic effect seemed to be independent of any agonist-mediated stimulation of 
the AT2R. In accordance to this study, Yan et al. showed that transgenic mice 
overexpressing AT2R had altered left ventricular function and increased cardiac 
myocyte diameter and collagen levels which led to dilated cardiomyopathy (Yan et 
al., 2003b). At the molecular level an increase in phosphorylated PKC- α and β was 
also demonstrated (Yan et al., 2003b). Overall the role of AT2R signalling in cardiac 
hypertrophy is unclear.  
Conversely the AT2R has also been demonstrated to mediate an anti-fibrotic role. 
AT2R blockade in rat heart and kidney increases fibrosis (Morrissey and Klahr, 
1999). In cardiac fibroblasts overexpressing the AT2R, blocking its activation via the 
antagonist PD123,319 increased the production of collagenous protein, fibronectin, 
collagen type I and overall protein synthesis (Ohkubo et al., 1997). In AT2R 
knockout mice an increase in interstitial and perivascular fibrosis has been observed 
(Wu et al., 2002, Yan et al., 2003b)(Ichihara et al., 2001) . These results have also 
been reported in AT2R overexpressing transgenic mice, where AngII-induced 
perivascular fibrosis was abolished (Kurisu et al., 2003). 
Ang1-7 is one of the novel peptides of the renin-angiotensin system. ACE2 is 
responsible for its generation by cleaving AngII. It has been reported that Ang1-7 
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blocks the classical effects of AngII, such as proliferation in vascular smooth muscle 
cells, cardiomyocyte hypertrophy, and fibroblast proliferation (Santos et al., 2006, 
Mercure et al., 2008, Grobe et al., 2007b, Grobe et al., 2006, De Mello, 2009), 
among others by interacting with the Mas receptor (Santos et al., 2003, Pinheiro et 
al., 2009). Although described as one of the peptides formed by ACE2 (by cleaving 
AngI) (Donoghue et al., 2000) and being a substrate to form Ang1-7 (by ACE 
cleavage) (Schluter and Wenzel, 2008), no direct effect of Ang1-9 has been 
described. Ang1-9 has, however, been described as a competitive inhibitor of ACE, 
as Ang1-9 is a substrate for this hormone (Snyder and Wintroub, 1986). 
Furthermore, Erdos et al. demonstrated that Ang1-9 had a potentiating effect on 
bradykinin-induced intracellular Ca
2+
 concentration and NO synthesis in 
cardiomyocytes and endothelial cells (Erdos et al., 2002). 
Here, the role of AngII, Ang1-7 and Ang1-9 were investigated in two in vitro models 
of cardiomyocyte hypertrophy using the rat H9c2 neonatal cardiomyocyte cell line 
and adult rabbit primary cardiomyocytes. 
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3.2 Results 
3.2.1 AngII mediated induction of hypertrophy in rat neonatal 
H9c2 and adult rabbit left ventricular cardiomyocytes 
It has been reported that when cardiomyocytes are stimulated with AngII an increase 
in hypertrophy markers, sarcomeric rearrangement and an increase in cell size can be 
observed (Chien et al., 1991, Carreno et al., 2006, Rajabi et al., 2007). To study the 
role of angiotensin peptides in hypertrophy, we first established an AngII-induced 
hypertrophy model in H9c2 cardiomyocytes and adult rabbit left ventricular 
cardiomyocytes.  
In order to determine the optimal dose of AngII for hypertrophy induction in H9c2 
and rabbit primary cardiomyocytes, both cell types were stimulated with a range of 
AngII concentrations. The range of doses found in the literature for H9c2 cells were 
from 100 nM to 1 µM (Li et al., 2005d, Guo et al., 2009, Kodama et al., 1998, 
Nakagami et al., 2003). Therefore H9c2 cardiomyocytes were incubated with 100 
nM, 300 nM, 500 nM and 1 µM AngII. Following 96 hours of incubation with AngII 
H9c2 cells were fixed and stained with 2% Crystal violet and cell size measured 
blindly (section 2.6). The same AngII dose range was used in rabbit primary 
cardiomyocytes, however cell width and length were measured and volume 
calculated following 24 hour incubation. 
For AngII stimulated H9c2 cardiomyocytes there was a trend for an increase in cell 
size at all doses of AngII (Figure 3-1 A), however, only at 100nM and 500nM was a 
significant increase in cell size compared to unstimulated cells observed 
(unstimulated = 196.8 ± 8.3 µm; AngII 100 nM = 262.3 ± 10.8 µm; AngII 500 nM = 
235.3 ± 7.9 µm; p < 0.05, n = 50 cells) (Figure 3-1 B). 100 nM of AngII was 
therefore selected for use in the H9c2 cardiomyocyte hypertrophy model.  
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Figure 3-1. AngII-induced hypertrophy in H9c2 cardiomyocytes. 
(A) Representative photomicrographs of unstimulated and AngII-stimulated H9c2 rat neonatal 
cardiomyocytes (Scale bar = 100μm. Magnification:10x). (B) H9c2 cardiomyocytes were incubated 
for 24 hours in serum free media before addition of AngII at 100, 300, 500 or 1000 nM AngII for 96 
hours. Cells were then fixed, stained with crystal violet and cell size measured using ImageProPlus. * 
p<0.05 vs. control unstimulated cells. 
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Reorganization of α-actin microfilaments in cardiac myocytes occurs during 
hypertrophy (Samuel et al., 1984) and has been established as a hypertrophic 
phenotype. Furthermore, in cultured cardiomyocytes AngII has been shown to 
induce reorganization of sarcomeres (Thomas et al., 2002). In order to investigate 
any reorganization in cardiomyocytes sarcomeres induced by AngII, α-actin 
filaments of H9c2 cardiomyocytes were stained with a F-phalloidin-FITC conjugate 
following stimulation with AngII. Unstimulated cardiomyocytes displayed an 
irregular pattern of sacromere units throughout the cytoplasm of the cell (Figure 3-
2). The increased organization of the sarcomeres was clearly evident in AngII-
stimulated H9c2 cardiomyocytes (Figure 3-2 A). Next, BNP gene expression was 
analysed in AngII-stimulated H9c2 cardiomyocytes using Q-RT-PCR. Physiological 
BNP gene expression was significantly upregulated when cardiomyocytes were 
stimulated with 100 nM AngII compared to unstimulated H9c2 cells (Figure 3-2 B). 
In adult rabbit left ventricular primary cardiomyocytes cell volume was calculated 
using width and length measurements (section 2.6). Upon quantifying measurements 
of width and length separately a significant difference in cell size was only apparent 
for cell width, suggesting that AngII may induce concentric hypertrophy in these 
cells (Figure 3-3 A, B and C). At 100nM AngII did not cause a significant increase 
in cell volume. However, at 300 nM, 500 nM and 1 µM a significant increase in cell 
width was induced (31.7 ± 7 nm vs. 37.8 ± 8.3 nm; p<0.01), leading to an increase in 
volume (unstimulated = 68.4 ± 1.8 µm
3
; AngII 100 nM = 72.4 ± 1.9 µm
3
; AngII 300 
nM = 75.9 ± 2.1 µm
3
; AngII 500 nM = 78.7 ± 2.1 µm
3
; AngII 1 µM = 78.3 ± 2 µm
3
) 
(Figure 3-3 D). Since 500 nM AngII induced the greatest difference in cell volume 
compared to unstimulated cells this dose was selected for use in further experiments 
in rabbit primary cardiomyocytes. 
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Figure 3-2. Characterization of AngII-induced hypertrophy in H9c2 cardiomyocytes. 
H9c2 cardiomyocytes were incubated for 96 hours with 100 nM AngII to induce hypertrophy. To 
evaluate α-actin filament reorganization (A) cardiomyocytes were fixed and stained with FITC-
labelled phalloidin (Magnification: top panel 40x, bottom panel 100x; scale bar = 100 µm); to 
evaluate BNP expression (B) the mRNA from H9c2 cardiomyocytes +/- AngII-stimulation was 
extracted and cDNA generated subjected to QRT-PCR for BNP. Results were normalized to 
expression of 18S RNA (* p<0.001). 
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Figure 3-3. AngII-induced hypertrophy in left ventricular adult rabbit primary 
cardiomyocytes.  
(A) Representative photomicrographs of unstimulated and AngII-stimulated left ventricular adult 
rabbit primary cardiomyocytes (Scale bar = 100 μm. Magnification: 20x). Left ventricular primary 
cardiomyocytes were extracted from adult rabbits via collagenase digestion, plated and immediately 
stimulated with 100 nM, 300 nM, 500 nM and 1 µM AngII for 24 hours. (B) Cell width and (C) 
length was measured using ImageProPlus. (D) Cell volume was calculated using cardiomyocyte width 
and length. The increase of volume in primary cardiomyocytes was due to increase of width in the 
cell. * p<0.01 vs. control unstimulated cells. 
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3.2.2 The effect of Ang1-7 and Ang1-9 on AngII-induced 
Hypertrophy  
First any basal effects of Ang1-7 or Ang1-9 on cardiomyocyte phenotype were 
assessed. H9c2 cardiomyocytes were incubated with Ang1-7 or Ang1-9 at the dose 
used for blocking hypertrophy (100 nM) in the absence of AngII. Cardiomyocytes 
did not show any difference in cell size compared to unstimulated cells 
(unstimulated = 176.3 ± 6.1 µm; Ang1-7 100 nM = 182.4 ± 5.4 µm; Ang1-9 100 nM 
= 172.8 ± 4.9 µm) (Figure 3-4 A).  
Next, the effect of Ang1-7 and Ang1-9 on AngII-induced hypertrophy was analysed. 
Either 10 nM, 100 nM or 1 µM Ang1-7 or Ang1-9 were added 30 minutes before 
addition of AngII. In H9c2 cardiomyocytes, all three doses of Ang1-7 blocked Ang-
II induced hypertrophy and there was no significant difference when compared to 
unstimulated cardiomyocytes (Figure 3-4 B and C). With Ang1-9 similar results 
were observed however, only at concentrations of 100 nM and 1 µM was Ang1-9 
able to completely block AngII-induced hypertrophy (Figure 3-4 B and C) 
(unstimulated = 186.4 ± 5.4 μm, AngII = 232.8 ± 9.9 μm, Ang1-7 = 203.8 ± 7.4 μm; 
Ang1-9 = 195.9 ± 7.1 μm; p<0.05). Furthermore, Ang1-7 and Ang1-9 also blocked 
AngII-induced BNP gene expression in H9c2 cardiomyocytes (Figure 3-5 A). Next 
the effects of Ang1-7 and Ang1-9 on sarcomeric α-actin re-organization in AngII-
stimulated H9c2 cardiomyocytes were analysed. H9c2 cardiomyocytes were 
incubated with Ang1-7 and Ang1-9 before AngII stimulation. AngII-stimulated 
H9c2 cardiomyocytes showed an increased organization of actin filaments as 
expected, conversely, Ang1-7 and Ang1-9 stimulated H9c2 cardiomyocytes showed 
the same irregular sarcomeric pattern as unstimulated cells (Figure 3-5 B). 
To assess effects of Ang1-7 or Ang1-9 on cardiomyocyte viability a MTT assay was 
performed.  H9c2 cardiomyocytes were incubated with Ang1-7, Ang1-9 and AngII 
as described previously and MTT assay was performed to assess cell viability 96 
hours after AngII-stimulation. Results showed no significant difference between 
unstimulated and stimulated cells, suggesting that Ang1-7, Ang1-9 or AngII did not 
have any effect on cardiomyocyte viability (Figure 3-6).  
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Figure 3-4. Effect of Ang1-7 and Ang1-9 on unstimulated and AngII-induced 
hypertrophy in H9c2 cardiomyocytes.  
(A) H9c2 cardiomyocytes were incubated with 100 nM Ang1-7 or Ang1-9 alone for 96 hours. Cells 
were fixed, stained and measured using ImageProPlus; * p<0.001 vs. unstimulated cells. Next, H9c2 
cardiomyocytes were incubated with Ang1-7 or Ang1-9 at 10 nM, 10 nM or 1 µM 30 minutes before 
stimulation with 100 nM AngII. Cells were then incubated for a further 96 hours before fixing, 
staining and cell size measured.  (A) Representative photomicrographs of unstimulated and AngII-
stimulated H9c2 cardiomyocytes +/- Ang1-7 or Ang1-9 (Scale bar = 100 μm. Magnification: 10x). 
(B) Cell size was measured using ImageProPlus (* p<0.001 vs. unstimulated cells, # p<0.05 vs. 
AngII-stimulated cells). 
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Figure 3-5. Characterization of the effects of Ang1-7 and Ang1-9 on AngII-induced 
hypertrophy in H9c2 cardiomyocytes. 
Ang1-7 or Ang1-9 were added to H9c2 cardiomyocytes 30 minutes before addition of AngII and 
incubated for 96 hours. (A) BNP gene expression was quantified by TaqMan following mRNA 
extraction and cDNA generation from unstimulated and AngII-stimulated H9c2 cardiomyocytes +/- 
Ang1-7 or Ang1-9. Results were normalized to expression of 18S RNA. (B) At 96 hours α-actin 
filament reorganization was evaluated by fixing the cardiomyocytes and staining with FITC-labelled 
phalloidin (Magnification: top panel 40x, bottom panel 100x; scale bar = 100 µm). (* p<0.001 vs. 
unstimulated cells). 
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Figure 3-6. The effect of AngII, Ang1-7 and Ang1-9 on H9c2 cardiomyocyte viability. 
H9c2 cardiomyocytes were incubated with 10 nM, 100 nM or 1 µM of Ang1-7 or Ang1-9 30 minutes 
prior to stimulation with AngII. After incubation for 96 hours, cardiomyocyte viability was assessed 
using the MTT assay, before absorbance was recorded at 570 nm on a Wallac Victor2 
spectrophotometer. 
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The effect of Ang1-7 and Ang1-9 was also studied in rabbit primary cardiomyocytes 
(Figure 3-7 A). Primary cardiomyocytes were incubated with 100 nM, 500 nM and 1 
µM Ang1-7 or Ang1-9 30 minutes before addition of AngII, and 24 hours later cell 
length and width were measured. Similar to H9c2 cardiomyocytes significant 
differences in cell size were observed, this was only apparent for width (Figure 3-7 B 
and C). All 3 doses of either Ang1-7 or Ang1-9 blocked AngII-induced hypertrophy 
produced by AngII (unstimulated = 67.1 ± 2.9 µm
3
; AngII = 85.7 ± 4 µm
3
; Ang1-7 
100 nM = 61.4 ± 2.2 µm
3
; Ang1-7 500 nM = 66.6 ± 4.3 µm
3
; Ang1-7 1 µM = 64.7 ± 
3.2 µm
3
; Ang1-9 100 nM = 65.5 ± 2.5 µm
3
; Ang1-9 500 nM = 59.6 ± 3.5 µm
3
; 
Ang1-9 1 µM = 64.2 ± 3 µm
3
; p < 0.001) (Figure 3-7 D). 
Several studies have shown that higher concentration of Ang1-7 cause opposite 
effects to what was described with lower concentrations (De Mello, 2009, Garcia 
and Garvin, 1994, Haulica et al., 2003). To investigate if Ang1-7 or Ang1-9 had 
different effects at supra-physiological concentration, both peptided were added at 
10 and 100µM. These concentrations were based on receptors pharmacology and a 
literature search. When H9c2 cardiomyocytes were stimulated with higher 
concentrations of Ang1-7 or Ang1-9 (10 µM and 100 µM), 100 µM Ang1-7 induced 
a significant increase in cell size compared to unstimulated cells (unstimulated = 
187.1 ± 5 µm; AngII = 247.2 ± 6.6 µm; Ang1-7 10 µM = 219.3 ± 6.2 µm; Ang1-7 
100 µM = 235 ± 6.7 µm; Ang1-9 10 µM = 194.2 ± 6.6 µm; Ang1-9 100 µM = 178.8 
± 4.9 µm; p < 0.01; n = 100 cells per group) (Figure 3-8). However when Ang1-9 
was added to cardiomyocytes at these same concentrations, cell length was no 
different from unstimulated cells. 
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Figure 3-7. Role of Ang1-7 and Ang1-9 in AngII-induced hypertrophy in left ventricular 
adult rabbit primary cardiomyocytes.  
(A) Representative photomicrographs of unstimulated and AngII-stimulated left ventricular adult 
rabbit primary cardiomyocytes +/- Ang1-7 or Ang1-9 (Scale bar = 100 μm. Magnification: 20x). 
Rabbit left ventricular primary cardiomyocytes were incubated with Ang1-7 or Ang1-9 at 100 nM, 
500 nM or 1 µM 30 minutes before stimulation with 500 nM AngII. Cells were then incubated for a 
further 24 hours before measurement. (B) Cell width and (C) length was measured using 
ImageProPlus. (D) Cell volume was calculated using cardiomyocyte width and length. * p<0.001 vs. 
control unstimulated cells; # p<0.05 vs. AngII-stimulated cells. 
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Figure 3-8. Supra-physiological effects of Ang1-7 or Ang1-9 on H9c2 cardiomyocytes.  
H9c2 cardiomyocytes were incubated with 10 µM or 100 µM Ang1-7 or Ang1-9 in the presence of 
100 nM AngII. * p<0.001 vs. control unstimulated cells; # p<0.01 vs. AngII-stimulated cells. 
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3.2.3 Inhibition of Angiotensin Converting Enzyme  
Ang1-9 has been described to generate Ang1-7 through its cleavage by ACE (Snyder 
and Wintroub, 1986). To test whether conversion to Ang1-7 was necessary for the 
effects of Ang1-9 in cardiomyocytes, hypertrophy was assessed in the presence of 
the ACE inhibitor captopril to block any conversion of Ang1-9 to Ang1-7. Captopril 
(1 mM) was added to Ang1-9 + AngII stimulated cells. Ang1-9 still blocked AngII-
induced hypertrophy, even in the presence of Captopril (unstimulated = 135.7 ± 5.3 
μm; AngII = 169.4 ± 8 μm; Ang1-9 = 133.9 ± 6.9 μm; Ang1-9 + captopril = 137.9 ± 
7.4 μm; p<0.01) (Figure 3-9 A). Similar findings were observed in adult rabbit left 
ventricular primary cardiomyocytes (unstimulated = 71 ± 9.8 μm3; AngII = 114.2 ± 
14.1 μm3; Ang1-9 = 86.8 ± 1.9 μm3; Ang1-9 + captopril = 84.7 ± 13 μm3; p<0.001) 
(Figure 3-9 A).   
3.2.4 Analysis of the role of the Mas Receptor in 
cardiomyocyte hypertrophy 
The orphan G-protein coupled receptor Mas has been described to interact with 
Ang1-7 (Santos et al., 2003) and through this receptor, Ang1-7, antagonizes the 
effects of AngII (Pinheiro et al., 2009, Santos et al., 2006). To confirm Mas 
expression RT-PCR was performed on cDNA generated from H9c2 cardiomyocytes 
+/- addition of AngII (as described in section 2.16). Mas expression was detected in 
H9c2 cardiomyocytes and expression was not regulated by AngII stimulation. 
(Figure 3-10 A). Mas protein detection by western immunoblotting on H9c2 
cardiomyocytes was also performed, however, the lack of specificity of the available 
antibodies for Mas resulted in no detection of the receptor. To assess if Ang1-7 or 
Ang1-9 were signalling their anti-hypertrophic effects via Mas we used the 
pharmacological antagonist, A779. In the H9c2 cardiomyocyte model A779 had no 
effect on unstimulated or AngII-stimulated cell size (unstimulated = 191.1 ± 6.6 μm; 
unstimulated + A779 = 208.4 ± 7.3 µm; AngII = 288.6 ± 12.3 μm; AngII + A779 = 
273.6 ± 10.9 µm; p < 0.001) (Figure 3-10 B). 
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Figure 3-9. Ang1-9 mediated inhibition of hypertrophy in the presence of ACE 
inhibition.  
(A) H9c2 cardiomyocytes were incubated with 1 mM captopril 15 minutes before addition of Ang1-9 
(100 nM) and AngII. (B) Freshly isolated rabbit primary cardiomyocytes were plated, incubated with 
1 mΜ captopril 15 minutes before addition of 500 nM Ang1-9. Cells were then incubated for a further 
30 minutes period before stimulation with 500 nM AngII. Cell size was measured 24hours later using 
ImageProPlus. *p<0.001 vs. unstimulated cells; # p<0.001 vs. AngII stimulated cells. 
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Preincubation of AngII stimulated cardiomyocytes with A779 15 minutes prior to 
Ang1-7 addition blocked the antihypertrophic effect of Ang1-7 (Ang1-7 = 218.3 ± 
9.8 μm; Ang1-7 + A779 10 µM = 275.5 ± 14.0 μm; Ang1-7 + A779 100 µM = 304.9 
± 13.0 µm; p<0.001). However, A779 did not effect on Ang1-9 (Ang1-9 = 242.4 ± 
10.7 µm; Ang1-9 + A779 10 µM = 223.5 ± 8.4 µm; Ang1-9 + A779 100 µM = 213.4 
± 8.9 µm; p<0.01) (Figure 3-10 B).  
In similarity with the data observed in H9c2 cardiomyocytes, in adult left ventricular 
rabbit primary cardiomyocytes A779 was also able to block the anti-hypertrophic 
effect of Ang1-7 without affecting the actions of Ang1-9 (Figure 3-10 C). These 
results provided further evidence that Ang1-9 has independent effects from those 
expected if it merely generated Ang1-7.  
MBP7 is a phage-display derived peptide identified by Bikkavilli et al., as a novel 
partial Mas agonist (Bikkavilli et al., 2006). Using 2 different concentrations of 
MBP7 (10 and 100 µM) previous data have shown differential effects on Mas 
signalling, defining it as a partial agonist. To further study the role of Mas, AngII-
stimulated H9c2 cardiomyocytes were incubated with 10 µM and 100 µM MBP in 
the presence or absence of Ang1-7 or Ang1-9. At 10 µM and 100 µM MBP7 had no 
effect on unstimulated cell size but did however block AngII-induced hypertrophy at 
both doses. Importantly, a significant difference between MBP7 doses was observed, 
suggesting an agonist effect at low doses and an antagonist effect at high dose, 
supporting its definition as a classical partial agonist. Furthermore, upon co-
incubation with AngII and Ang1-7 at 10 µM MBP7 partially reversed the anti-
hypertrophic effect of Ang1-7 suggesting that Ang1-7 was a more efficacious ligand 
for the Mas receptor, but that MBP7 might have higher affinity. This was supported 
by the finding that at 100 µM MBP7 completely blocked the anti-hypertrophic 
effects of Ang1-7. However, MBP7 had no effect on the anti-hypertrophic effects of 
Ang1-9 at either dose. These results demonstrate that at low concentrations MBP7 
acts as a partial agonist of Mas, but acts with a lower efficiency but higher affinity 
than Ang1-7. Conversely, at higher concentrations (100 µM) MBP7 acts as an 
antagonist of Mas, blocking the engagement of Ang1-7 (Figure 3-11). 
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Figure 3-10. The role of the Mas receptor in Ang1-7 and Ang1-9 signalling 
cardiomyocytes.  
(A) mRNA of unstimulated or AngII-stimulated (100 nM) H9c2 cardiomyocytes was extracted, 
cDNA generated and PCR performed to detect Mas. PCR product = 343bp. (B) Cells were 
preincubated with the Mas antagonist A779 (10 µM) 15 minutes before addition of Ang1-7 or Ang1-
9. Cells were then incubated for 30 minutes before stimulation with 100 nM AngII and then incubated 
until 96 hours. * p<0.001 vs. unstimulated cells, # p<0.01 vs. AngII stimulated cells. (C) Isolated 
rabbit primary cardiomyocytes were plated, A779 (10 μM) added, 15 minutes before addition of 
Ang1-7 or Ang1-9 (500 nM), and 500 nM AngII. Cell size was measured at 24 h using ImageProPlus. 
* p<0.001 vs. unstimulated cells; # p<0.001 vs. AngII stimulated cells. 
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Figure 3-11. The effect of the partial Mas agonist MBP7 in H9c2 cardiomyocyte 
hypertrophy.  
H9c2 cardiomyocytes were plated and incubated for 24 hours. MBP7 (10 and 100 µM) was added and 
cells incubated for 15 minutes before adding Ang1-7 or Ang1-9 (100 nM). Following a further 30 
minutes incubation cells were stimulated with AngII (100 nM). After 96 hours incubation, cells were 
fixed, stained with crystal violet and cell size was measured using ImageProPlus. * p< 0.001 vs. 
unstimulated cells; # p< 0.001 vs. AngII stimulated cells; ** p< 0.01 vs. Ang1-7 stimulated cells; ## 
p<0.001 vs. AngII + MBP 10 µM stimulated cells. 
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3.2.5 Assessment of the role of the AT1R in cardiomyocyte 
hypertrophy 
The AT1R is the AngII receptor associated with most of the classical actions of 
AngII, including vasoconstriction, proliferation, inflammation, coagulation, 
extracellular matrix remodelling and hypertrophy. To test any association of Ang1-9 
with the AT1R or crosstalk between Mas and the AT1R, hypertrophy was induced 
via a different agonist. Arg-vasopressin triggers cardiomyocyte hypertrophy via the 
arginine-vasopressin receptor 1A (Hiroyama et al., 2007, Sharma et al., 2007).  
H9c2 and rabbit primary cardiomyocytes were stimulated with different 
concentrations of arg-vasopressin (10 nM, 100 nM and 1µM) to establish a role in 
inducing hypertrophy. In H9c2 cardiomyocytes all three concentrations of arg-
vasopressin induced hypertrophy (unstimulated = 199 ± 3.9 µm; arg-vasopressin 10 
nM = 236 ± 5.3 µm; arg-vasopressin 100 nM = 258.67 ±7.6 µm; arg-vasopressin 
1µM = 253.9 ± 5.3 µm, p < 0.01) (Figure 3-12 A).  
Additionally, in rabbit primary cardiomyocytes all 3 doses of vasopressin also 
induced significant increases in cell volume (unstimulated = 75.7 ± 2.3 µm
3
; arg-
vasopressin 10 nM = 96.5 ± 2 µm
3
; arg-vasopressin 100 nM = 92.4 ± 3.6 µm
3
; arg-
vasopressin 1 µM = 92.8 ± 3.1 µm
3
; p < 0.01) (Figure 3-12 B, C, D). This increase in 
cardiomyocyte volume was also due to the increase in the width of the cells, in 
similarity to AngII-induced hypertrophy (Figure 3-12 B and C); therefore 1 µM was 
selected for further experiments. 
Next, the AT1R antagonist losartan was utilised at either 1 or 10 µM in the arg-
vasopressin-induced hypertrophy model. In H9c2 cardiomyocytes preincubation 
with losartan blocked AngII-induced hypertrophy (Figure 3-13 A) however, it did 
not affect the pro-hypertrophic effect of vasopressin (unstimulated = 179.2 ± 5.4 μm;  
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Figure 3-12. Vasopressin-induced hypertrophy in cardiomyocytes.  
(A) H9c2 cardiomyocytes were plated and incubated for 24 hours in serum free media before addition 
of different concentrations of arg-vasopressin (10 nM, 100 nM and 1 µM) for 96 hours to induce 
hypertrophy. Cells were then fixed, stained with crystal violet and cell size measured using 
ImageProPlus. * p<0.01 vs. control unstimulated cells. Furthermore, freshly isolated primary 
ventricular cardiomyocytes were plated and immediately stimulated with 10, 100 and 1 µM of arg-
vasopressin and then incubated for 24 hours. (D) Cell volume was measured using ImageProPlus. 
*p<0.01 vs. control unstimulated cells. The increase in volume of primary cardiomyocytes was due to 
an increase in the width of the cells (C), as the length of the primary cardiomyocytes (B) did not differ 
between groups. 
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AngII = 253.4 ± 8.4μm; AngII + losartan 10 µM = 201 ± 6.1 µm; arg-vasopressin = 
227.4 ± 9.8 μm; arg-vasopressin + losartan 10 µM = 247.8 ± 7.2 μm; p<0.001) 
(Figure 3-13 A). Next, arg-vasopressin-stimulated H9c2 cardiomyocytes were 
incubated with losartan, and Ang1-7 or Ang1-9. Blocking AT1R with 1 or 10 µM 
losartan had no effect on the anti-hypertrophic effects of Ang1-7 or Ang1-9 (Ang1-7 
= 190.4 ± 4.8 µm; Ang1-7 + losartan 10 µM = 181.9 ± 6.1 µm; Ang1-9 = 189.7 ± 
5.3 µm; Ang1-9 + losartan 10 µM = 173.4 ± 4.6 µm; p< 0.001) (Figure 3-13 A). This 
suggested that Ang1-7 or Ang1-9 did not antagonize AngII signalling by competition 
for the AT1R. In rabbit primary cardiomyocytes blocking AT1R with 10 µM 
losartan confirmed the findings as both Ang1-7 and Ang1-9 blocked the pro-
hypertrophic effects of arg-vasopressin in the presence of losartan (Figure 3-13 B). 
3.2.6  Assessment of the role of the AT2R in cardiomyocyte 
hypertrophy 
Although the AT2R was described over 2 decades ago, the mechanisms of how it 
acts are still controversial. AT2R expression has been described only in foetal, 
neonatal and in diseased rodent cardiomyocytes (Mehta and Griendling, 
2007)(Bastien et al., 1996). However, in both normal adult and failing human hearts 
the predominant AngII receptor was found to be the AT2R accounting for 70% of 
AngII binding sites (Regitz-Zagrosek et al., 1995), suggesting a difference in AngII 
receptor expression between species. First, the expression of AT2R was confirmed in 
cDNA generated from H9c2 cardiomyocytes +/- AngII via RT-PCR (Figure 3-14 A).  
Next, the effects of the commercial AT2R agonist (CGP42112A) (Ohkubo et al., 
1997) were assessed (Figure 3-14 B). The addition of CGP42112A (10 nM, 100 nM 
and 1 µM) efficiently blocked AngII-induced hypertrophy (30% increase in cell size 
induced by AngII was normalized by addition of CGP42112A; p < 0.001). 
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Figure 3-13. The role of the AT1R in Ang1-7 and Ang1-9 signalling in  cardiomyocytes.  
(A) H9c2 cardiomyocytes were stimulated with arg-vasopressin (1 µM) to induce hypertrophy. 
Losartan (1 µM and 10 µM) blocked AngII-induced hypertrophy but not the action of arg-
vasopressin. Cells were preincubated with losartan before addition of Ang1-7 or Ang1-9. After 
incubation for 30 minutes cells were stimulated with arg-vasopressin and incubated for 96 hours. (B) 
Isolated primary cardiomyocytes were plated and incubated with losartan (10 µM) 15 minutes before 
the addition of Ang1-7 or Ang1-9 (500 nM). Cells were incubated for 30 minutes before the addition 
of AngII (500 nM) or arg-vasopressin (1 µM) to induce hypertrophy and cells were incubated for a 
further 24 hours. * p<0.001 vs. control unstimulated cells; # p<0.001 vs. arg-vasopressin stimulated 
cells. 
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Figure 3-14. AT2R expression and activation in H9c2 cardiomyocytes.  
(A) H9c2 cardiomyocytes were plated and stimulated with AngII (100 nM) for 24 hours. MRNA 
from unstimulated and AngII-stimulated H9c2 cardiomyocytes was extracted and cDNA generated. 
PCR was performed to detect AT2R. PCR product 330 bp (100 bp ladder). (B) H9c2 cardiomyocytes 
were incubated for 24 hours in serum free media before addition of the specific AT2R agonist 
CGP42112A at 10 nM, 100 nM or 1 μM for 30 minutes followed by addition of 100 nM AngII. Cells 
were incubated for a further 96 hours, fixed, stained with crystal violet and cell size measured using 
ImageProPlus. * p<0.001 vs. unstimulated cells; # p<0.001 vs. AngII stimulated cells. 
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To assess the role of the AT2R in the effects of Ang1-7 and Ang1-9 the AT2R 
antagonist PD123,319 was utilised. In H9c2 cardiomyocytes preincubation with 
Ang1-7 or Ang1-9 blocked AngII-induced hypertrophy as shown previously (Figure 
3-15 A). Addition of PD123,319 at 100, 500 or 1000 nM alone did not affect AngII-
induced hypertrophy. Additionally, the anti-hypertrophic effect of Ang1-7 was not 
abolished in the presence of PD123,319 (Ang1-7 = 221.1 ± 6.4 µm; Ang1-7 + 
PD123,319 500 nM = 216.2 ± 7.0 µm; p < 0.001). However, when PD123,319 was 
added to Ang1-9-stimulated cardiomyocytes, the anti-hypertrophic effect of Ang1-9 
was blocked in a dose dependent manner (Ang1-9 = 216.3 ± 6.1μm; Ang1-9 + 
PD123,319 500 nM = 290.8 ± 8.3 µm; p<0.001). These findings were replicated in 
rabbit primary cardiomyocytes (Figure 3-15 B) suggesting that Ang1-9 signals 
through the AT2R. 
3.2.7  Assessment of the role of the B2 bradykinin receptor in 
cardiomyocyte hypertrophy 
The bradykinin B2 receptor has been reported to heterodimerize with the AT2R and 
Mas receptor, leading to inhibition of fibrosis and promotion of vasodilatation 
(Soares de Moura et al., 2004, Peiro et al., 2007, Kurisu et al., 2003). In addition 
Erdos et al. showed that Ang1-9 potentiated bradykinin B2 receptor activity, by 
enhancing the release of arachidonic acid in human atria and ventricles and an 
increase in intracellular Ca
2+
 concentration and NO synthesis in endothelial cells 
(Erdos et al., 2002). In order to investigate if the bradykinin receptor was 
participating in Ang1-7 or Ang1-9 signalling the B2 blocker HOE 140 was utilized. 
H9c2 cardiomyocytes were incubated with either A779 (10 µM) or PD123,319 (500 
nM) and HOE 140 (1 µM) for 15 minutes before addition of Ang1-7 or Ang1-9. 
HOE 140 was unable to effect AngII-induced hypertrophy indicating there was no 
cross-talk between the B2 receptor and the AT1R (unstimulated = 174.7 ± 5.5 µm; 
unstimulated + HOE 140= 161.6 ± 4.4 µm; AngII = 246.5 ± 9.8 µm; AngII + HOE 
140= 248.3 ± 7.5 µm; p < 0.001) (Figure 3-16). However, blockade of the B2 
receptor in cardiomyocytes stimulated with Ang1-7, had a reduced effect on the anti-
hypertrophic effect of Ang1-7 (Figure 3-16).  
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Figure 3-15. The role of the AT2R in Ang1-7 and Ang1-9 signalling in cardiomyocytes.  
(A) H9c2 cardiomyocytes were incubated for 24 hours in serum free media before addition of the 
AT2R antagonist PD123,319 (100 nM, 500 nM or 1 µM) followed by incubation for 15 minutes 
before addition of Ang1-7 (100 nM) or Ang1-9 (100 nM). Cells were incubated for a further 30 
minutes and then stimulated with AngII (100 nM). After 96 hours incubation, cells were fixed, stained 
with crystal violet and cell size measured using ImageProPlus. * p<0.001 vs. unstimulated cells, 
#p<0.001 vs. AngII stimulated cells. (        100 nM PD123,319;         500 nM PD123,319;         1 µM 
PD123,319). (B) Freshly isolated rabbit primary cardiomyocytes were plated and stimulated with 
PD123,319 (500 nM) for 15 minutes prior to addition of Ang1-7 or Ang1-9. AngII (500 nM) was 
added 30 minutes later, and cells were incubated for 24 hours. Cell volume was calculated from 
length and width measurements using ImageProPlus. * p<0.01 vs. unstimulated cells; # p<0.01 vs. 
AngII stimulated cells. 
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Although there was no significant difference between AngII-stimulated cells and 
Ang1-7 + HOE 140 stimulated cells, there was a significant increase in cell size 
observed between cardiomyocytes incubated with HOE 140 and Ang1-7 compared 
to cardiomyocytes incubated with Ang1-7 alone (Ang1-7 = 167.8 ± 4.2 µm; Ang1-7 
+ A779 = 226.4 ± 7 µm; Ang1-7 + HOE = 209.1 ± 6.2 µm) (Figure 3-16). 
Furthermore, HOE 140 had no effect on the anti-hypertrophic effect of Ang1-9 
(Ang1-9 = 174.7 ± 4.5 µm; Ang1-9 + PD123,319 = 228.2 ± 8.0 µm; Ang1-9 + HOE 
140 = 185.5 ± 5.5 µm) (Figure 3-16).  
3.2.8 Cell Signalling 
3.2.8.1  Protein Kinase C Translocation 
 PKC is activated and translocates rapidly from the cytosol to the cell membrane 
following exposure of cardiomyocytes to AngII (Jalili et al., 1999a)(Li et al., 2002). 
PKC membrane translocation was assessed in unstimulated and AngII-stimulated 
H9c2 cardiomyocytes at 1, 5 and 10 minutes. A marked mobilization of PKC from 
the cytosol to the membrane when H9c2 cardiomyocytes were stimulated with AngII 
was observed which was apparent following 1 minute of AngII stimulation (Figure 
3-17). After 5 minutes PKC was still localized to the cell membrane but by 10 
minutes the stain had returned to the same levels of unstimulated cells (Figure 3-17). 
This loss of fluorescence at 10 minutes led to the assessment of PKC translocation in 
H9c2 cells incubated with the Ang1-7 or Ang1-9 at 1 and 5 minutes. Co-addition of 
Ang1-7 or Ang1-9 to AngII stimulated cells produced a similar relocalization pattern 
of PKC staining to that observed with AngII alone. 
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Figure 3-16. The role of the B2 bradykinin receptor in AngII-induced hypertrophy in 
H9c2 cardiomyocytes.  
H9c2 cardiomyocytes were incubated for 24 hours in serum free media before adding HOE 140 (1 
µM), A779 (10 µM) or PD123,319 (500 nM). Cells were incubated for 15 minutes before addition 
Ang1-7 or Ang1-9 (100 nM) followed by AngII 30 minutes later. Following 96 hours incubation, 
cells were fixed, stained with crystal violet and cell size measured with ImageProPlus. * p<0.001 vs. 
unstimulated cells; # p<0.001 vs. AngII stimulated cells; ** p<0.001 vs. Ang1-7 stimulated cells. (PD 
= PD123,319; HOE = HOE140). 
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Figure 3-17. PKC translocation in the H9c2 hypertrophy model.  
H9c2 cardiomyocytes were plated and incubated for 24 hours. Cells were then incubated with AngII 
for 1, 5 and 10 minutes and PKC translocation assessed in unstimulated and AngII-stimulated H9c2 
cardiomyocytes. Next, H9c2 cardiomyocytes were preincubated with Ang1-7 or Ang1-9 (100 nM) 
and PKC translocation assessed after 1 and 5 minutes of AngII stimulation. Scale bar = 100µm; 
Magnification: 100x.  
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3.2.8.2 Assessment of receptor activation via the measurement of 
calcium transients in individual cells 
To explore the functionality of the AT1R, AT2R and Mas receptor more fully Ca
2+
 
transients were assessed in single cells following Fura-2 loading (section 2-18). 
H9c2 cardiomyocytes loaded with Fura-2 were exposed to AngII, Ang1-9 or Ang1-7 
(1 µM) and Ca
2+
 mobilization recorded as an indicator of receptor activation. 
Cytosolic Ca
2+
 increased when H9c2 cardiomyocytes were exposed to AngII (Figure 
3-18 A). Although mobilization of Ca
2+
 induced by AngII has been previously 
described (Samain et al., 2002), our findings showed that only one third of the 
cardiomyocytes actually responded to AngII in this setting (Figure 3-18 B). In order 
to evaluate that engagement to a GPCR induced Ca
2+
 transients in these cells we 
assessed arg-vasopressin-induced Ca
2+ 
mobilization as positive control. Arg-
vasopressin also induced an increase in cytosolic Ca
2+ 
in H9c2 cardiomyocytes.  
When cardiomyocytes were exposed to Ang1-9 or Ang1-7, no increase in Ca
2+ 
was 
registered (Figure 3-19 A and B). Moreover, exposure of H9c2 cardiomyocytes to 
the commercial AT2R agonist CGP42112A also failed to produce a Ca
2+
 transient, 
similar to that observed when perfusing with Ang1-9 (Figure 3-19 C). However, 
when H9c2 cardiomyocytes were re-exposed to ionomycin as a positive control an 
increase in intracellular Ca
2+
 was observed indicating the assay was functioning.  
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Figure 3-18. Assessment of calcium transients in H9c2 cardiomyocytes.  
H9c2 cardiomyocytes were plated and incubated for 24 hours. Cells were loaded with the Ca
2+
 
indicator Fura-2 (1.5 µM) and incubated for a further 30 minutes at 37ºC. Cells were placed into a 
microscope chamber which was then perfused with AngII (1 µM), following acquisition of 60 images 
the change in cytoplasmic Ca
2+
 was recorded for a further 140 images. The agonist was then removed 
and a further 200 images collected followed by perfusion with (arg-vasopressin 10 µM). (A) Traces of 
grouped cells perfused with AngII. (B) Traces of individual cardiomyocytes showing the actual 
number of cells that responded to AngII stimulation. Results are expressed as fluorescence ratio at 
340 / 380 nM. Red traces represent cardiomyocytes that responded to AngII stimulation; black traces 
represent cardiomyocytes not responding to AngII stimulation (AVP = arg-vasopressin). 
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Figure 3-19. Assessment of the effects of Ang1-7, Ang1-9 and CGP42112A on calcium 
signalling.  
H9c2 cardiomyocytes were loaded with the Ca
2+
 indicator Fura-2 (1.5 µM) and incubated for 30 
minutes at 37ºC. Cells were placed into a microscope chamber and perfused with Ang1-7, Ang1-9 or 
CGP42112A (1 µM) followed by acquisition of 60 images before any change in cytoplasmic Ca
2+
 was 
recorded for a further 140 images. Once agonist was removed, a further 200 images were collected 
before the positive control agonist (ionomycin 1 µM) was added and a further 140 images collected. 
(A) Traces of changes in cytoplasmic Ca
2+
 in Ang1-9 stimulated cardiomyocytes grouped in slides; 
(B) Traces of changes in cytoplasmic Ca
2+
 in Ang1-7 stimulated cardiomyocytes grouped in slides; 
(C) Traces of cardiomyocytes stimulated with CGP42112A grouped in slides. Results are expressed 
as fluorescence at a ratio of 340 / 380 nm. 
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3.2.9 Assessment of the role of individual G-Protein Coupled 
Receptor Subunits 
PTX has been described to inactivate Gαi proteins (Teschemacher and Seward, 2000, 
Huang et al., 2009, Lee et al., 2009, Lane et al., 2007). To investigate whether Gαi 
mediates the antihypertrophic effects of Ang1-7 and Ang1-9 on AngII-stimulated 
H9c2 cardiomyocytes, cell size was assessed in the presence of PTX. In the presence 
and absence of PTX, AngII was able to induce hypertrophy (unstimulated = 189.7 ± 
5.5 µm; unstimulated + PTX = 189.3 ± 5.6 µm; AngII = 241.5 ± 6.2 µm; AngII + 
PTX = 239.8 ± 4.9 µm; p < 0.001) (Figure 3-20). However, the anti-hypertrophic 
effect of both Ang1-7 and Ang1-9 were abolished by PTX (Ang1-7 = 201.0 ± 5.0 
µm; Ang1-7 + PTX = 235.0 ± 4.8 µm; Ang1-9 = 184.5 ± 4.0 µm; Ang1-9 + PTX = 
222.0 ± 4.7 µm) (Figure 3-20). These preliminary results suggest that when Mas and 
AT2R are bound to Ang1-7 and Ang1-9 respectively, they may initiate cell 
signalling cascades through activation of the Gαi-subunit. 
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Figure 3-20. Gαi mediates the anti-hypertrophic effect of Ang1-7 and Ang1-9 in H9c2 
cardiomyocytes.  
H9c2 cardiomyocytes were incubated for 8 hours before exchanging the media for serum free media 
supplemented with PTX (25 ng/ml), followed by addition of Ang1-7 or Ang1-9 (100 nM). Cells were 
incubated for 30 minutes before addition of AngII (100 nM). Cells were then incubated for a further 
96 hours before fixing, staining with crystal violet and cell size measured with ImageProPlus. * 
p<0.001 vs. control; # p<0.001 vs. AngII. 
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3.3 Discussion  
In this chapter, a novel role for the angiotensin peptide Ang1-9 has been established. 
The data show that Ang1-9 is an antagonist of in vitro cardiomyocyte hypertrophy. 
This peptide metabolite of AngII has not been shown to mediate any specific 
receptor interactions, although it was thought to contribute to reduced AngII 
(through being generated from AngI via the actions of ACE2) and also to act as a 
substrate for Ang1-7 generation via ACE metabolism. These data indicate that 
Ang1-9 appears to have direct effects, antagonizing pro-hypertrophic signals from 
different stimuli in cardiomyocytes from different species, representing both 
neonatal and adult lineages. Additionally, Ang1-9 utilizes the AT2R to mediate its 
signals, segregating its actions from those of Ang1-7, which engages the Mas 
receptor.  
The difference between neonatal and adult cardiomyocytes is well established. 
Neonatal cardiomyocytes have the ability to divide, while adult cardiomyocytes have 
lost this ability. This makes neonatal cells easier to culture and they are the most 
widely used. However, adult cardiomyocytes are more reflective of the adult heart in 
vivo. Adult cardiomyocytes are larger and the transverse tubule system is fully 
developed (Schaub et al., 1997). Adult and neonatal cardiomyocytes not only differ 
in morphology and mitotic ability but also gene expression is different, for example, 
the AT2R is expressed at lower levels in normal adult rodent cardiomyocytes (Lijnen 
and Petrov, 1999, Schaub et al., 1997). Therefore it is important to assess 
hypertrophy in different developmental stages of cardiomyocytes and in different 
species to reinforce the importance and relevance of the results. 
The classical definition of the RAS as a systemically acting hormone system is 
increasingly being re-defined by tissue-specific actions following the description of 
local generation of RAS components in individual organs. The heart has been a 
major focus for studying the local RAS since the discovery of ACE2 (Crackower et 
al., 2002).  In the heart, Ang1-7 has been described to antagonize the 
pathophysiological signalling of Ang-II. Furthermore, Ang1-7 blocks hypertrophy 
and interstitial fibrosis in heart of rats infused with AngII (Grobe et al., 2007b, 
Mercure et al., 2008). Furthermore, Grobe et al. showed that Ang1-7 not only 
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blocked AngII-induced hypertrophy but also hypertrophy induced by other stimuli 
such as corticosteroids (Grobe et al., 2006). In addition, Ang1-7 antagonizes AngII 
signalling in other tissues. For example, in blood vessels intraarterial infusion of 
Ang1-7 into the human forearm antagonized AngII-induced vasoconstriction (Ueda 
et al., 2000), while in rat aortas Ang1-7 prevented superoxide formation induced by 
AngII (Polizio et al., 2007). In kidney proximal tubular cells Ang1-7 inhibited 
AngII-induced activation of p30, ERK1/2 and JNK (Su et al., 2006). In the brain 
Ang1-7 has been shown to block the increased release of norepinephrine from the 
hypothalamus of rats following stimulation with AngII (Gironacci et al., 2004). All 
these studies highlight the importance of Ang1-7 in the counter-regulatory arm of the 
RAS. Although certain studies have proposed that Ang1-7 may interact with the 
AT1R and AT2R (Silva et al., 2007, Walters et al., 2005) it is now established that 
Ang1-7 utilises the proto-oncogene G-protein coupled receptor Mas (Santos et al., 
2003, Santos et al., 2006, Sampaio et al., 2007b, Dias-Peixoto et al., 2008).  
Hypertrophy in cardiomyocytes has been defined as an increase in cell size and in 
protein synthesis, reorganization of sarcomeres and expression of hypertrophy 
markers (Carreno et al., 2006, Frey and Olson, 2003, Dorn et al., 2003). The most 
established markers are ANP, BNP, β-MHC and skeletal α-actin (Dorn et al., 2003). 
However the difference in expression of ANP, β-MHC and skeletal α-actin can 
depend on the species and the developmental stage of the cardiomyocyte thus BNP 
has been defined as the most reliable acute hypertrophy marker (Schaub et al., 1997, 
Stuck et al., 2008). In accordance with this, we were able to induce increases in cell 
size following AngII stimulation in both neonatal rat cardiomyocyte line (H9c2) and 
in adult primary rabbit ventricular cardiomyocytes. AngII also induced an increase 
expression of BNP as well as inducing reorganization of α-actin filaments in H9c2 
cardiomyocytes. Importantly, in adult rabbit primary cardiomyocytes the increase in 
cell volume induced by AngII was due to an increase in cell width. This has been 
reported to be related to the addition of sarcomeres in parallel in the cardiomyocyte, 
characteristic of concentric hypertrophic growth (Dorn et al., 2003). Assessment of 
sarcomere staining using phalloidin in primary adult cardiomyocytes would help 
address this. The addition of both Ang1-7 and Ang1-9 was able to block the increase 
in cell size, sarcomere reorganization and increase in BNP gene expression, induced 
by AngII stimulation, resulting in an effective block of hypertrophy at least in vitro.  
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The first interesting finding which segregated the actions of Ang1-7 from Ang1-9 
was the observation of a bi-phasic mechanism of Ang1-7 action (Figure 3-8). At 
concentrations up to 1 μM Ang1-7 antagonized the pro-hypertrophic effects of 
AngII, however at higher concentrations (100 µM) Ang1-7 induced hypertrophy 
even in the absence of AngII (Figure 3-8). In contrast, Ang1-9 was not pro-
hypertrophic at any concentration tested and retained the ability to antagonize AngII 
signalling. Since a bi-phasic effect was also observed with the partial Mas agonist 
MBP7 (Figure 3-11), Mas signalling effects may underline the biphasic effects of 
Ang1-7. Previous data have demonstrated that MBP7 promotes internalization of the 
Mas receptor with no increase in [H
3
] inositol phosphate in CHO cells expressing the 
Mas receptor (Bikkavilli et al., 2006). However, MBP7 at 100 µM significantly 
increased the accumulation of [H
3
] inositol phosphate, suggesting MBP7 acted as a 
partial agonist. A bi-phasic mechanism of action for Ang1-7 has been reported 
previously in several studies (Garcia and Garvin, 1994, Haulica et al., 2003, De 
Mello, 2009). In rat aorta Ang1-7 concentrations above 10 µM stimulated 
vasoconstriction while lower concentrations produced vasodilatation (Haulica et al., 
2003). In kidney proximal tubules 1
 
pM Ang1-7 stimulated fluid absorption, 
however at 10
 
nM fluid absorption decreased (Garcia and Garvin, 1994). In 
cardiomyopathy 10
 
nM Ang1-7, hyperpolarized cardiomyocytes and increased 
conduction velocity through the heart, while 100 nM triggered the opposite effect 
(De Mello et al., 2007). The data here provide further evidence for a bi-phasic role 
for Mas signalling via Ang1-7 and highlight differences between Ang1-7 and Ang1-
9 function.  
In contrast to Ang1-7 very little is known about Ang1-9. Ang1-9 was originally 
reported to be generated in the heart through metabolism of AngI via ACE2 and 
further metabolised to Ang1-7 through ACE cleavage (Donoghue et al., 2000). 
Jackman et al. demonstrated that cathepsin A could stimulate Ang1-7 and Ang1-9 
production in human heart tissue (Jackman et al., 2002) but experiments to dissect 
differential effects of Ang1-7 or Ang1-9 were not performed. In the study performed 
here inhibition of ACE to prevent Ang1-9 conversion to Ang1-7 did not block its 
effects. It is important to mention that when attempting to asses the efficacy of 
captopril we were unable to mesure ACE activity in vitro. However, blockade of the 
Mas receptor with the antagonist A779, did not abolish the antihypertrophic effects 
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of Ang1-9, supporting the theory of an independent role for Ang1-9 in 
cardiomyocyte hypertrophy and furthermore highlighting that Ang1-9 signalled via a 
different receptor. 
Through the antagonism of the AT1R with losartan, it was demonstrated that Ang1-9 
does not act as a competitive inhibitor of AngII signalling via the AT1R. 
Furthermore, Ang1-9 and Ang1-7 blocked arg-vasopressin-induced hypertrophy, 
demonstrating that they could both inhibit hypertrophy induced by alternative 
agonists. 
The results here demonstrate the use of the AT2R by Ang1-9 in mediating its effects. 
The role of the AT2R in the RAS is controversial. AngII is reported to signal via 
both the AT1R and the AT2R (Bartunek et al., 1999, Bai et al., 2004)(Oudot et al., 
2005, Aranguiz-Urroz et al., 2009) however the AT1R is the main mediator of the 
classical effects of AngII and the AT2R is considered a counter-regulatory signalling 
mechanism by which AngII could negatively feedback on signals mediated via the 
AT1R. This was due to the discovery that engagement of the AT2R by AngII led to 
bradykinin and NO release (Abadir et al., 2006).  
It is important to mention that even though A779 and PD123,319 are the most 
established antagonist for Mas and the AT2R, there is no certainty that these 
peptides are complete selective to the receptors (Brechler et al., 1993). More studies 
to evaluate their pharmacology are required. 
There is evidence of heterodimerization between the bradykinin B2 receptor and the 
AT1R, as well as the AT2R and Mas (Soares de Moura et al., 2004, AbdAlla et al., 
2005, Canals et al., 2006). It has also been reported that captopril, besides inhibiting 
ACE, potentiates the antihypertrophic effect of bradykinin (Carreno et al., 2006). 
Jackman et al. showed that Ang1-9 and Ang1-7 potentiated the B2 receptor by 
enhancing the release of arachidonic acid and NO generation in CHO cells 
expressing human ACE and B2 receptor and also in endothelial cells (Jackman et al., 
2002). However, Ang1-9 is also further transformed to Ang1-7 via ACE mediated-
cleavage, and a study to differentiate a direct role to segregate Ang1-7 from Ang1-9 
was not performed. Here, no interaction between bradykinin B2 receptor and the 
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AT2R was observed as blocking the B2 receptor by HOE 140 did not affect Ang1-9. 
However, the antihypertrophic effect of Ang1-7, although not abolished completely, 
was affected by antagonism of the B2 receptor, suggesting a potential interaction 
between Mas and B2 receptors. Furthermore, antagonism of the B2 receptor supports 
the direct antihypertrophic effect of Ang1-9, rather than potentiation of bradykinin 
and/or inhibition of ACE. 
Intracellular Ca
2+
 mobilization has been previously demonstrated for agonist binding 
to a G-protein coupled receptor (Thomas et al., 1996, Samain et al., 2002, Emkey 
and Rankl, 2009). The results here suggest that such a Ca
2+
 transient is not induced 
by Ang1-7 or Ang1-9 acutely, supporting the idea that Mas and the AT2R are not 
classical GPCR. In agreement with the data here presented, Dias-Peixoto et al. was 
unable to induce changes in intracellular Ca
2+
 in cardiomyocytes when stimulated 
with Ang1-7 (Dias-Peixoto et al., 2008). It is important to mention that even though 
grouped results of AngII perfusion of H9c2 cardiomyocytes stimulated a Ca
2+
 
transient, however when analysing traces for single cells, only one third of cells 
responded. This suggests that there may be low levels of receptor expression in H9c2 
cardiomyocytes preventing observation of acute effects. This agrees with the 
requirement for 96 hour incubation to induce hypertrophy with AngII. Further 
experiments in primary cells in which hypertrophy occurs in a 24 hour time period 
are important. 
G-proteins can couple to several different receptors and depending on the G-protein 
subunit, different pathways can be activated (Fredholm et al., 2007, Rang, 2007, 
Milligan, 2008). It is well established that AngII induces hypertrophy through Gαq/11 
in vascular smooth muscle cells and cardiomyocytes (Bai et al., 2004, Ohtsu et al., 
2008, Lorenz et al., 2009b). However AT2R signalling is still not well defined and 
the findings are conflicting. In COS-7 cells over-expressing recombinant AT2R 
some studies have showed activation of the Gαi-subunit following AT2R stimulation 
(Hansen et al., 2000), while others have failed to show AT2R association with G-
proteins (Mukoyama et al., 1993). The Mas receptor is also less clearly understood 
but evidence does indicate Gαq/11-subunit activation (Canals et al., 2006). Here, 
blocking the Gαi-subunit with PTX completely blocked the anti-hypertrophic effects 
of Ang1-7 and Ang1-9 suggesting that they may signal via the Gαi-subunit. 
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Stimulation of cardiomyocytes with AngII has been demonstrated to induce 
translocation of PKC from the cytoplasm to the cell membrane (Li et al., 2002). 
Detection of PKC in H9c2 cardiomyocytes stimulated with AngII triggered a rapid 
movement of PKC as within 1 minute of stimulation PKC was detected in the cell 
membrane where it was retained for at least 5 minutes. When Ang1-7 and Ang1-9 
were added to AngII-stimulated cardiomyocytes PKC translocation to the membrane 
was also observed within a similar timeframe and with a similar distribution. The 
antibody used detects several isoforms of PKC (α, β and γ), therefore, does not allow 
identification of any difference in specific PKC isoforms following differential 
stimuli. Different PKC isoforms are activated following exposure of cardiomyocytes 
to different hypertrophic stimuli leading to activation of different pathways such as 
intracellular Ca
2+
 handling and ANP production (Church et al., 1994, Takeishi et al., 
2000). It is therefore important that further experiments are performed in the future 
to distinguish such differences. Furthermore, Ang1-7 and Ang1-9 induced PKC 
translocation was detected in the presence of AngII and not the peptides alone; 
therefore no data regarding the basal effects of the peptides was generated. 
The findings reported here have implications for our understanding of the integrated 
functioning of the RAS. Although Ang1-9 is a previously reported angiotensin 
metabolite, this is the first demonstration of a direct biological effect of this peptide 
which can be separated from the actions of either AngII or Ang1-7 via the use of 
pharmacological reagents. Our findings are replicated in two different cardiomyocyte 
types representing different species and both adult and neonatal lineages. In 
summary, the data presented here demonstrates that Ang1-9 is able to antagonize 
AngII signalling in cardiomyocytes, selectively via the AT2R. 
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Figure 3-21. Diagram of findings.  
Figure representing the findings of this chapter. A) AngII induces cardiomyocyte hypertrophy 
signalling through the AT1R. Both Ang1-9 and Ang1-7 block AngII-induce hypertrophy by coupling 
to the AT2R and Mas receptor respectively. B) Through coupling to the AT2R, Ang1-9 is able to 
block hypertrophy. Once bound to the AT2R it is the Gαi-subunit that mediates translocation of PKC 
to the cell membrane and block hypertrophy. However, there is still a gap between PKC translocation 
and blocking hypertrophy to be elucidated. 
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4.1 Introduction 
The SHRSP is an experimental model of hypertension developed over 30 years ago 
by Okamoto et al. and frequently used for the study of CVD (Okamoto and Aoki, 
1963). This rat strain was developed by inbreeding the SHR strain with selected 
offspring of parents that developed stroke (Okamoto and Aoki, 1963). The main 
characteristics of this strain include lower body weight compared to SHR, early 
development of high blood pressure (10 weeks of age) and stroke. High blood 
pressure in the SHRSP is maintained by later development of high peripheral 
vascular resistance due to neurogenic vasoconstriction to maintain normal cardiac 
output (Tanase et al., 1982). Stroke is most frequently due to cerebral haemorrhage 
or infarction in the anteriomedial and occipital cortex, and the basal ganglia around 
100 to 150 days of age (Tanase et al., 1982). SHRSP portrays a phenotype similar to 
human essential hypertension as it presents end-organ damage such as left 
ventricular hypertrophy, stroke and renal failure and is sexually dimorphic (Badyal, 
2003, Tanase et al., 1982).  
The role of the RAS as an important regulator of blood pressure and its involvement 
in the pathophysiology of hypertension is very clear. In vivo animal models have 
demonstrated the participation of the different components of the RAS in the control 
of blood pressure. For example, in animals infused with AngII elevated blood 
pressure has been shown (Frank et al., 2007, Guzik et al., 2007)(Kawada et al., 
2002). In vivo delivery of AngII induces cardiac hypertrophy (Majalahti et al., 2007, 
Sriramula et al., 2008) and fibrosis (Brilla et al., 1993, Chintalgattu and Katwa, 
2009). In transgenic mice that over-express the AT1R it has been shown that this 
receptor mediates AngII-induced hypertension, cardiac hypertrophy and fibrosis 
(Majalahti et al., 2007)(Billet et al., 2008). Although there is clear evidence for 
AT2R-mediated signalling in hypertension (Metcalfe et al., 2004, Kaschina et al., 
2008, Bartunek et al., 1999), the exact role of it is controversial. In vivo over-
expression of AT2R using vectors or transgenic mice attenuates cardiac hypertrophy, 
fibrosis and promotes vasodilatation (Kurisu et al., 2003, Metcalfe et al., 2004, 
Yayama and Okamoto, 2008, Yan et al., 2008). Stimulation of AT2R after 
myocardial infarction has been demonstrated to improve ventricular function 
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(Kaschina et al., 2008), while blockade or deletion of the AT2R gene promotes 
cardiac hypertrophy and high blood pressure (Ichiki et al., 1995, Bartunek et al., 
1999). Conversely, it has also been shown that over-expression of AT2R promotes 
dilated cardiomyopathy (Yan et al., 2003b) and cardiac fibrosis (Masson et al., 
2009). 
The role of the more recently discovered components of RAS is not well defined. 
Over-expression of ACE2 has given controversial results. Some studies show a 
reduction in blood pressure, cardiac hypertrophy and fibrosis (Huentelman et al., 
2005, Diez-Freire et al., 2006, Grobe et al., 2007a) as well as improved cardiac and 
endothelial function (Der Sarkissian et al., 2008, Rentzsch et al., 2008). 
Alternatively, ACE2 over-expressing mice demonstrated abnormalities in heart 
conduction as well as fibrosis and poor cardiac function (Donoghue et al., 2003), 
whereas overexpression via gene delivery results in severe cardiac fibrosis and heart 
failure (Masson et al., 2009). The role of Ang1-7 has also been studied in vivo. 
Benter et al. showed that Ang1-7 had a protective role against hypertension and 
cardiac damage in the SHR (Benter et al., 2006). Ang1-7 has also shown 
antihypertrophic and antifibrotic effects in hypertensive animal models (Grobe et al., 
2007b, Mercure et al., 2008). Vasodilatation and anti-inflammatory effects have also 
been described as actions of Ang1-7 in vivo (Lee et al., 2009)(Sampaio et al., 2003). 
Pharmacological blockade and deletion of the Ang1-7 receptor Mas has provided 
evidence that Ang1-7’s in vivo effects are mediated by the Mas receptor (Soares de 
Moura et al., 2004, Santos et al., 2006, Dias-Peixoto et al., 2008). 
Osmotic minipumps have been a useful tool to investigate the physiological and 
pathophysiological role of specific agents in a systemic environment. A major 
advantage of osmotic minipumps is the subcutaneous delivery of a reagent at a 
constant dose over a defined period of time which would not be affected by any 
other manipulations, procedures or homeostatic adjustments (Struyker-Boudier and 
Smits, 1978). Osmotic minipumps have been used widely to study the systemic 
effects of angiotensin peptides hormones. AngII has been delivered through osmotic 
minipumps in several studies (Metsarinne et al., 1996, Castoldi et al., 2007)(Saito et 
al., 2004). Metsarinne et al. described AngII-mediated regulation of ACE expression 
in lung, heart and kidney as subcutaneous delivery for 3 days to normal rats 
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decreased ACE activity and expression in lung, but did not affect ACE expression in 
heart and kidney (Metsarinne et al., 1996). In the kidney, Saito et al. demonstrated 
that AngII was an important regulator of renal damage (Saito et al., 2004). AngII 
delivered by osmotic minipumps to rats for 7 days increased kidney expression of 
TGF-β1 and deposition of collagen I and IV. The involvement of AngII in vascular 
remodeling has been studied using osmotic minipumps, leading to increased 
expression of tissue inhibitors of metalloproteinases-2 (TIMP-2) in aortic smooth 
muscle cells (Castoldi et al., 2007). In these studies AngII infusion also triggered 
increased blood pressure and cardiac hypertrophy. Osmotic minipumps have also 
been useful to study pharmacological reagents. Delivery of AT1R and AT2R 
antagonists has been used to study the regulation of the local RAS (Zhou et al., 2006, 
Ishiyama et al., 2004). Blockade of the AT1R using candersatan in rats resulted in 
increased expression of angiotensinogen, ACE, and AT2R in the microvasculature of 
the brain (Zhou et al., 2006) and also decreased cardiac hypertrophy with improved 
contractility (Ishiyama et al., 2004). Furthermore, osmotic minipump-mediated 
delivery of Ang1-7 has also been used to prove its effects in different tissues (Lu et 
al., 2008, Mendes et al., 2005). Analysis of expression of different components of 
the RAS in heart and kidney when Ang1-7 was subcutaneously delivered showed a 
decrease in AngII levels and increased ACE 2 expression in the heart, while in 
kidney AngII was not affected but Ang1-7 and AngI levels were increased (Mendes 
et al., 2005).  
Other features of hypertension include endothelial dysfunction and altered cardiac 
function parameters such as cardiac performance are cardiac output, stroke volume 
and ejection fraction. Cardiac output (CO) refers to the amount of blood ejected from 
the heart per minute, and is a product of stroke volume (SV) and heart rate (HR). In 
SHRSP CO is approximately 250ml/min (Badyal, 2003). SV is the difference 
between the end diastolic volume and the end systolic volume and represents the 
mechanical function of the heart. SV can be affected by changes in preload, afterload 
and contractility of the cardiac muscle. Afterload represents the force the ventricular 
muscle needs to contract in order to eject the blood, while preload refers to the 
amount of blood in the ventricle at the end of the diastole. Ejection fraction is the 
main parameter to evaluate ventricular function as it represents the fraction of blood 
in the ventricle that is ejected in every ventricular contraction. This parameter is 
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usually 60% and is measured as the ratio between SV and end diastolic volume 
(Fauci, 2008, Guyton, 2007, Andreoli, 2001). According to Frank-Starling Law, if 
the preload increases, the ventricular muscle increases contractile tension in order to 
pump blood efficiently and maintain CO and tissue perfusion. (Fauci, 2008, 
Andreoli, 2001). With the advent of radiotelemetry and ECHO, assessment of blood 
pressure and cardiac function in vivo became non-invasive and less stressful for the 
animal and hence more accurate. Here, Ang1-9 was infused via osmotic minipumps 
into SHRSP to assess its effects on blood pressure, cardiac and endothelial function. 
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4.2 Results 
4.2.1 Effects of Ang1-9 infusion on blood pressure 
Analysis of blood pressure was performed by radio-telemetry. The transmitter was 
implanted in the peritoneum of the rats 10 days before osmotic minipump 
implantation (Figure 2-1) and blood pressure was measured constantly over the 4 
weeks of the study. The average of one week blood pressure readings was used to 
analyse the data. All three groups started the study with similar values of mean 
arterial blood pressure (control = 155.8 ± 1.6 mmHg; Ang1-9 = 160.3 ± 5.9 mmHg; 
Ang1-9 + PD123,319 = 164.5 ± 4.2 mmHg). Following minipump implantation, 
mean arterial blood pressure changed and an approximate increase of 10 mmHg in 
Ang1-9 infused rats and 20 mmHg in SHRSP co-infused with Ang1-9 and 
PD123,319 was observed compared to controls, although this difference did not 
reach statistical significance (control = 149.0 ± 1.0 mmHg; Ang1-9 = 158.8 ± 8.0 
mmHg; Ang1-9 + PD123,319 = 162.9 ± 5.9 mmHg) (Figure 4-1 A). This tendency 
was sustained until the 4 weeks end point of the study (control = 152.7 ± 1.0 mmHg; 
Ang1-9 = 164.3 ± 9.8 mmHg; Ang1-9 + PD123,319 = 172.0 ± 8.4 mmHg). Similar 
results were observed in systolic and diastolic blood pressure readings (Figure 4-1 B 
and C).  
4.2.2 Effects of Ang1-9 on cardiac function 
In order to evaluate cardiac function ECHO was performed during the study. The 
first ECHO was performed at the 11
th
 week of age prior to implantation of the 
minipump. The second ECHO was performed 2 weeks after osmotic minipump 
implantation (15
 
weeks of age) and on the third day before animal sacrifice (17
 
weeks of age). Left ventricular motion mode (M-mode) images captured at the 
papillary muscle level were used to calculate wall thickness and left ventricular 
internal diameter. Left ventricular end diastolic measurements, endocardial fractional 
shortening and ejection fraction were used to assess left ventricular systolic function. 
Wall thickness measurements included those for the posterior wall (LVPW) and 
anterior wall (LVAW). Internal left ventricular diameter (ILVD) and wall thickness 
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were measured in diastole and systole to allow accurate assessment of left ventricle 
mass index (LVMI) and left ventricular systolic function (Figure 4-2).  
To calculate LVMI from M-mode imaging the cube function formula (ASE-cube 
formula) with Deveroux correction was used (see section 2.19.3.1) (Devereux et al., 
1986) and then normalized  to tibia length. ASE-cube formula is used based on the 
assumption that the left ventricle’s shape is a prolate ellipsoid of regular 
configuration and a ratio of long- to short-axis lengths of 2:l (Devereux et al., 1986). 
Left ventricle mass index (normalized through tibia length) was not different 
between the control and Ang1-9 groups (control = 1.8 ± 0.1; Ang1-9 = 1.9 ± 0.1) 
(Table 6; Figure 4-3). However, in animals co-infused with Ang1-9 and PD123,319 
a significant increase in LVMI was observed when compared to control or Ang1-9 
infused animals (Ang1-9 + PD123,319 = 2.8 ± 0.1; p < 0.001) (Table 6; Figure 4-3).  
Extrapolation of the data from M-mode ECHO to calculate cardiac output showed a 
significant difference in cardiac output between groups (Figure 4-4). SHRSP infused 
with Ang1-9 had a significant increase in cardiac output when compared to control 
rats (control = 188.5 ± 14.5 mL/min; Ang1-9 = 229.4 ± 1 mL/min; p < 0.05). 
Furthermore, the Ang1-9-induced increase in cardiac output was abolished when rats 
were coinfused with PD123,319 (Ang1-9 + PD123,319 = 194.3 ± 7 mL/min). 
Interestingly, the change in cardiac output was not induced by increases in stroke 
volume or heart rate as either of these were significantly different between any of the 
groups. No changes in ejection fraction or fractional shortening were observed 
between groups (Table 6). 
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Figure 4-1. Effects of Ang1-9 infusion on blood pressure in SHRSP.  
Blood pressure was monitored via radiotelemetry from 11 weeks of age until the end of the 
experimental protocol. Infusion of either water (control), Ang1-9 or Ang1-9 + PD123,319 initiated at 
week 13 and continued for 4 weeks. (A) Mean arterial pressure (MAP); (B) Systolic blood pressure 
(BP); (C) Diastolic blood pressure (BP). Rat’s age in weeks. Two way ANOVA analysis was 
performed and no significant difference between groups was found. n = 6 rats per group. 
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Figure 4-2. M-mode echocardiography.  
Representative traces for the M-mode echocardiography performed in SHRSP at 11, 15 and 17
 
weeks 
of age. (A) Control group, (B) Ang1-9 infused, (C) Ang1-9 + PD123,319 infused. ILVESD = internal 
left ventricular end systolic diameter; ILVEDD = internal left ventricular end diastolic diameter; 
LVAWd = left ventricle anterior wall in diastole; LVPWd = left ventricle posterior wall in diastole; 
LVAWs = left ventricle anterior wall in systole; LVPWs = left ventricle posterior wall in systole; PD 
= PD123,319.  
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Figure 4-3. Quantification of left ventricular mass index.  
ECHO performed on 17 weeks old rats following 4 weeks infusion via osmotic minipump. Left 
ventricular mass (LVM) is the difference between the epicardium delimited volume and the left 
ventricular chamber volume multiplied by an estimate of myocardial density (1.04). LVM was 
normalized to tibia length to adjust physiologic variation between animals producing a value for left 
ventricular mass index (LVMI). LVMI showed a significant difference between the Ang1-9 + 
PD123,319 group and control and Ang1-9 groups. * p < 0.001; n = 6 rats per group. 
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Figure 4-4. Assessment of cardiac output. 
Based on ECHO data, cardiac output was calculated at sacrifice in control, Ang1-9 and Ang1-9 + 
PD123,319 infused rats. A significant increase was observed in cardiac output in SHRSP infused with 
Ang1-9 for 4 weeks. Co-infusion of PD123,319 abolished the increase in cardiac output observed in 
Ang1-9 infused animals. * p < 0.05; n = 6 rats per group. 
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4.2.3 Effects of Ang1-9 on fibrosis 
Signalling via the AT2R has been reported to mediate reduced cardiac fibrosis in 
different models (Falcon et al., 2004, Morrissey and Klahr, 1999, Wu et al., 2002, 
Yan et al., 2003b). To assess the effects of Ang1-9 on cardiac fibrosis, hearts of 
SHRSP from each group were stained with Masson’s trichrome and picrosirius red 
staining. Masson’s trichrome selectively stains muscle, collagen fibers, and 
erythrocytes, with nuclei dyed black, muscle fibers and erythrocytes dyed red and 
collagen fibers blue. Picrosirius red stains collagen I and III in a brilliant red colour. 
There was no obvious evidence of irregularity in cardiac structure between groups 
when assessing heart sections with haematoxylin and eosin stain (Figure 4-5). 
Histological analysis of hearts of control SHRSP with Masson’s trichrome revealed a 
marked increase in collagen fibers in the perivascular region (Figure 4-6 A). This 
observation is in agreement to that reported, where perivascular fibrosis is observed 
at 8 weeks of age (Sawamura et al., 1990). In contrast, the extent of perivascular 
fibrosis was attenuated in SHRSP infused with Ang1-9 for 4 weeks. Interestingly, 
following co-infusion of PD123,319 and Ang1-9, fibrosis levels were similar to 
those observed in control animals, however, fibrosis was apparent with a different 
distribution. Whereas, in control animals only perivascular fibrosis was observed, in 
Ang1-9 + PD123,319 infused animals the deposits of collagen were interstitial, with 
negligible collagen deposits observed in perivascular regions (Figure 4-6 A). 
Quantification of cardiac fibrosis indicated that Ang1-9 infusion significantly 
blocked the endogenous fibrosis evident in the SHRSP and this appeared to be 
mediated through the AT2R since PD123,319 abolished the anti-fibrotic effect of 
Ang1-9 (Figure 4-6 B). In similarity to what was observed with Masson’s trichrome, 
picrosirius red staining of control SHRSP hearts revealed perivascular and interstitial 
deposits of collagen type I and III (Figure 4-7 A). In Ang1-9 infused animals the 
collagen deposition was reduced, an effect reversed by co-infusion of PD123,319. 
Quantification of collagen fibers in the heart sections also showed a significant 
difference between control and Ang1-9 infused rats (Figure 4-7 B). Furthermore, 
PD123,319 significantly attenuated the effects of Ang1-9 on fibrosis (Figure 4-7 A 
and B). These findings suggest Ang1-9 has an anti-fibrotic effect on the heart in vivo 
and that these actions are mediated by the AT2R. 
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Figure 4-5. Histological analysis of cardiac structure. 
Cardiac structure of SHRSP infused for 4 weeks with water (control), Ang1-9 or Ang1-9 + 
PD123,319 was assessed on histological sections with haematoxylin and eosin. No apparent 
difference was found between groups in haematoxylin and eosin stain. Scale bar = 10 µm, top panel 
magnification 10x, bottom panel magnification 20x. 
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Figure 4-6. Effects of Ang1-9 on cardiac fibrosis assessed with Masson’s trichrome 
staining.  
Hearts from SHRSP infused with water (control), Ang1-9 or Ang1-9 + PD123,319 for 4 weeks were 
analysed histologically with Masson’s trichrome staining. Masson’s trichrome revealed perivascular 
fibrosis in the control group, which was reduced by infusion of Ang1-9. However, the anti-fibrotic 
effect of Ang1-9 was reversed by co-infusion with PD123,319. Scale bar = 10 µm, top panel 
magnification 10x. 3 bottom panels magnification 20x. * p<0.01 compared to control. AU = arbitrary 
units 
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Figure 4-7. Effects of Ang1-9 on cardiac fibrosis assessed with picrosirius red 
staining.  
Histological sections from SHRSP hearts infused with water (control), Ang1-9 or Ang1-9 + 
PD123,319 for 4 weeks were analysed for collagen type I and III content with picrosirius red staining. 
Heart sections from control animals showed increased perivascular and interstitial deposition of 
collagen. Ang1-9 infusion blocked collagen deposition, whereas co-infusion of PD123,319 with 
Ang1-9 reversed the antifibrotic effect of Ang1-9. Scale bar = 10 µm, top panel magnification 10x, 
bottom panel magnification 20x. * p < 0.05 compared to control. AU = arbitrary units.
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4.2.4 Effects of Ang1-9 on endothelial function 
Immediately following sacrifice, aortas were isolated to perform large vessel 
pressure myography to evaluate the direct effect of Ang1-9 on endothelial function. 
The principle of myography is based on the bioavailability of NO in vessel 
endothelium (Anderson et al., 1995). NO is released by vascular endothelial cells 
producing vessel relaxation. The synthesis of NO is catalyzed by nitric oxide 
synthases (eNOS, nNOS and iNOS) (Palmer et al., 1988). Inhibition of NOS with L-
NAME triggers vessel contraction due to the loss of NO production (Ibarra et al., 
2006). Performing pressure myography in the absence and presence of L-NAME 
gives an indication of endothelial function as the difference between the two curves 
reflects the amount of NO produced. In control SHRSP inhibition of NOS with L-
NAME did not modify basal arterial tension [induced by phenylephrine (PE)] as 
there was no significant difference between the contraction curves (Control PE = 
64.1 ± 10.3%; Control PE + L-NAME = 74.0 ± 10.4%)(Figure 4-8 A). This indicates 
a lack of basal NO availability suggesting dysfunctional endothelium in the control 
SHRSP, which is consistent with observations in previous studies in the SHRSP 
(Kerr et al., 1999, Hamilton et al., 2002). However, when pressure myography was 
performed on aortas from Ang1-9 infused animals L-NAME significantly increased 
the contractile response of the aorta (Figure 4-8 B). An approximately 30% 
difference was observed between the curves (Ang1-9 PE = 68.3 ± 11.0%; Ang1-9 PE 
+ L-NAME = 99.0 ± 12.0%; p<0.01) (Figure 4-8 B). These findings indicate that 
Ang1-9 improves NO bioavailability, suggesting Ang1-9 is able to improve 
endothelial function. In contrast, animals co-infused with Ang1-9 and the AT2R 
antagonist PD123,319 showed no significant difference between basal contraction 
and contraction in the presence of L-NAME (Ang1-9 + PD123,319 PE = 62.6 ± 
11.0%; Ang1-9 + PD123,319 PE + L-NAME = 72.5 ± 17.7%) (Figure 4-8 C), 
suggesting PD123,319 reversed the effects of Ang1-9 on endothelial function. 
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Figure 4-8. Effects of Ang1-9 infusion on endothelial function.  
Large vessel myography was performed in freshly isolated aortic rings of SHRSP infused with (A) 
water (control), (B) Ang1-9 or (C) Ang1-9 + PD123,319 for 4 weeks. Basal contractile response was 
induced by phenylephrine (PE). To inhibit endogenous production of NO, vessels were incubated 
with L-NAME and contraction induced with PE. Endothelial function was evaluated as NO 
bioavailability assessed as the difference between contractile response curves. * p < 0.01; n = 6 
animals per group. 
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4.3 Discussion 
Here, SHRSP were used to study the effects of Ang1-9 on blood pressure, cardiac 
function, hypertrophy and fibrosis and endothelial function. SHRSP were infused for 
4 weeks with water (control), Ang1-9 or Ang1-9 + PD123,319 via osmotic 
minipumps. Ang1-9 infusion had no effect on blood pressure. However, Ang1-9 
increased cardiac output, blocked cardiac fibrosis assessed histologically and 
improved endothelial function assessed by ex-vivo vessel myography. Importantly, 
PD123,319 was able to reverse all the effects of Ang1-9, suggesting Ang1-9 actions 
were mediated by the AT2R. Interestingly, PD123,319 also had effects on cardiac 
hypertrophy, increasing left ventricular mass index when compared to control or 
Ang1-9-infused animals. # 
Human hypertension is a, complex multifactorial, polygenic disease. To study this 
entity many animal models have been developed. SHRSP is one of the most used 
animal models to study hypertension. As already mentioned, this model develops 
end-organ damage such as left ventricular hypertrophy, stroke and renal failure 
resembling a human hypertensive phenotype (Tanase et al., 1982, Badyal, 2003). 
However there are better rodent models to study heart failure such as transverse 
aortic constriction in mice. Cardiac overload in this mice cause dilatated 
cardiomyopathy and heart failure and has been extensively used as a reproducible 
model for cardiac hypertrophy. As future work, assessment of Ang1-9 effects on this 
model would be fundamental.  
The RAS is the main regulator of systemic blood pressure and furthermore, in 
animal models it has been shown that systemic delivery of AngII induces an increase 
in blood pressure, cardiac remodelling (increasing left ventricular mass and 
cardiomyocyte size and induction of fibrosis) (Chintalgattu and Katwa, 2009, Frank 
et al., 2007, Guzik et al., 2007). Novel components of the local tissue-specific RAS 
have been shown to mediate beneficial effects on blood pressure and cardiac 
remodelling when delivered in animal models via minipump or overexpression. 
ACE2 and Ang1-7 have both been shown to reduce cardiac hypertrophy and fibrosis, 
as well as lower blood pressure but by different mechanisms (Benter et al., 2006, 
Diez-Freire et al., 2006). However, it has also been described that delivery of ACE2 
Chapter 4 
154 
can promote the development of cardiac fibrosis and HF, while delivery of Ang1-7 
does not affect blood pressure (Grobe et al., 2007b, Masson et al., 2009) indicating 
the difficulty in defining the direct roles of these proteins. Even though results are 
conflicting these local novel components of the RAS are clearly importantly 
involved in the pathophysiology of hypertension and end organ damage. Based on 
this we assessed the role of Ang1-9 in a hypertensive rat model, the SHRSP, with 
associated end organ damage. Ang1-9 has been described to have an indirect effect 
on cardiac tissue via potentiating bradykinin in endothelial cells (Jackman et al., 
2002) or by forming Ang1-7 through ACE cleavage (Donoghue et al., 2000). Until 
now there is no evidence of direct actions of this peptide. In the present study Ang1-
9 was delivered into SHRSP for 4 weeks and assessed its effects in a hypertensive in 
vivo model by analysing blood pressure, cardiac function and remodelling, and 
endothelial function.  
Even though a cardinal sign of hypertension is high blood pressure, in the present 
study Ang1-9 had no effect on blood pressure. However, it has been shown that 
lentiviral over-expression of AT2R in the myocardium of the SHRSP after 
completion of embryonic development had no effect on blood pressure when 
compared to control SHR (Metcalfe et al., 2004). In addition in an AngII chronic 
infusion rat model to induce hypertension, Ang1-7 had no effects on blood pressure, 
however, Ang1-7 was able to attenuate AngII-induced cardiomyocyte hypertrophy 
and interstitial fibrosis (Grobe et al., 2007b). Furthermore, Mercure et al. showed 
that under a hypertensive challenge transgenic mice over-expressing Ang1-7 in the 
heart, had reduced ventricular hypertrophy and fibrosis when compare to control 
animal, but had no effect on hypertension development (Mercure et al., 2008). 
Hence, there is evidence for target end-organ effects of angiotensin peptides and for 
AT2R function in the absence of systemic effects on blood pressure. However it is 
important to mention that in both treated groups (Ang1-9 infused and Ang1-9 + 
Pd123,319 coinfused rats) there is an increased variability in blood pressure 
(observed in standard error bars). It has been described that arterial blood pressure 
has a beat-to-beat fluctuation. This fluctuation has been explained as the dynamic 
response of the cardiovascular system to control perturbations, and the renin-
angiotensin system together with the autonomic nervous system have been 
considered to be the main players on this short-term control (Akselrod et al., 1981). 
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In this study further analysis of these fluctuations between groups should be carried 
out using power spectrum analysis to assess the short-term cardiovascular control 
systems and address if there is any difference between groups. 
In order to evaluate cardiac function transthoracic ECHO was performed in the 
SHRSP. From the parameters studied only CO was significantly higher in the Ang1-
9 group, an effect that was blocked when the AT2R antagonist PD123,319 was co-
infused with Ang1-9. Despite CO being derived from SV and HR via the formula 
CO = SV x HR, here neither HR nor SV were significantly different between groups. 
However, according to Darcy’s Law, CO is influenced in an inverse manner by 
vascular resistance (Fauci, 2008, Andreoli, 2001) and therefore even with no 
changes in SV or HR the increase in CO in SHRSP infused with Ang1-9 could be 
related to the decreased vascular resistance resulting in increased CO to maintain 
tissue perfusion. This hypothesis is supported by the large vessel myography in 
which Ang1-9 improves endothelial function. Since, NO is a vasodilatator agent that 
can decrease vascular resistance, Ang1-9 may reduce vascular resistance by 
improving endothelial function leading to increased NO bioavailability. 
Interestingly, when Ang1-9 infused rats were co-infused with the AT2R antagonist 
PD123,319, both CO and vasorelaxation / NO bioavailability decreased to basal 
values equivalent to control SHRSP. This further supports a role for the AT2R in 
mediating Ang1-9 signalling. Furthermore, and supporting these findings, AT2R 
stimulation has been described to increase synthesis of NO in cardiac and endothelial 
cells and promote vasodilatation (Abadir et al., 2006, Ritter et al., 2003).  
An interesting finding is the lack of effect of Ang1-9 on cardiac hypertrophy in vivo. 
This obviously does not correlate with the in vitro data where Ang1-9 showed clear 
antihypertrophic effects. However, the in vitro and in vivo results do support the 
notion that Ang1-9 may signal through the AT2R in vitro and in vivo. The AT2R has 
been described as a non-classical GPCR (Schluter and Wenzel, 2008, Funke-Kaiser 
et al., 2009). With this knowledge the different in vivo and in vitro actions of Ang1-9 
maybe due to the AT2R having different roles in different conditions. In addition left 
ventricule weigth normalized with tibia length as well as cross sectional staining 
with wheat germ agglutinin to measure cardiomyocyte area histologically would 
support any changes in cardiac hypertrophy. However echocardiography 
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measurements of cardiac hypertrophy have been previously validated (Graham et al., 
2004). As most of the in vitro data is performed in neonatal rat cardiomyocytes, 
younger rats might be needed to extrapolate results from the in vitro to the in vivo 
stimulation. Furthermore, the in vitro data is the result of the preventive effects of 
Ang1-9, whereas in vivo Ang1-9 was infused to reverse cardiac hypertrophy and 
hypertension in an in-bred rat strain which has been in-bred for many generations for 
the phenotype and is extremely well compensated. However, Ang1-9 was able to 
reverse interstitial and perivascular fibrosis, an effect that was blocked by co-
infusion with PD123,319. In addition to this data, other studies have shown that 
AT2R activation can mediate an antifibrotic effect in vivo, without having an 
antihypertrophic effect supporting the findings presented here (Yan et al., 2003b, 
D'Amore et al., 2005). Studies have implicated the AT2R as a therapeutic target in 
cardiac remodeling, though transgenic data is controversial. Two groups have 
developed cardiac-selective AT2R over-expressing mouse lines (Sugino et al., 2001, 
Yan et al., 2003b). The first line shows no differences in blood pressure, baseline or 
pressure overload-induced cardiac hypertrophy compared to wild type mice, 
however there was a reduction in cardiac fibrosis (Sugino et al., 2001). The second 
study reported an increase in basal hypertrophy, a decrease in pressure overload-
induced hypertrophy, an increase in cardiac fibrosis and reduction in blood pressure 
(Yan et al., 2003b). Conversely, in the two knockout strains described to date one 
demonstrates decreases in cardiac hypertrophy and fibrosis without any changes in 
blood pressure (Ichihara et al., 2001), while the other demonstrates increases in 
blood pressure, although cardiac parameters have not been reported (Ichiki et al., 
1995). Although some of the differences in these studies maybe due to technical 
differences in the methods used for phenotyping, the true function of the AT2R 
remains elusive. Activation of AT2R with the oral agonist C21 blocked 
phosphorylation of p38 and p44/42 in infarcted cardiac tissue increasing cell 
survival, as well as blocking the inflammatory response. In the data here we did not 
observe competition between AngII and Ang1-9, suggesting it may be a preferential 
ligand for the AT2R. This is also supported by the fact that the AT2R agonist 
CGP4211A produces similar effects to those seen with Ang1-9. Recently the 
development of a new AT2R agonist, compound 21 (C21) has indicated that the 
AT2R may be a therapeutic target in myocardial infarction (Kaschina et al., 2008). 
Our data shows that co-infusion of Ang1-9 + PD123,319 significantly increased 
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LVMI. Furthermore, even though the AT2R antagonist was able to reverse the anti-
fibrotic effect of Ang1-9, the collagen deposition observed in the Ang1-9 + 
PD123,319 co-infused rat hearts was interstitial instead of perivascular as observed 
in control SHRSP. This data suggest that PD123,319 may have an intrinsic effect on 
basal AT2R signalling. In addition, based on the evidence of beneficial effects of the 
AT2R on cardiac remodeling described earlier, blocking the AT2R with PD123,319 
might cause blockade of the receptor effects resulting in an increase in LVMI. 
In animal models the local RAS components have been shown to have a role in 
cardiac remodeling (Huentelman et al., 2005, Grobe et al., 2006, Grobe et al., 2007a, 
Mercure et al., 2008). Chronic infusion of Ang1-7 to rats blocked AngII-induced 
interstitial cardiac fibrosis and cardiomyocyte hypertrophy (Grobe et al., 2007b). 
Similarly, in deoxycorticosterone acetate-salt rats Ang1-7 prevented interstitial and 
perivascular collagen deposition in the heart, resulting in prevention of cardiac 
fibrosis (Grobe et al., 2006). Lentiviral over-expression of ACE2 in rat hearts also 
blocked AngII-induced hypertrophy and fibrosis (Diez-Freire et al., 2006, 
Huentelman et al., 2005). In relevance to this, our data shows reduced perivascular 
and interstitial fibrosis in animals infused with Ang1-9 compared to control SHRSP. 
This data suggests that the anti-fibrotic effect of Ang1-9 can act as a counter-
regulatory mechanism to AngII signalling, supporting a potential therapeutic role for 
Ang1-9. Since, this anti-fibrotic property of Ang1-9 is reversed when PD123,319 is 
co-infused in the SHRSP these results support the hypothesis that Ang1-9 signals 
through the AT2R.  
The data here shows an effect of Ang1-9 on interstitial and perivascular fibrosis. In 
addition Ang1-9 improved endothelial function leading to decreased perivascular 
resistance and increased cardiac output. Furthermore, PD123,319 blocked all the 
observed effects of Ang1-9 supporting the assertion that the AT2R mediates Ang1-9 
signalling.  
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5.1 Introduction 
The development of gene transfer is a powerful approach for research in the 
cardiovascular system. The ability to over-express specific genes in different 
cardiovascular tissues has permitted the assessment of their mechanisms of action in 
cardiovascular physiology and pathophysiology, increasing understanding of CVD 
and highlighting novel pathological targets for the development of treatments.  
To characterise the effects and molecular pathways of the RAS in vivo has been a 
challenge. Although classical systemic actions have been widely investigated, 
studying new tissue-specific components of the RAS in vivo is difficult, limiting the 
ability to distinguish systemic from local effects. A system which enabled delivery 
of peptides in a tissue-specific manner would be useful to study the mechanisms of 
these peptides action in specific cardiovascular disease phenotypes, such as cardiac 
hypertrophy or heart failure. This is important as recent studies have highlighted the 
importance of separate tissue specific actions of the RAS in kidney (Crowley et al., 
2005) and central nervous system (CNS) (Lee-Kirsch et al., 1999). Generation of 
gene transfer tools able to overexpress RAS components and peptides in specific 
tissues would facilitate research into the tissue-specific actions of the RAS. 
Due to the involvement of the RAS in hypertension this system has been a target for 
gene transfer strategies to treat hypertension. Inhibition of different components of 
the RAS using short oligonucleotides or full length antisense DNA was one of the 
first approaches for RAS gene transfer. Tomita et al. cloned antisense 
oligonucleotides for angiotensinogen into the hemagglutinating virus of Japan for 
delivery into the SHR, resulting in reduced blood pressure (Tomita et al., 1995). 
Gene transfer of antisense mRNA for the AT1R delivered to SHR also reduced 
blood pressure (Phillips et al., 1997). Furthermore, intracardiac delivery of retroviral 
vectors expressing full-length antisense DNA for the AT1R in SHR neonates 
prevented development of hypertension and changes in Ca
2+
 regulation in the kidney 
(Gelband et al., 1999). Inhibition of ACE by antisense oligonucleotides has also 
been studied by the use of retroviral vectors and increased AngII-induced 
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intracellular Ca
2+
 transients into pulmonary artery endothelial cells and decreased 
blood pressure when delivered in SHR (Wang et al., 1999, Wang et al., 2000). 
In order to design technology to enable the study of the tissue-specific roles of the 
RAS peptides Methot et al. developed a fusion protein able to direct the production 
of RAS peptides in transgenic mice (Methot et al., 1997). This protein is able to 
over-express these peptides in specific tissues or cells due to the unique design of its 
conformation consisting of a signal peptide from human prorenin linked to a portion 
of the mouse heavy chain constant region immunoglobulin (Ig) G. This is followed 
by a portion of the human prorenin prosegment containing a cleavage site for furin 
protease and finally the biologically active RAS peptide (Figure 5-1 A) (Methot et 
al., 1997).  
The individual expression cassette components function in several ways to facilitate 
secretion of the biologically active RAS peptide from the cell. First the renin signal 
peptide ensures the entrance of the fusion protein to the endoplasmic reticulum 
(Methot et al., 2001). This is possible due to the binding of the renin signal peptide 
to the signal recognition particle (SRP) during synthesis in the ribosome (Walter et 
al., 1981). The SRP then delivers the protein along with the ribosome to the SRP 
receptor on the endoplasmic reticulum (Walter et al., 1981). The protein passes 
through the endoplasmic reticulum membrane via the membrane protein translocator 
complex and into the secretory pathway (Leslie, 2005, Kanner et al., 2003).  The 
heavy chain immunoglobulins bind to the binding immunoglobulin protein (BiP) in 
the secretory pathway while they await arrival of the light chain to form disulfide 
bridges (Methot et al., 2001). The IgG in the fusion protein has the characteristic that 
it is secreted as a monomer and so does not bind to the BiP or form di-sulphide 
bridges, therefore facilitating efficient transgene expression and mature peptide 
production. Furthermore, the IgG maintains a stable conformation enabling the 
expression of proteins that would otherwise be poorly folded and therefore degraded, 
such as small peptides. The prosegment of human prorenin is a molecular spacer that 
is necessary to expose the protease processing site for the cleavage of the peptide 
(Methot et al., 2001). 
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The cleavage site is the key element for successful secretion of the peptide from the 
cell. Proteases are enzymes that destroy proteins by hydrolysis of the bonds between 
amino acids. Furin is a serine protease present in the Golgi apparatus bound to the 
membrane of almost all mammalian cells. Methot et al. designed a peptide cleavage 
site for furin modifying the prorenin prosegment cleavage site from PMKR to 
RVRTKR. After cleavage, the encoded peptide is released into the secretory 
pathway of the cell (Methot et al., 2001). Although amino acids in the amino-
terminal side of the cleavage are essential for furin, the amino acids in the carboxy-
terminal are also important. Reudelhuber et al. analysed the array of sequences for 
successful furin cleavage and concluded that although a broad spectrum of sequences 
can be used not all amino acid combinations are compatible limiting the biologically 
active peptides that can be expressed by the fusion protein (Figure 5-1 B) 
(Reudelhuber et al., 1998).  The first amino acid of most angiotensin peptides is 
aspartic acid (D) which is compatible with furin cleavage (Methot et al., 2001).  
The angiotensin peptide fusion protein approach has been used to generate several 
transgenic models. Van Kats et al. developed the first transgenic mouse model over-
expressing AngII specifically in the heart using this fusion protein (van Kats et al., 
2001). This group showed that the increase of AngII production in the mice hearts 
lead to left ventricular hypertrophy and cardiac fibrosis, confirming that the secreted 
AngII was functional. A transgenic rat with targeted over-expression of Ang1-7 in 
the testis resulted in increased plasma levels of Ang1-7 (Santos et al., 2004, Botelho-
Santos et al., 2007). Furthermore, Santos et al. showed that in these transgenic rats 
Ang1-7 over-expression protected against isoproterenol-induced cardiac hypertrophy 
as well as having a protective effect on postischemic cardiac function (Santos et al., 
2004). Furthermore, in the same rat model a decrease in vascular resistance in lung, 
spleen, kidney, brain and testis has been described, suggesting Ang1-7 as an 
important regulator of regional hemodynamics and highlighting the potential of this 
transgenic approach to study actions of angiotensin peptides (Botelho-Santos et al., 
2007). 
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Figure 5-1. Schematic of expression cassette used to express RAS peptides in 
transgenic models.  
(A) Explanatory diagram of fusion protein used to over-express RAS peptides. The expression 
cassette consists of a renin signal peptide to ensure secretion, a mouse heavy chain IgG to provide 
mass for efficient production of the protein, a furin protease cleavage domain (to release the peptide 
for secretion), and each peptide (figure modified from Methot et al. 2001). (B) Compatible amino 
acids on the carboxy-terminal side of the furin cleavage. For example the first amino acid of AngII 
and Ang1-7 is aspartic acid (D) or for ANP it is serine (S), making these peptides potential candidates 
for expression. 
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Other studies have used the fusion protein to over-express Ang1-7 selectively in 
other organs to study its effects (Burgelova et al., 2009, Ferreira et al., 2010, Ferreira 
et al., 2006, Gomes et al., 2010, Mercure et al., 2008). In a transgenic rat model 
over-expressing Ang1-7 selectively in the heart from the α-MHC promoter, Ang1-7 
was protective against AngII and isoproterenol induced hypertrophy and fibrosis, by 
blocking activation of p38 and c-Src and deposition of interstitial collagen (Mercure 
et al., 2008, Ferreira et al., 2010). Recently using the same transgenic model Ang1-7 
was described to drive production of nNOS in ventricular myocytes, leading to 
activation of cGMP, counteracting AngII-mediated stimulation of the 
calcineurin/NFAT hypertrophic pathway (Gomes et al., 2010). Furthermore, 
selective over-expression of Ang1-7 in the rat kidney using this approach indicated 
that Ang1-7 controlled urinary volume by increasing urine osmolality and decreasing 
free water clearance, as well as having a protective role against renal hypertension 
(Ferreira et al., 2006, Burgelova et al., 2009). 
Gene transfer via vector-mediated delivery is an alternative potential approach to 
drive angiotensin peptide production. Gene transfer vectors, in general, have been 
classified as non-viral and viral. Non-viral vectors have the advantage that they are 
safe, effective, and have the potential for repeated applications but they have a poor 
transfection efficiency and require high concentrations to achieve a therapeutic level 
(Bobek et al., 2006, Gardlik et al., 2005, Melo et al., 2004, Melo et al., 2005). 
Viruses are the vectors of choice for gene transfer in cardiovascular tissue as they 
provide high efficiency gene transfer compared to non-viral vectors. Although 
vectors based on viruses still have some safety issues, they are the most efficient way 
to transfer genetic material into most target cardiovascular cells. Viral vectors 
efficiently transduce genetic material into a wide range of cells and are the most used 
vectors for manipulating gene expression in cardiovascular disease. Viral vectors 
have been developed based on adenovirus (Ad), adeno-associated virus (AAV), 
lentivirus, retrovirus, herpes simplex virus and alphavirus. Although certain viral 
vectors show promise for CVD applications, e.g. AAV1 and 6 which are in gene 
therapy clinical trials for heart failure for over-expression of SERCA2a (Pleger et al., 
2007, Rengo et al., 2009, Hajjar et al., 2008), Ad vectors have been the most widely 
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investigated for acute over-expression of genes in cardiovascular tissues for both 
therapeutic approaches and for probing molecular mechanisms of disease. 
Ads are a family of 51 serotypes divided into 6 subspecies (A-F), mainly classified 
according to their ability to haemagglutinate erythrocytes. Adenoviral vectors are the 
most widely investigated as gene therapy vectors including in clinical trials, and of 
them species C, particularly serotype 5 (Ad5) (Chien, 1999). This virus is the most 
used viral vector and the most widely used for clinical trials. 
Ads are icosahedral non-enveloped, double stranded DNA viruses of approximately 
70 nm in diameter, with a 36 kB genome encoding for 50 polypeptides. The capsid 
of the virus has 3 principal protein components: the hexon, the penton base and the 
fiber. These structures are responsible for the immune response and for the cell 
tropism of the virus (Kim et al., 2002) (Figure 5-2). 
The adenoviral genome is organized into 2 sets of expressed regions; the early 
regions (E1, E2, E3 and E4) expressed before DNA replication and the late regions 
(L1, L2, L3, L4 and L5) expressed after DNA replication initiates. The E1 region 
encodes for E1a and E1b proteins and is essential for viral replication as it induces 
expression of multiple transcripts that promote DNA transcription. For example, E1a 
forces the cell to enter S phase so the virus can replicate and E1b expression inhibits 
the p53 pathway in the cell in order to prevent cell apoptosis triggered by the forced 
entry to S phase (Debbas and White, 1993, Cardoso et al., 2008). The transcripts 
needed for DNA replication are encoded by the E2 region (Caravokyri and Leppard, 
1996) and E3 encodes products that block the transport of the major 
histocompatibility complex to the cell surface inhibiting the host immune response 
(Flomenberg et al., 1992). E4 is responsible for encoding the products needed for 
inhibiting host mRNA trafficking to the Golgi apparatus and facilitating viral mRNA 
shuttling to the Golgi complex to ensure viral production. The late region encodes 
for the fiber, penton base and hexon needed for packaging mature virions (Schaack, 
2005).  
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Figure 5-2. Diagram of an adenovirus.  
Representation of the icosahedral structure of the adenovirus. The viral capsid has 3 principal 
proteins: the trimeric hexon (240 copies), the pentameric base (12 copies) and the trimeric fiber that 
consists of tail, shaft and knob domain (12 copies).  
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 First generation replication-deficient Ads are deleted of the E1a and E1b genes 
which are essential for viral replication, thus rendering the virus replication defective 
and providing space for insertion of the expression cassette. Ad vectors are produced 
in a permissive cell line such as the 293 cell line, a human embryonic kidney cell 
line transformed with the left hand end of the Ad genome, including the E1 region, 
to provide the missing E1a and E1b genes in trans (Graham et al., 1977). Generation 
of first generation Ad is either by a two plasmid or one plasmid transfection method. 
For the two plasmid transfection method, the first plasmid encodes the expression 
cassette flanked by sequences of the E1 region, and the second plasmid encodes the 
adenoviral genome, with a large insertion in the E1 region to avoid self packaging. 
Co-transfection into 293 cells and recombination between the plasmids generates a 
1
st
 generation replication deficient recombinant Ad expressing the transgene. One of 
the problems encountered in the production of these Ads is the spontaneous 
generation of replication-competent Ad caused by the recombination between the 
plasmid containing the Ad genome and the E1 region of 293 cells. The second 
method generates an intact E1-deleted Ad genome containing the expression cassette 
which is then transfected into 293 cells to package virus and is termed AdEASY (He 
et al., 1998). Even though the region for initiating viral DNA replication is deleted in 
these viruses there is evidence of leaky expression of viral genes which is thought to 
occur via transactivation by endogenous transcription factors, inducing host 
inflammatory and immune responses which leads to inactivation of transgene 
expression and death of virally transduced cells (Yang et al., 1994).  
First generation adenoviral gene transfer vectors have the advantage of infecting 
dividing and non-dividing cells. Ads are relatively easy to manipulate, grow 
efficiently in tissue culture and can encode ≤8kB expression cassettes, they are 
stable, and high titer production is readily achievable. Disadvantages of Ad vectors 
include the innate and humoral immune response they induce preventing repeat 
administrations and approximately 70% of the general population carry antibodies 
and memory T-cells to the common serotypes (Muruve, 2004). In the cardiovascular 
setting Lemarchand et al. first described Ad gene delivery to endothelial cells and 
transgene expression in more than 90% of cells in vitro, but in situ in blood vessels 
just 2-5% of cells were transduced, indicating that gene delivery may not be as 
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efficient into intact blood vessels (Lemarchand et al., 1993, Merrick et al., 1996, 
Setlow, 2003). The transient expression from 1
st
 generation Ads can be advantageous 
in some clinical scenarios such as gene therapy for vein graft failure, where only 
short term expression of the transgene is needed, to avoid acute remodeling of the 
graft that leads to its failure (Baker, 2002, Baker et al., 2006). Recently 3
rd
 
generation Ads (with all viral genes deleted) have been demonstrated to produce up 
to 2.5 years expression after a single delivery, indicating the inflammatory response 
can be overcome (Brunetti-Pierri et al., 2005, Toietta et al., 2005, Brunetti-Pierri et 
al., 2006). In summary, adenoviral vectors provide an efficient tool to deliver genes 
in vitro and in vivo for transient over-expression of genes to study their role in 
physiology and pathophysiology. 
In order to develop tools to study the effects of Ang1-7 and Ang1-9 specifically in 
cardiac myocytes in vitro and in vivo a fusion protein expression cassette was 
engineered into Ad vectors to over-express angiotensin peptides. 
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5.2 Results 
5.2.1 Production of recombinant adenovirus Ang1-7 
(RAdAng1-7) and Ang1-9 (RAdAng1-9) 
pBluescript-pre-fc-proAngII fusion protein over-expressing AngII contains an AngII 
fusion protein encoding sequence flanked by BglII and EcoRI restriction sites. To 
replace AngII with Ang1-7 or Ang1-9 encoding sequences (Figure 5-3), 
oligonucleotides encoding Ang1-7 or Ang1-9 flanked by BglII and EcoRI restriction 
sites were commercially synthesised (Table 5). Single stranded complementary 
oligonucleotides were annealed as described (section 2.21.1). To confirm successful 
annealing, both double stranded and single stranded oligonucleotides were subjected 
to electrophoresis which indicated slower migration for annealed double stranded 
oligonucleotides compared to the single stranded oligonucleotides confirming 
successful annealing (Figure 5-4 A and B). Next pBluescript-pre-fc-proAngII was 
digested with BglII and EcoRI to excise the AngII encoding oligonucleotides, which 
was confirmed by electrophoresis (Figure 5-4 C). 
Ligation of the annealed oligonucleotides encoding Ang1-7 or Ang1-9 with 
pBluescript-pre-fc-pro was performed in competent E.coli JM109. Ligation reaction 
was used at 5:1, 3:1, 1:1, 1:3 and 1:5 molar ratio of vector:insert. Single colonies 
were picked and amplified to extract plasmid DNA and sequenced to confirm correct 
ligation of the peptide encoding sequence into the fusion protein (Figure 5-3). 
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Figure 5-3. Cloning of Ang1-7 or Ang1-9 into pBLUESCRIPT-pre-fc-pro plasmid.  
The sequence of events to clone Ang1-7 or Ang1-9 into the expression cassette. AngII was excised 
from pBLUESCRIPT-pre-fc-pro-AngII. pBLUESCRIPT-pre-fc-pro was then ligated with annealed 
Ang1-7 or Ang1-9 encoding oligonucleotides in E.Coli JM109, resulting in the generation of 
pBLUESCRIPT-pre-fc-pro-Ang1-7 and pBLUESCRIPT-pre-fc-pro-Ang1-9. 
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Figure 5-4. Cloning of Ang1-7 and Ang1-9 into pBluescript-pre-fc-pro.  
Oligonucleotides encoding for (A) Ang1-7 or (B) Ang1-9 were annealed and subjected to 
electrophoresis in a 16% acrylamide gel (L: 100 bp ladder; FO: forward oligonucleotide; RO: reverse 
oligonucleotide; AO: annealed oligonucleotides). C) Digestion of 50 µg of pBLUESCRIPT-pre-fc-
pro-AngII with 5 U of BglII and EcoRI (L: 1 kb ladder; pBpfp: pBLUESCRIPT-pre-fc-pro digested; 
pBpfpAngII: pBLUESCRIPT-pre-fc-pro-AngII native DNA; DS = double stranded; SS = single 
stranded). 
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5.2.1.1  Transfer of the expression cassette to an adenoviral 
shuttle vector 
Next the fusion protein encoding Ang1-7 or Ang1-9 was excised from pBluescript-
pre-fc-pro via HindIII and EcoRI digestion (Figure 5-5 A and B), and purified 
expression cassettes were cloned into HindIII/EcoRI digested pVQ-CMV-KNpA 
(the Ad shuttle vector) (Figure 5-6). Single colonies were picked, amplified and 
DNA extracted and successful ligation of the expression cassette into pVQ-CMV-
KNpA was confirmed by digestion of the DNA with HindIII and EcoRI (Figure 5-7 
[pVQ colonies]).  
5.2.1.2  Generation of recombinant adenoviral vectors 
To generate recombinant adenoviral vectors (RAd) a two plasmid transfection 
method was used (Figure 5-8 A) utilising pacAd5 9
.
2-100 (Anderson et al., 2000), 
which expresses the adenovirus genome deleted of the E1 and E3 genes and each 
representative Ad shuttle vector,  pVQ-CMV-KNpA Ang1-7 or Ang1-9. First, pVQ-
CMV-KNpA-Ang1-7, pVQ-CMV-KNpA-Ang1-9 and pacAd5 9
.
2-100 were 
linearized with PacI (Figure 5-8 B). Co-transfection of the linearized plasmid into 
293 cells was mediated by Ca
2+
-phosphate-mediated gene transfer. Recombination of 
plasmids and generation of recombinant adenovirus Ang1-7 or Ang1-9 (RAdAng1-7 
or RAdAng1-9) was apparent within two weeks following co-transfection. 
Crude adenoviral stocks were tested for expression of the fusion protein in Ad 
infected 293 cells lysate by western immunoblotting using a mouse anti-IgG 
antibody. Western immunoblotting indicated expression of fusion protein in its 
uncleaved (32 kDa) and cleaved (30 kDa) form, indirectly confirming expression, 
cleavage and secretion of Ang1-7 or Ang1-9 (Figure 5-9). 
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Figure 5-5. Digestion of pBLUESCRIPT-pre-fc-pro-Ang1-7 or pBLUESCRIPT-pre-fc-
pro-Ang1-9 with HindIII and EcoRI.  
50 µg of pBLUESCRIPT-pre-fc-pro-Ang1-7 or pBLUESCRIPT-pre-fc-pro-Ang1-9 was digested with 
5 U of HindIII and EcoRI (L: 1 kb ladder) to confirm the correct insertion of the expression cassette. 
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Figure 5-6. Cloning each expression cassette into the adenoviral shuttle vector pVQ 
CMV-NpA.  
Schematic representing the transfer of the fusion protein from pBLUESCRIPT-pre-fc-pro to pVQ-
CMV KNpA to generate pVQ-CMV-KNpA-Ang1-7 and pVQ-CMV-KNpA-Ang1-9 adenoviral 
shuttle vectors. 
Chapter 5 
 
175 
 
 
 
 
1 2 3 4 2 3 41
pBpfp
Ang1-9
pBpfp
Ang1-7
pVQAng1-9 pVQAng1-7
1000
pVQ
fusion protein
3000
500
250
1 kb
ladder
 
Figure 5-7. Confirmation of the correct cloning of the expression cassette into pVQ-
CMV-KNpA plasmid.  
10 µg of plasmid DNA extracted from single bacterial colonies was digested with 5 U of HindIII and 
EcoRI to confirm successful insertion of expression cassettes. p-Bluescript-pre-fc-pro-Ang1-7 and p-
Bluescript-pre-fc-pro-Ang1-9 were also digested as positive controls. Lanes 1 – 4 individual screened 
colonies (L: 1 kb ladder; pBpfp: pBluescript-pre-fc-pro). 
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RAds were purified as described in the section 2.23.3. Protein titer was carried out 
via microBCA assay to quantify virus particle and end-point dilution in 293 cells to 
calculate plaque forming units. Mean titer calculated with microBCA assay were: 
RAdAng1-7 = 2.6 x 10
12
 vp/ml 
RAdAng1-9 = 2.9 x 10
12 
vp/ml 
Plaque forming units was performed as described in the section 2.23.7.2. Pfu/cell 
titers were as followed: 
RAdAng1-7 = 1.11 x 10
11
 pfu/cell 
RAdAng1-9 = 1.11 x 10
11
 pfu/cell 
 
The ratio between virus particle and plaque forming units titer for each RAd prep 
was 23.9 for RAdAng1-7 and 26.1 for RAdAng1-9, which is within expected limits. 
To confirm that RAdAng1-7 and RAdAng1-9 were replicant incompetent, end point 
dilution assays in HeLa cells in parallel with 293 cell titers were performed. HeLa 
cells demonstrated no sign of viral replication within 8 days at any viral dilution, 
confirming the lack of contamination of the adenoviral preparations with replication-
competent adenovirus.  
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Figure 5-8. Method for generation of Adenovirus.  
(A) Schematic of Ad generation. PacI linearized pVQ-CMV-KNpA plasmids encoding each fusion 
protein producing Ang1-7 or Ang1-9 and pacAd5 9
.
2-100 were co-transfected into 293 cells to enable 
recombination to take place to generate crude stocks of replication-deficient adenoviral vectors over-
expressing Ang1-7 or Ang1-9. (B)  PacI digestion of pVQAng1-7, pVQAng1-9 and pacAd5 9.2-100.  
50 µg of pVQAng1-7 or pVQAng1-9 and 50 µg of pacAd5 9.2-100 were digested with 5 U of PacI to 
linearize the plasmids followed by electrophoresis. Lanes: 1-1 kb ladder; 2-pVQ-CMV-KNpA-Ang1-
7; 3 and 4-pVQ-CMV-KNpA-Ang1-7 digested with PacI; 5-pVQ-CMV-KNpA-Ang1-9; 6-8-pVQ-
CMV-KNpA-Ang1-9 digested with PacI; 10-pacAd5 9.2-100; 11-13-pacAd5 9.2-100 linearized with 
PacI. 
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Figure 5-9. Detection of fusion protein expression in 293 cells.  
293 cells transduced with RAdAng1-7 or RAdAng1-9 at different dilutions were lysed and subjected 
to electrophoresis and fusion protein expression was detected by western immunoblotting using an α-
IgG2b antibody to detect the cleaved (30 kDa) and uncleaved (32 kDa) forms of the fusion protein. 
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5.2.2 Optimizing adenoviral transduction into H9c2 
cardiomyocytes 
To establish the dose at which RAds efficiently transduced H9c2 cardiomyocytes, 
cells were transduced with the reporter gene expressing RAd35. RAd35 expresses 
the lacZ gene which encodes β-galactosidase from the cytomegalovirus immediate 
early promoter (CMVIEP) (Wilkinson et al., 1998). H9c2 cardiomyocytes were 
transduced with RAd35 at 50, 100, 300, 500 and 1000 pfu/cell and transgene 
expression assessed 24 hours later using X-gal staining (section 2.24.1). RAd35 
transduction efficiency increased proportionally to the dose (Figure 5-10). At 500 
and 1000 pfu/cell 70 to 90% of the cells expressed β-galactosidase. Furthermore, no 
sign of toxicity was observed at any concentration (Figure 5-10). Therefore, titers of 
500 and 1000 pfu/cell were selected for characterization of the effects of RAdAng1-
7 and RAdAng1-9 in H9c2 cardiomyocytes. 
RAds efficiency transduction in left ventricular rabbit cardiomyocytes was 
previously established in the lab.  
5.2.3 Fusion protein expression in H9c2 cardiomyocytes and 
HeLa cells 
Western immunoblotting was used to detect fusion protein expression in H9c2 
cardiomyocytes and HeLa cells following delivery of RAdAng1-7 and RAdAng1-9. 
HeLa cells were plated and transduced with recombinant RAdAng1-7, RAdAng1-9 
or RAd60 (negative control) at 10 and 50 pfu/cell and incubated at 37 ºC for 24 
hours to assess transgene expression. Similarly, H9c2 cardiomyocytes were plated 
and transduced with RAdAng1-7, RAdAng1-9 or RAd60 at 500 and 1000 pfu/cell to 
assay each RAd in the hypertrophy model. Cells were then lysed and western 
immunoblotting was performed as previously described (section 2.9) with an anti-
mouse IgG2b antibody (Table 2) to detect the expression cassette. Detection of the 
secreted peptides directly in transduced cell media by western immunoblotting was 
not possible as the peptides were too small to resolve (~ 1 kDa). The western 
immunoblot showed 1 band of approximately 32 kDa, equivalent to the fusion 
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protein for both doses of RAdAng1-7 and RAdAng1-9 (Figure 5-11). This band 
corresponds to the uncleaved fusion protein, as the cleaved form is secreted from the 
cell to the media. 
Transduction with RAd60 produced no signal following western immunoblotting, as 
expected (Figure 5-11). 
5.2.4 Assessment of the effects of RAdAng1-7 and RAdAng1-
9 in the cardiomyocyte hypertrophy 
H9c2 cardiomyocytes were transduced with 500 and 1000 pfu/cell of RAdAng1-7, 
RAdAng1-9 or RAd60 (negative control). After 24 hour incubation, transduced 
H9c2 cardiomyocytes were stimulated with AngII (100 nM) and incubated for 96 
hours. AngII induced cardiomyocyte hypertrophy as expected (Figure 5-12). Ad 
gene delivery per se did not have any effect as the size of the cardiomyocytes 
transduced with RAd60 was not different to AngII stimulated cells. However, at 
either concentration both RAdAng1-7 and RAdAng1-9 were able to block AngII-
induced hypertrophy (AngII = 231.4 ± 79 µm; RAdAng1-7 500pfu = 176.9 ± 4.8 
µm; RAdAng1-7 1000pfu = 189.6 ± 6.2 µm; RAdAng1-9 500pfu = 192.7 ± 5.8 µm; 
RAdAng1-9 1000pfu = 176.1 ± 4.2 µm; p<0.05) (Figure 5-12), indicating that each 
viral vector was functional and able to antagonize AngII-induced hypertrophy as was 
previously observed with exogenous peptide addition (see chapter 3). Next, 
RAdAng1-7 and RAdAng1-9 were assessed in the adult rabbit left ventricular 
primary cardiomyocyte hypertrophy model. Primary cardiomyocytes were 
transduced with 50, 100 and 300 pfu/cell of RAdAng1-7, RAdAng1-9 or RAd60, 
before stimulating with 500 nM AngII. Similarly to what was observed in H9c2 
cardiomyocytes, RAd60 had no effect on AngII-induced hypertrophy (Figure 5-13). 
Importantly, RAdAng1-7 and RAdAng1-9 were able to block AngII-induced 
hypertrophy at all doses by normalizing cell width and hence volume (Figure 5-13). 
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Figure 5-10. Transduction optimization in H9c2 cardiomyocytes.  
H9c2 cardiomyocytes were transduced with RAd35 which encodes the lacZ gene at 50, 100, 300, 500 
and 100 pfu/cell. After 48 hours incubation cells were fixed and β-galactosidase expression visualized 
using X-gal (Magnification = 10x; Scale bar = 10 µm). 
Chapter 5 
 
182 
 
 
 
50
35
30
kDa Control 10 50 10 50 10 50
RAdAng1-7 RAdAng1-9 RAd60
A)
50
35
30
kDa Control 500 1000 500 1000 500 1000
RAdAng1-7 RAdAng1-9 RAd60
B)
Uncleaved 
fusion protein
32 KDa
Uncleaved 
fusion protein
32 KDa
 
Figure 5-11. Fusion protein expression in transduced cells.  
The uncleaved fusion protein (32 kDa) was detected by western immunoblotting in (A) HeLa cells 
transduced with 10 and 50 pfu/cell of RAdAng1-7, RAdAng1-9 or RAd60 or in (B) H9c2 
cardiomyocytes transduced with 500 and 1000 pfu/cell. Control = unstimulated cells. 
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Figure 5-12. Assessment of the effects of RAdAng1-7 and RAdAng1-9 in AngII-
induced hypertrophy in H9c2 cardiomyocytes.   
H9c2 cardiomyocytes were transduced with RAdAng1-7, RAdAng1-9 or RAd60 at 500 and 1000 
pfu/cell 24 hours before stimulation with AngII. Cells were fixed, stained with crystal violet and 
measured after 96 hours incubation with AngII. * p<0.01 vs. unstimulated cells; # p<0.05 vs. AngII 
stimulated cells. 
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Figure 5-13. Effect of RAdAng1-7 and RAdAng1-9 in AngII-induced hypertrophy in 
primary cardiomyocytes.  
Freshly isolated left ventricular adult rabbit primary cardiomyocytes were transduced with RAdAng1-
7, RAdAng1-9 or RAd60 (50, 100 and 300 pfu/cell) 1 hour before stimulation with AngII (500 nM). 
After 24 hours incubation (A) cell length, (B) cell width and (C) cell volume of the cardiomyocytes 
was calculated. * p<0.01 vs. unstimulated cells; # p<0.01 vs. AngII stimulation.  
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5.2.5 Assessment of peptide secretion from RAdAng1-7 and 
RAdAng1-9 transduced cells 
As secretion of Ang1-7 and Ang1-9 by each Ad vector was unable to be detected by 
standard western blotting due to the small molecular weight of the peptides, an 
indirect method was used to provide evidence that the peptides were secreted using a 
conditioned media assay. HeLa cells were transduced with 100 pfu/cell of either 
RAdAng1-7, RAdAng1-9 or RAd60 and incubated in serum free media for 48 hours 
at 37ºC. The media then was collected and added to AngII-stimulated H9c2 
cardiomyocytes. (Figure 5-14 A). 
Transfer of conditioned media from untransduced or RAd60 transduced HeLa cells 
to AngII-stimulated cells had no effect on AngII induced hypertrophy (RAd60 = 
253.4 ± 12.7 µm). However, transfer of conditioned media from RAdAng1-7 or 
RAdAng1-9 transduced HeLa cells to AngII-stimulated cardiomyocytes blocked 
hypertrophy (RAdAng1-7 conditioned media = 162.3 ± 8.5 µm; RAdAng1-9 
conditioned media = 176.2 ± 7 µm; p<0.01) (Figure 5-14 B). This provides indirect 
evidence that each RAd expressed the fusion protein and secreted the active peptide 
from the cell. 
To demonstrate that the peptides secreted from each RAd function similarly to the 
exogenous peptides the effects of antagonists of both Mas and AT2R function were 
assessed. H9c2 cardiomyocytes transduced with 500 and 1000 pfu/cell of RAdAng1-
7, RAdAng1-9 or RAd60 in the presence or absence of A779 (10 µM) or PD123,319 
(500 nM). 24 hours later, transduced cardiomyocytes were stimulated with AngII 
(100 nM) and incubated for 96 hours. In similarity to the observations with 
exogenous peptides, addition of A779 abolished the anti-hypertrophic effect of 
RAdAng1-7, while RAdAng1-9 was able to block AngII-induced hypertrophy in the 
absence and presence of A779 (Figure 5-15 A). Addition of PD123,319 had no effect 
on the antihypertrophic effect of Ang1-7, but, completely eliminated the 
antihypertrophic effect of RAdAng1-9 (Figure 5-15 B). 
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Figure 5-14. Conditioned media assay.  
(A) HeLa cells were transduced with RAdAng1-7, RAdAng1-9 or RAd60 (R60) (negative control) 
(100 pfu/cell) and incubated for 48 hours. Culture media from HeLa transduced cells was transferred 
to H9c2 cardiomyocytes and incubated for 30 minutes before stimulating with AngII (100 nM). 96 
hours later cells were fixed, stained with crystal violet and cell size measured. (B) Culture media from 
untransduced HeLa cells or cells transduced with RAd60 had no effect on AngII-induced 
hypertrophy. Conditioned media from RAdAng1-7 or RAdAng1-9 transduced HeLa cells blocked 
AngII-induced hypertrophy in H9c2 cardiomyocytes. * p<0.01 vs. unstimulated cells; # p<0.01 vs. 
AngII stimulated cells (H.M. = HeLa Media). 
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Figure 5-15. Effect of Mas and AT2R antagonism on AngII-stimulated H9c2 
cardiomyocytes transduced with recombinant adenoviruses. 
H9c2 cardiomyocytes were transduced with RAdAng1-7, RAdAng1-9 or RAd60 (negative control) in 
the presence or absence of (A) the Mas antagonist A779 (10 µM) or (B) the AT2R antagonist 
PD123,319 (500 nM) 24 hours before AngII stimulation. Cells were incubated for a further 96 hours 
before fixing, staining and measurement of cell size. * p<0.01 vs. unstimulated cells, # p<0.001 vs. 
AngII stimulated cells. 
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5.3 Discussion 
In this chapter tools for the selective over-expression of Ang1-7 or Ang1-9 were 
generated. This will enable study of their function selectively in tissues and 
assessment of their utility as potential therapeutic gene targets. RAdAng1-7 and 
RAdAng1-9 were able to transduce neonatal rat and adult rabbit cardiomyocytes and 
secrete the RAS peptides. Furthermore, Ang1-7 and Ang1-9 secreted from 
transduced cardiomyocyte were able to block AngII induced hypertrophy in the same 
manner as exogenous peptides, via Mas and AT2R respectively, confirming over-
expression of active peptides via RAdAng1-7 and RAdAng1-9 transduction. 
In the last decade genetic approaches to study cardiac hypertrophy have been 
developed. Transgenic mice have become one of the most used tools to study single 
pathways leading to cardiac hypertrophy by knocking out a gene, for over-
expression or over-expression of a mutant form of the gene. For example Ahmad et 
al., demonstrated a diminished activation of Akt and RhoA by AngII signalling in 
transgenic mice over-expressing a mutant AT1R resulting in reduction of cardiac 
hypertrophy and blood pressure when compared to wild type animals (Ahmad et al., 
2009). Gusev et al. showed a direct effect of AngII on Ca
2+
 handling and 
cardiomyocyte contractility of transgenic mice over-expressing angiotensinogen 
(Gusev et al., 2009), while by knocking out the Mas receptor, Pinheiro et al. showed 
an increase in fibrosis and microalbuminuria in transgenic mice (Pinheiro et al., 
2009). Although clearly transgenic models have revolutionised our understanding of 
the molecular basis of cardiac hypertrophy there are disadvantages. First, the cost of 
producing transgenic animals is very high and time consuming. Second, 
manipulation of genomic DNA is still random increasing the risks for epigenetic 
effects and the possibility of developmental abnormalities caused by embryonic 
over-expression. Also, transgenic mice represent the end-point of a disease which 
differs greatly to the initial stages. These effects may explain the discrepancies 
between transgenic studies and gene over-expression studies. For example ACE2 
null mice have been reported to have increased blood pressure with no change in 
heart morphology (Gurley et al., 2006) while over-expression of ACE2 driven by 
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AAV-mediated gene delivery in the SHRSP led to severe fibrosis in the heart 
(Masson et al., 2009).  
Cardiomyocytes are a difficult target for gene therapy as they differentiate into their 
mature terminally differentiated form within the first few weeks of life. Due to these 
characteristics specific vectors to transduce these cells would be valuable. 
Adenoviral vectors have the attributes to mediate gene delivery to adult 
cardiomyocyte in vitro and in vivo (Woo et al., 2007, Cutler et al., 2009, Porrello et 
al., 2009a, Maddaford et al., 2009, Heineke et al., 2007). Although there are more 
efficient vectors for long term gene delivery to cardiomyocytes, there are several 
advantages to using adenoviral vectors. Adenoviral vectors are capable of 
transducing quiesced cells, the tropism is efficient for both cardiomyocytes and other 
tissues such as kidney, brain, skeletal muscle and reproductive organs which are also 
important targets to study tissue-specific RAS effects (Paul et al., 2006, Hirsch et al., 
1991, Tipnis et al., 2000, Roks et al., 1999, Elased et al., 2008, Leal et al., 2009, 
Pinheiro et al., 2009, Xia and Lazartigues, 2008). Although AAV vectors, 
particularly serotypes such as 1, 6 and 9 (Rengo et al., 2009, Palomeque et al., 2007, 
Yang et al., 2009) can produce long term expression in myocardium, high titers are 
required and the use of adenoviral vectors enables acute over-expression to further 
dissect the molecular mechanisms of action of Ang1-7 and Ang1-9.  
The recombinant adenoviral vectors generated here efficiently transduced 
cardiomyocytes and expressed the RAS fusion protein. Ang1-7 and Ang1-9 were 
secreted from transduced cells and were able to block AngII-induced hypertrophy in 
cardiomyocytes from 2 different species, in similarity to the observations with the 
exogenous peptides. This confirmed that the Ad vectors secreted a functional 
peptide. Future work with these vectors is required in vivo to assess the phenotype 
induced following cardiac-selective delivery. Furthermore, RAdAng1-7 and 
RAdAng1-9 will be potentially useful to also investigate each peptides role in blood 
vessels, the kidney and in the brain. 
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Overall summary 
The renin angiotensin system is a vital hormonal cascade that regulates blood 
pressure, volume and electrolytes by acting in the cardiovascular and renal system. 
Overactivity of the RAS contributes to the pathophysiology of hypertension and 
heart failure making the RAS a target for its treatment. Blocking various facets of the 
RAS including ACE via ACE inhibitors and the AT1R via AT1R blockers, as well 
as renin inhibitors are some of the most successful pharmacological treatments for 
hypertension and heart failure, supporting the fundamental importance of this 
cascade in the development of these diseases. The recent description of expression of 
all “classical” RAS components as well as novel components in specific tissues has 
altered the view of the RAS being simply a systemic acting system, to one with 
tissue-specific effects. Our understanding of the role of RAS in individual tissues is 
far from complete. Many studies have been developed to elucidate the tissue-specific 
actions of the novel components including ACE2 and Ang1-7 and although this has 
generated a large body of literature, findings still remain controversial.  
The main focus of this thesis was the assessment of the novel RAS peptides Ang1-7 
and Ang1-9 in cardiac hypertrophy. First, an in vitro hypertrophy model induced by 
AngII in rat neonatal H9c2 cardiomyocyte cell line and adult rabbit left ventricular 
primary cells was established. Confirmation of AngII-induced hypertrophy was 
performed assessing increases in cell size, in BNP gene expression and re-
organization of α-actin sarcomeres. Next we evaluated the effects of Ang1-7 and 
Ang1-9 in the hypertrophy model. Both Ang1-7 and Ang1-9 blocked AngII-induced 
increases in cell size, as well as increased BNP expression and α-actin sarcomere re-
organization. To confirm if Ang1-9 cleavage and Ang1-7 generation was necessary 
for its anti-hypertrophic effect, captopril (an ACE inhibitor) was used. Interestingly, 
Ang1-9 blocked AngII-induced hypertrophy in the presence of captopril. 
Furthermore, when blocking the Mas receptor, using A779, the effects of Ang1-9 
were not affected, while A779 completely abolished the anti-hypertrophic effect of 
Ang1-7. Then, engagement of Ang1-9 with the AT1R and AT2R was assessed. To 
evaluate the AT1R, arg-vasopressin was used to induce hypertrophy. Blockade of the 
AT1R with losartan had no effect on either the effects of Ang1-7 or Ang1-9. 
Importantly, when blocking the AT2R with its antagonist PD123,319, the anti-
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hypertrophic effects of Ang1-9 were completely abolished. To further investigate if 
the bradykinin receptor B2 was participating in the Ang1-7 or Ang1-9 signalling the 
selective B2R inhibitor HOE 140 was used. Resulted showed interaction between the 
Mas receptor and the B2 receptor but not with the AT2R. To start investigating the 
cell signalling pathways, PKC membrane translocation was assessed by 
immunofluorescence. AngII was able to induce rapid PKC translocation from the 
cytoplasm to the membrane , an effect also observed with Ang1-7 or Ang1-9. Next, 
the functionality of the AT1R, AT2R and Mas was evaluated by induction of Ca
2+
 
transients with AngII, Ang1-9 or Ang1-7 respectively.  Although AngII was able to 
induce Ca
2+
 mobilization, only one third of the cardiomyocytes responded. No 
increase in Ca
2+
 was observed when the AT2R was stimulated with Ang1-9 or the 
Mas receptor with Ang1-7. Finally, Gαi-subunit activation by Ang1-7 or Ang1-9 
through the Mas and the AT2R was investigated. The Gαi-subunit antagonist, PTX, 
abolished the anti-hypertrophic effect of both Ang1-7 and Ang1-9. 
Second, to develop tools to facilitate the research of Ang1-7 and Ang1-9, adenoviral 
vectors encoding a fusion protein expression cassette which drives over-expression 
and secretion of either Ang1-7 or Ang1-9 was engineered. Successful over-
expression and secretion was confirmed when RAdAng1-7 and RAdAng1-9 blocked 
AngII-induced hypertrophy either by direct transduction of cardiomyocytes or by 
transfer of conditioned media from Ad transduced HeLa cells to AngII-stimulated 
cardiomyocytes. Moreover, the effects of RAdAng1-7 and RAdAng1-9 could be 
inhibited in the presence of 779 or PD123,310, respectively. 
Finally, the role of Ang1-9 in an in vivo setting was assessed by delivering the 
peptide for a 4 weeks period into SHRSP using osmotic minipumps. Co-infusion of 
Ang1-9 and PD12,319 was also performed in order to evaluate the role of the AT2R 
in any observed effects of Ang1-9. Blood pressure, monitored via radiotelemetry, 
was not different between any of the groups, however, echocardiography, performed 
during the study, showed a significant increase in cardiac output in the Ang1-9 
infused group compared to the control rats, an effect that was abolished by co-
infusion of PD123,319. In addition, LVMI was significantly increased in rats co-
infused with Ang1-9 and PD123,319. Histological assessment of the hearts showed 
reduced perivascular fibrosis in the Ang1-9 group, effect that was abolished with co-
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infusion of PD123,319. Interestingly, fibrosis in the PD123,319 co-infused group 
was predominantly interstitial. Furthermore, assessment of NO bioavailability with 
pressure myography in aortic rings showed an increase in  basal NO bioavailability 
in Ang1-9 infused SHRSP compared to control animals. Co-infusion of PD123,319 
also  abolished this effect. Overall, the data presented in this thesis supports the 
notion that Ang1-9 is an active RAS hormone, which is able to mediate beneficial 
effects in the cardiovascular system, including pathological effects of AngII, via the 
AT2R. These effects segregate its actions from those of Ang1-7, which signals via 
Mas. 
Future work 
Ang1-9 has been reported to act as a competitive inhibitor of ACE as well as to 
potentiate bradykinin B2 receptor activity (Snyder and Wintroub, 1986, Erdos et al., 
2002). However, no direct functions have been ascribe to Ang1-9 to date. Two 
different models of cardiomyocyte hypertrophy were used to demonstrate the effects 
of Ang1-9, representing different species and adult and neonatal lineages. In both 
these models cardiomyocyte hypertrophy was induced by the addition of AngII, 
which was assessed by increased cell size as well as imaging of actin cytoskeleton 
using phalloidin in H9c2 cardiomyocytes. Depending upon whether sarcomeres are 
added in parallel or in series, cardiac hypertrophy can be classified as either 
concentric or eccentric (Carreno et al., 2006). Here, width of the primary adult rabbit 
cardiomyocytes was increased significantly, presumably defining AngII as inducing 
a concentric hypertrophy phenotype. In retrospect, staining of the sarcomeres in 
rabbit cardiomyocytes with phalloidin to image the sarcomeres would have given an 
additional assessment of the type of hypertrophy induced by AngII. H9c2 
cardiomyocytes are a widely used cell line when investigating cell signalling in 
cardiomyocytes (Kee and Kook, 2009, Villeneuve et al., 2009, Stuck et al., 2008) 
therefore selected for initial assessment of RAS peptides in cardiomyocyte 
hypertrophy. However, the fact they are a proliferative cell line, may not reflect the 
in vivo setting as well as primary cultures therefore future work in Ang1-9 cell 
signalling assessment should be performed in freshly isolated cultures of primary 
neonatal cardiomyocytes. Importantly all data was reproduced in freshly isolated 
primary cardiomyocyte from rabbits, providing confidence in the data.  Although 
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cardiomyocyte hypertrophy was blocked in vitro by Ang1-9, in the in vivo study no 
difference was observed between control rats and rats infused with Ang1-9. Since 
Ang1-9 was also shown to have effects on cardiac fibrosis in vivo and the AT2R has 
also been recognized in several studies to reduce cardiac fibrosis (Falcon et al., 2004, 
Ohkubo et al., 1997, Oishi et al., 2003), primary fibroblast cultures would be 
essential in the future to study Ang1-9 signalling in response to proliferative agents 
such as AngII or TGF-β. Additionally, the in vivo data also support the notion that 
Ang1-9 signals through the AT2R to increase NO bioavailability in aortic rings. 
Therefore, future work to study the effects of Ang1-9 in endothelial cells would 
support the dissection of in vitro mechanisms of Ang1-9 actions. 
A full understanding of the role of Ang1-9 would be important to understand its role 
within the RAS and its potential as a future therapy. The use of pharmacological 
antagonists was an important tool to demonstrate differences in the cellular receptors 
engaged by Ang1-7 and Ang1-9. Through this procedure the actions of Ang1-9 were 
established as antihypertrophic and anti-fibrotic as well as promotion of improved 
endothelial function, effects which were all mediated by the AT2R. Nevertheless, 
future experiments showing direct binding of Ang1-9 to the AT2R would support 
this data. A radio labelled peptide binding assay would be a logical step to probe 
Ang1-9 / AT2R engagement, by assessing endogenous binding in the presence and 
absence of receptor inhibitors. Several groups have shown the use of a recombinant 
adenoviral vector for over-expression of the AT2R (Li et al., 2005a, Warnecke et al., 
2001, Porrello et al., 2009a). Transduction of non-AT2R expressing cell line with a 
recombinant adenovirus over-expressing AT2R and assessment of fluorescently 
labelled Ang1-9 binding would also help probe a direct Ang1-9 / AT2R association. 
In addition, analysis of Ca
2+
 transient and IP3 activation by Ang1-9 in AT2R 
transduced cells may also support Ang1-9 binding to the AT2R. Although, there is 
still controversy as to whether the AT2R engages G-proteins and therefore other 
activation mechanisms could also be studied such as the interaction with β-arrestins, 
as has been well established as for the AT1R (Kim et al., 2009). 
The AT2R has been described to produce non-classical GPCR signals. In human 
myometrium and bovine cerebellar cortex AngII was unable to induce AT2R-
mediated GTP gamma incorporation (Bottari et al., 1991). However, Zhang et al. 
demonstrated AT2R interaction with  the Gαi-subunit (Zhang and Pratt, 1996). 
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Although our data shows that blockade of the Gαi- subunit abolishes Ang1-9 effects, 
initial future work focusing on the G-protein subunits involved in Ang1-9 / AT2R 
signalling is needed. Selective inhibitors of the Gαq and Gαs-subunits, YM-25489 
(Canals et al., 2006) and cholera toxin (Pei et al., 2000), in AngII-stimulated 
cardiomyocytes, fibroblast and endothelial cells in the presence and absence of 
Ang1-9 would be an important tool to address this. Furthermore, short interfering 
RNA transfection to block expression of individual G-proteins will be helpful to 
define the role of each subunit in Ang1-9 signalling. To start differentiating 
downstream signalling induced by Ang1-9 through the AT2R, future work should be 
based on the knowledge of AngII cell signalling pathways. Blockade of PI3K, MAP 
kinase and PKC pathways with pharmacological inhibitors could identify potential 
differences between AngII and Ang1-9 signalling, in addition to identifying key 
pathways to focus on. In addition results in aortic rings showed a potential role of 
Ang1-9 in NO production. To further study this effect, the use of assays that measure 
NO production in Ang1-9 stimulated endothelial cells compared to AngII stimulated 
endothelial cells will be an important tool to investigate the ROS pathway. Finally, 
analysis of transcription factors and gene expression through reporter gene arrays, 
could lead to identification of novel targets regulated by Ang1-9. These could be 
further studied with immunofluorescence antibodies detecting specific transcription 
factors and evaluating nuclear translocation as western immunoblotting in Ang1-9 
stimulated cell lysates with phospho-antibodies, for example. 
Delivery of Ang1-9 with osmotic mini-pump implantation only enables the study of 
systemic effects. A system which enables delivery of peptides in a tissue-specific 
manner would be useful to study the mechanisms of Ang1-9 actions in specific 
cardiovascular disease phenotypes such as cardiac remodelling. This is important as 
recent studies have highlighted the importance of separating tissue-specific actions 
of the RAS in the kidney (Crowley et al., 2005) and CNS (Lee-Kirsch et al., 1999). 
Based on the fusion protein approach, generation of transgenic mice over-expressing 
Ang1-9 in the heart would also contribute to the understanding of Ang1-9’s local 
activity and dissect them from its systemic actions. The development of these mice 
will also allow for future cross-breeding between them and other available transgenic 
mouse strains (e.g. AT1R and AT2R knockout (Sugaya et al., 1995, Hein et al., 1995 
to further study the in vivo role of Ang1-9. Alternatively, tissue-specific effects of 
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Ang1-7 or Ang1-9 could be studied using direct delivery into the heart via 
intracardiac injection of the Ad vectors developed.  Moreover adeno-associated 
viruses have been describe to be a better choice for cardiovascular gene 
transfer{Melo, 2002 #203, Woo et al., 2005). Cloning fusion protein into AAV 6 
would also improve delivery of Ang1-9 and Ang1-7 to cardiovascular tissue. 
Furthermore, the use of RAdAng1-7 or RAdAng1-9 would avoid surgical 
implantation of the minipumps and all the associated side effects and risks. Since 
recombinant adenoviruses delivered intravenously target the liver, systemic delivery 
would enable the liver to express and secrete the peptides into the systemic 
circulation.  
In the SHRSP experimental model no significant difference in blood pressure 
between any groups was observed, suggesting Ang1-9 had no effect on this. 
Previously, it has been shown that the AT2R has a role in cardiac remodelling 
decreasing left ventricular wall thickness and cardiac fibrosis in hypertrophy animal 
models without affecting blood pressure (Metcalfe et al., 2004, Falcon et al., 2004). 
Conversely, in the SHRSP study here Ang1-9 increased cardiac output and improved 
NO bioavailability, data that can be translated into decreased vascular resistance, 
suggesting Ang1-9 promotes vasodilatation. SHRSP represents an experimental 
model of chronic hypertension. Over time SHRSP compensate the increase of blood 
pressure in order to survive as well as develop other pathophysiological traits that 
contribute to the disease phenotype, making it an extremely well compensated 
disease model. A prevention rather than a reversal study may provide additional 
important information regarding the effects of Ang1-9. Furthermore, for future work 
the role of Ang1-9 in the systemic circulation could be studied in an acute 
hypertensive model, such as infusion of AngII via minipumps to trigger hypertension 
and cardiac remodelling acutely as has been described previously in normal rodents 
(Falcon et al., 2004, Wang et al., 2006a, Huang et al., 2008).  
Interestingly, although no effect of Ang1-9 on cardiac hypertrophy was observed, 
there was a significant increase in LVMI when Ang1-9 was co-infused with 
PD123,319, suggesting that PD123,319 may be having an intrinsic effect on basal 
AT2R activity in the SHRSP. Furthermore, although PD123,319 was able to abolish 
the anti-fibrotic effect of Ang1-9, rats co-infused with Ang1-9 and PD123,319 
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presented differential fibrosis staining patterns, supporting the hypothesis of an 
intrinsic effect of PD123,319. To further study this, a group of SHRSP infused with 
PD123,319 alone is being performed. Due to the time of the thesis submission this 
group was still ongoing and data was not available. Additionally, to complete the in 
vivo study a SHRSP group co-infused with Ang1-9 and A779 would be useful to rule 
out any potential effects mediated by Ang1-9 conversion to Ang1-7.  Together future 
work to address the issues described above will enable a detailed dissection of the 
true role of Ang1-9 in the RAS. 
Translational studies 
Although animal models are useful tool to study actions of the novel RAS 
components, human biology can differ from this models, and assessment of the 
actions of peptides in clinical studies is the fundamental to determining the relevance 
of novel findings to human health and disease. Little is known about the local-tissue 
specific components of RAS in humans. Ang1-7 and Ang1-9 have been 
demonstrated to potentiate bradykinin in human pulmonary artery endothelial cells 
in vitro (Erdos et al., 2002), but further study in humans is important. The study here 
presented sets the grounds for the development of clinical studies. Although the 
actions of the tissue-specific RAS are starting to be widely documented most of the 
studies are performed in animal models. However, using cultures of human cells and 
patient screening a few groups have addressed the effects of Ang1-7 in humans. In 
patients with essential hypertension, plasma levels of Ang1-7 were measured and 
compared to normal subjects (Luque et al., 1996). The increase of Ang1-7 levels 
correlated inversely with the diastolic blood pressure of the patients with essential 
hypertension. In addition, Kono et al. showed a decrease in plasma levels of renin 
when Ang1-7 was infused to Bartter's syndrome patients (Kono et al., 1986). 
Moreover, when Ang1-7 was infused into the brachial artery of heart failure patients, 
Ang1-7 was unable to induce vasodilatation compared to bradykinin infusion (Davie 
and McMurray, 1999). Based on these examples, detection of Ang1-9 in systemic 
circulation of normal subjects compared to hypertensive or  groups of other patients, 
such as post-MI or heart failure by mass spectrometry or high performance liquid 
chromatography would be important to start elucidating Ang1-9 mechanisms in 
human pathologies. One group has recently reported the measurement of Ang1-9 
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using these techniques in human plasma (Campbell et al., 2004). This study would 
provide information on the systemic actions of Ang1-9 in such diseases. Moreover, 
comparing levels of Ang1-9 at the different stages of disease development in patients 
will increase the understanding of the role of Ang1-9. Furthermore, quantification of 
other RAS components such as AngII and Ang1-7 in hypertensive patients infused 
with Ang1-9, for example via the forearm, as described for Ang1-7 (Davie and 
McMurray, 1999) would provide information on the effects and interactions of 
Ang1-9 in the RAS. 
To determine the levels of Ang1-9 in specific tissues and organs immunodetection in 
human tissues would be a useful approach.  Heart homogenates obtain from patients 
undergoing cardiac transplantation due to heart failure, idiopathic dilated 
cardiomyopathy or congenital disease, have been used to study Ang1-7 and Ang1-9 
formation in human tissue (Zisman et al., 2003, Kokkonen et al., 1997). In both 
cases the production of these peptides was higher in diseased hearts compared to 
normal hearts (Kokkonen et al., 1997, Zisman et al., 2003). The use of myocardial 
biopsy of patients undergoing catheterism to obtain cardiac tissue would provide 
with human tissue to detect Ang1-9 in the heart using high performance liquid 
chromatography. Furthermore, the use of an Ang1-7 antibody has been useful to 
detect this peptide in human placenta by immunohistochemistry (Valdes et al., 
2006).  However, the development of a human antibody to detect Ang1-9 is still 
needed, but this would allow visualizing the distribution of Ang1-9 in the human 
heart. Human heart homogenates would also provide the means to test Ang1-9 
signalling in cardiac tissue. To address the effects of Ang1-9 on NO production in 
human blood vessels, analysis of contraction of human arteries rings obtained from 
coronary artery bypass grafting patients subjected to Ang1-9 treatment could be 
performed, as described for the study of Ang1-7, where Ang1-7 was able to block 
AngII-induce vasoconstriction (Roks et al., 1999). In addition, the use of human 
endothelial cells has been helpful in the elucidation of Ang1-7 cell signalling 
pathways and has demonstrated that Ang1-7 blocked AngII-mediated induction of 
ERK 1/2 and NAD(P)H (Sampaio et al., 2007a). This highlights that simple 
preliminary investigations in human cells in vitro would help dissect the translational 
relevance of the actions of Ang1-9.  
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In conclusion the data here presented demonstrates Ang1-9 as an independent and 
biological active peptide of the RAS. Importantly, we demonstrate that Ang1-9 acts 
as an antihypertrophic and anti-fibrotic peptide which also improved endothelial 
function, actions that are mediated by binding to the AT2R. These results give an 
initial view of the actions of Ang1-9 and its potential as a new therapeutic target in 
cardiovascular disease. Further work is required to determine its true role and 
relevance to human cardiovascular (patho)physiology.  
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